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Breast cancer is the leading cause of cancer death in women worldwide. 
Although significant advances have been made in the treatment of breast 
cancer, new therapeutic approaches are required. Protein synthesis is often 
found to be deregulated in cancer and there has been significant effort into 
developing strategies to inhibit protein synthesis for anti-cancer therapeutics. 
The addition of the 7-methylguanosine cap (methyl cap) at the 5’ end of mRNA 
is essential for efficient protein synthesis and cell viability. In humans, RNA 
guanine-7 methyltransferase (RNMT) methylates the guanosine cap. RNMT 
expression is essential for cell viability and efficient gene expression. 
This thesis demonstrates that a subset of breast cancer cells exhibit an 
enhanced dependence on RNMT for survival, in comparison to immortalised 
mammary epithelial cells. Moreover, RNMT depletion induces apoptosis in a 
subset of breast cancer cell lines. Further analyses reveal that this cellular 
sensitivity to RNMT depletion does not correlate with cellular RNMT expression, 
RNMT enzymatic activity, global protein synthesis levels, basal cell proliferation 
rate or c-Myc protein expression. It was found that activating mutations in the 
gene PIK3CA, which encodes the p110α catalytic subunit of PI3K, contributes 
to cellular RNMT dependency. Moreover, inhibition of PI3K signalling in a 
RNMT depletion sensitive breast cancer cell line reverses the sensitivity. These 
findings provide the first evidence that RNMT dependency in breast cancer is 
related to PI3K activity/ signalling. Since an estimated 18-40% of breast 
tumours have activating mutations in PIK3CA, my findings could potentially 






Chapter 1: Introduction 
 
1.1 Gene expression  
 
1.1.1 The gene expression pathway 
Gene expression is the process by which genetic information is used to direct 
the production of protein. During gene expression, DNA is transcribed into RNA 
and then RNA is translated into protein. This multistep process was first 
described by Francis Crick and is known as the central dogma of molecular 
biology. Higher eukaryotes consist of many different cell types; each performing 
a specific function and displaying a unique pattern of gene expression. Every 
one of these cells contain the same genetic information and the remarkable 
cellular diversity is achieved through the differential regulation of genes. Cells 
respond to environmental and intracellular signalling by regulating the 
expression of their genes. Gene expression in higher eukaryotes is known to be 
regulated at multiple stages including: transcription, pre-mRNA processing 
(such as the addition of the 7-methylguanosine cap at the 5’ end of mRNA), 
mRNA nuclear export and mRNA translation (Orphanides and Reinberg, 2002). 
The tight regulation of gene expression is required for normal cell proliferation. 
Consequently, deregulated gene expression can lead to abnormal cell 
proliferation and is often found to be associated with cancer (White, 2008, 
Blagden and Willis, 2011, Silvera et al., 2010). 
Following transcription by RNA Polymerase (Pol) II, pre-mRNAs undergo a 
series of processing events which result in the production of mature translatable 
mRNA. The addition of the 7-methylguanosine cap (methyl cap) at the 5’ end of 
mRNA is the first pre-mRNA processing event to occur. The methyl cap is 
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known to be essential for efficient gene expression and cell viability. This thesis 
focuses on investigating whether targeting the methyl cap is a viable strategy 
for inhibiting breast cancer cell proliferation. 
This thesis introduction describes the formation and function of the 7-
methylguanosine cap and the deregulation of gene expression in cancer. This 
introduction also describes the development of cancer and particularly focuses 
on breast cancer, which is of special relevancy for this thesis. However, the 
basic processes of the gene expression pathway will first be described in this 
subchapter. 
 
1.1.2 Transcription initiation 
The first step in gene expression is the transcription of DNA into RNA; a 
process which occurs in the nucleus. RNA Pol II is the multi-subunit enzyme 
which is responsible for the transcription of mRNAs, some micro RNAs and 
some small nuclear RNAs (snRNAs). The formation of a transcription 
competent RNA Pol II complex at the gene promoter is essential for the 
initiation of transcription. The large subunit of RNA Pol II contains a carboxyl-
terminal domain (CTD) which consists of heptad repeats of the sequence Tyr-
Ser-Pro-Thr-Ser-Pro-Ser (52 repeats in mammals) and it is essential for RNA 
Pol II function (Hsin and Manley, 2012, Bartolomei et al., 1988). Several 
residues of the CTD heptad repeats are dynamically phosphorylated during 
transcription, with serine 2 and 5 being the best characterised. Serine 5 
phosphorylation is mediated by the kinase subunit of Transcription Factor II 
Human (TFIIH) and is primarily detected in gene promoters (Trigon et al., 1998, 
Komarnitsky et al., 2000b). Serine 2 CTD phosphorylation is mediated by the 
kinase subunit of Positive Transcription Elongation Factor b complex (PTEFb) 
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and it is found predominately in gene bodies (Marshall et al., 1996, Komarnitsky 
et al., 2000b). Following transcription initiation, the CTD is phosphorylated on 
serine 5 and RNA Pol II subsequently pauses at promoter proximal sites. RNA 
Pol II pausing is known to be an important event in the control of transcription 
(Saunders et al., 2006, Adelman and Lis, 2012). The CTD phosphorylation of 
serine 2 then stimulates RNA Pol II to release from pausing, thereby allowing 
transcription elongation to proceed (Egloff and Murphy, 2008, Zhou et al., 
2012). The phosphorylated CTD serves as a binding platform for several pre-
mRNA processing proteins, including the enzymes which form the mRNA 
methyl cap, thereby recruiting these proteins to the transcript (Komarnitsky et 
al., 2000b, Buratowski, 2009). These proteins have changing affinities for the 
CTD according to its phosphorylation pattern, thus allowing different proteins to 
be recruited to the mRNA at different stages of transcription (Komarnitsky et al., 
2000b, Darnell, 2013).  
 
1.1.3 pre-mRNA processing  
A series of pre-mRNA processing events result in the production of mature 
translatable mRNA. These events include: the addition of 7-methylguanosine 
cap at the 5’ end of mRNA, splicing out of introns and the formation of a 3’ poly 
(A) tail. Historically, it was believed that these pre-mRNA processing events 
were a linear series of unconnected events; however, emerging evidence 
indicates that these events are interconnected and can influence the efficiency 
of one another (Darnell, 2013). It is likely that the dynamic recruitment of the 
pre-mRNA processing proteins to the RNA pol II CTD coordinates these 
processing events (Orphanides and Reinberg, 2002, Proudfoot et al., 2002). 
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The first pre-mRNA processing event to occur is the addition of the 7’ 
methylguanosine cap structure to the 5’ end of mRNA. The methyl cap is found 
on most, if not all, eukaryotic mRNAs. There is considerable evidence that 
mRNA capping influences the efficiency of other pre-mRNA processing events 
such as: splicing, polyadenylation and mRNA export (Hocine et al., 2010). The 
formation of the methyl cap and the role of the methyl cap in gene expression 
are described in detail later in this introduction. 
Splicing is the process by which non-coding sequences (introns) are removed 
and the coding sequences (exons) are joined together. Splicing is catalysed by 
the splicesome; which is a large ribonucleoprotein (RNP) complex consisting of 
U1, U2, U4, U5, U6 smaller nuclear RNPs and an additional 150 proteins (Stark 
and Luhrmann, 2006). Since several splicing proteins associate with the 
phosphorylated CTD of RNA pol II, it is likely that splicing occurs predominately 
co-transcriptionally (Braunschweig et al., 2013, Hsin and Manley, 2012). 
The final pre-mRNA processing event is polyadenylation. Polyadenylation is a 
two-step event which involves the endonucleolytic cleavage of the pre-mRNA at 
the 3’ end, approximately 10-30 nucleotides downstream of a AAUAAA signal 
sequence, followed by the addition of a poly(A) tail onto the cleaved 3’ end 
(Colgan and Manley, 1997). Polyadenylation is catalysed by a large complex of 
proteins, of which several are recruited to the pre-mRNA by the CTD of RNA pol 
II (Shi et al., 2009). Polyadenylation is required for efficient mRNA transcription, 
mRNA export and mRNA translation (Weill et al., 2012, Hsin and Manley, 
2012). Following polyadenylation, the mature mRNA is exported to the 




1.1.4 Translation initiation 
The translation of mRNA into protein is the final step in gene expression. mRNA 
translation consists of three main stages: initiation, elongation and termination. 
Although each of these stages are regulated to some degree, translation is 
predominately regulated at the initiation stage in which the 43S pre-initiation 
complex associates with the methyl cap at the 5’ end of mRNA. This association 
is mediated by the eIF4F complex which consists of: (1) eIF4E, an mRNA 5’ cap 
binding protein, (2) eIF4G, a scaffold protein and (3) eIF4A, an ATP-dependent 
RNA helicase. The binding of the eIF4F complex to the 5’ mRNA methyl cap is 
essential for the efficient cap-dependent translation of most cellular mRNAs. 
The 43S pre-initiation complex consists of the 40S ribosomal subunit, the eIF2-
GTP-Met-tRNA ternary complex, eIF3, eIF1, eIF1A and most likely eIF5. The 
recruitment of the 43S pre-initiation complex to mRNA is aided by the 
association of eIF4G with eIF3 and eIF4E. Once recruited to mRNA, the 43S 
pre-initiation complex scans the mRNA downstream of the 5’ methyl cap until it 
finds the initiation codon. After the dissociation of several translation factors, the 
60S ribosomal subunit joins to form the 80S translation initiation complex and 
translation elongation subsequently initiates (Jackson et al., 2010, Merrick, 
2004, Sonenberg and Hinnebusch, 2009, Gingras et al., 1999). 
Although the translation of most mRNAs is dependent on the mRNA methyl 
structure, a subset of cellular mRNAs can be translated by a distinct mechanism 
which is independent of the methyl cap. It has been proposed that these 
mRNAs recruit the 43S pre-initiation complex near, or directly to, the initiation 
start codon using secondary structures elements within their 5’ untranslated 
region (UTR) called internal ribosomal entry sites (IRES). Several cellular IRES-
containing mRNAs have been described and these mRNAs often contain 
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complex secondary structure in their 5’ UTR (Macejak and Sarnow, 1991, 
Stoneley and Willis, 2004, Johannes et al., 1999). In optimal growth conditions, 
cap-dependent mRNA translation predominates and IRES-dependent 
translation is rather inefficient. However, the repression of cap-dependent 
translation during states of cellular stress results in a large pool of available 
ribosomes and translation initiation factors to translate IRES-containing mRNAs. 
Cellular stress conditions which supress mRNA translation include: hypoxia, 
apoptosis, nutrient limitation and viral infection (Holcik and Sonenberg, 2005, 
Stoneley and Willis, 2004, Svitkin et al., 2005a, Liwak et al., 2012). Moreover, 
the availability of eIF4E has been implicated in the switch from cap-dependent 
to IRES-dependent translation (Braunstein et al., 2007, Miskimins et al., 2001, 
Dyer et al., 2003, Svitkin et al., 2005b). 
Interestingly, many proteins that can be translated via IRES elements are 
known regulators of cell survival, proliferation or death (Liwak et al., 2012, 
Komar and Hatzoglou, 2011, Holcik and Sonenberg, 2005, Miskimins et al., 
2001). For example the tumour suppressor p53, which regulates cell cycle 
progression and apoptosis, can be translated in an IRES-dependent manner 
(Halaby and Yang, 2007, Ray et al., 2006, Yang et al., 2006). However, it is 
important to note that the full spectrum of endogenous mammalian mRNAs 
which are translated via an IRES element remains unknown. 
The exact mechanisms of cellular IRES-mediated translation remains poorly 
understood, but it thought that IRES-containing mRNAs can be translated by 
different mechanisms. That is, IRES-containing mRNAs have different 
requirements for ITAFs (IRES trans-acting factors), which are RNA-binding 
proteins that can either enhance or repress IRES activity, and for the canonical 
translation initiation factors. Potential mechanisms for the translation of cellular 
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IRES-containing mRNAs include: (1) most, if not all, the canonical translation 
initiation factors and several ITAF are required; (2) a few canonical factors and 
ITAFs are required; (3) canonical factors are not necessary, but some ITAFs 
are required (Komar and Hatzoglou, 2011, Stoneley and Willis, 2004). 
 
1.2 Methyl cap structures 
The 7-methylguanosine cap structure (termed Cap0) (Figure 1.1) was first 
identified on eukaryotic viral mRNA and was subsequently found on eukaryotic 
mRNA (Furuichi and Miura, 1975, Furuichi et al., 1975). The 7-methylguanosine 
cap structure consists of an inverted guanosine group that is linked to the first 
transcribed nucleotide, via a 5’-5’ triphosphate linkage, and is methylated at the 
N-7 position (Figure 1.1). The 7-methylguanosine cap is found at the 5’ end of 
eukaryotic mRNAs and eukaryotic viral RNA, but it is absent from bacterial and 
archaeal RNA (Furuichi and Shatkin, 2000, Shatkin, 1976, Shuman, 2002).  
Additional cap structures have been identified in which the methyl cap structure 
is further methylated at the 2’-O ribose position of the first and second 
nucleotide (termed Cap1 and Cap2, respectively) (Figure 1.1). Cap1 and Cap2 
containing mRNAs are present in higher eukaryotes (including humans) but are 
absent in lower eukaryotes (including yeast). Despite the enzymatic activities for 
Cap1 and Cap2 methylation being identified in human cell extracts over 30 
years ago (Langberg and Moss, 1981), the enzymes which catalyse 2’-O ribose 
methylation in humans  were only recently identified (Belanger et al., 2010, 
Werner et al., 2011). Evidence indicates that 2’-O-ribose methylation of the first 
transcribed nucleotide occurs in the nucleus, whereas 2’-O-ribose methylation 
of the second nucleotide occurs in the cytoplasm (Langberg and Moss, 1981, 
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Furuichi and Shatkin, 2000). The exact mechanisms by which Cap1 and Cap2 







Figure 1.1 The methyl cap structures (Cap0, Cap1, Cap2) of eukaryotic 
mRNA 
a) The 7-methylguanosine cap (Cap0) consists of an inverted guanosine group 
linked to the first transcribed nucleotide via a 5’-5’ triphosphate linkage and is 
methylated at the N-7 position (shown in red).  
b) Cap1 and Cap2 are methylated at the N-7 position and are further 
methylated at the 2-0’ ribose of the first and second nucleotide, respectively.  
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1.3 Enzymology of 7-methylguanosine cap formation 
The 7-methylguanosine cap structure at the 5’ end of mRNA is formed by three 
sequential enzymatic activities. Firstly, the 5’ RNA triphosphatase hydrolyses 
the terminal phosphate from the 5’ nascent RNA to produce a diphosphate end. 
Next, the RNA guanylyltransferase catalyses the addition of a guanosine 
monophosphate (GMP) to the diphosphate RNA end via a two-step reaction. In 
the first step, the enzyme reacts with the α phosphate of guanosine 
triphosphate (GTP) to form a covalent GMP-enzyme complex. In the second 
step, the enzyme adds the GMP to the diphosphate RNA end to form the 
guanosine cap. To finalise the 7-methylguanosine structure, the RNA 
methyltransferase transfers a methyl group from S-adenosylmethionine (SAM) 
to the N-7 position of the guanosine cap and releases S-adenosylhomocysteine 
(SAH) (Shuman, 2002, Furuichi and Shatkin, 2000). The enzymology of 7-
methylguanosine cap formation is shown in Figure 1.2.  
The biochemical reactions involved in 7-methylguanosine cap (methyl cap) 
formation were initially elucidated using viral capping systems (Furuichi and 
Shatkin, 2000, Shuman, 2002, Shatkin, 1976), but for the purpose of this thesis, 
only eukaryotic capping systems will be described further in this introduction. 
The three enzymatic activities (triphosphatase, guanylyltransferase, 
methyltransferase) required for the formation of the methyl cap are conserved 
across all eukaryotes, but there are differences in the way the enzymes are 
configured. The capping enzymes found in Saccharomyces cerevisiae, 
Schizosaccharomyces pombe and Homo sapiens are summarised in Table 1.1. 
In lower eukaryotes, such as yeast, the three activities are found in three 
distinct proteins (Table 1.1) (Shibagaki et al., 1992, Tsukamoto et al., 1997, 
Mao et al., 1995, Shuman et al., 1994, Pei et al., 2001). Whereas, in higher 
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eukaryotes, such as mammals and other metazoa, the RNA triphosphatase and 
guanylyltransferase activities reside in a bi-functional protein and the RNA 
methyltransferase activity reside in a separate protein. In humans, the capping 
enzyme (RNGTT) contains both RNA triphosphatase and guanylyltransferase 
activities and RNA guanine 7-methyltransferase (RNMT) contains 
methyltransferase activity (Yokoska et al., 2000, Tsukamoto et al., 1998a, 
Tsukamoto et al., 1998b, Yue et al., 1997, Pillutla et al., 1998a, Shuman, 2002, 
Saha et al., 1999).  
The capping enzymes in yeast and humans are essential for methyl cap 
formation and cell viability (Wang and Shuman, 1997, Mao et al., 1995, 
Tsukamoto et al., 1997, Chu and Shatkin, 2008, Shafer et al., 2005b). The fact 
that the yeast capping enzymes can be functionally replaced by the mammalian 
capping enzymes suggests that the capping enzymes are functionally 
conserved from yeast to humans (Saha et al., 1999, Yue et al., 1997).  
The entire 7-methylguanosine cap structure can be removed by several well-
characterised decapping enzymes (Chang et al., 2012, Wang et al., 2002, Song 
et al., 2010, Arribas-Layton et al., 2013). To date, there is no experimental 
evidence to suggest that the methyl cap can be demethylated and that a cap 




Figure 1.2 Enzymatic synthesis of the mRNA 7-methylguanosine cap 
The synthesis of the 7-methylguanosine cap is described in the text. The 
enzymatic reactions are shown on the left and the reactions are graphically 
illustrated on the right. RNGTT and RNMT are the human capping enzymes. 
RNGTT contains both triphosphatase and guanylyltransferase activity. RNMT 
contains methyltransferase activity. The guanylyltransferase reaction is 





Table 1.1 Enzymes which synthesise the 7-methylguanosine cap in yeast 
and humans 
The 7-methylguanosine cap in eukaryotes is formed by three sequential 
enzymatic activities (RNA triphosphatase, RNA guanylyltransferase and RNA 
methyltransferase). The proteins which contain these activities in Homo sapiens 
and the yeast species Saccharomyces cerevisiae and Schizosaccharomyces 
pombe are indicated. 
 
1.4 The human mRNA cap methyltransferase complex 
As mentioned above, the final step in methyl cap formation is the transfer of a 
methyl group from SAM to the guanosine cap at the N-7 position (Figure 1.2). 
Human RNA cap methyltransferase activities were first isolated from HeLa cells 
extracts (Ensinger and Moss, 1976) and RNMT, the human RNA cap 
methyltransferase, was subsequently identified based on sequence homology 
to Abd1, the S. cerevisiae cap methyltransferase (Pillutla et al., 1998b, 
Tsukamoto et al., 1998b). RNMT is only able to methylate a GTP group 
attached to RNA (Cowling lab, unpublished) and RNMT expression is essential 
for cellular cap methylation. Since RNMT expression is required for efficient 
gene expression and cell viability, it is likely that there are no other cellular RNA 
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methyltransferases that can compensate for the loss of cellular RNMT  (Chu 
and Shatkin, 2008, Shafer et al., 2005a, Aregger and Cowling, 2013, Cowling, 
2009a, Gonatopoulos-Pournatzis et al., 2011).  
Our laboratory recently discovered that RNMT exists in a complex with a novel 
protein RAM (RNMT activating-mini protein). This RNMT-RAM hetero-dimer 
complex is termed the human mRNA cap methyltransferase complex (Figure 3). 
It has been observed that RAM enhances RNMT activity in vitro up to 5-fold and 
RAM expression is essential for cellular cap methylation, efficient gene 
expression and cell viability. Moreover, it has been shown that RAM is an RNA-
binding protein and promotes the recruitment of RNA to RNMT(Gonatopoulos-
Pournatzis et al., 2011). RNMT and RAM are predominately localised to the 
nucleus (Gonatopoulos-Pournatzis and Cowling, 2014, Gonatopoulos-
Pournatzis et al., 2011). RNMT contains three nuclear localisation signals and 
RAM contains two PY nuclear localisation signals, which ensure their correct 
cellular localisation (Gonatopoulos-Pournatzis et al., 2011, Shafer et al., 2005b, 
Wen and Shatkin, 2000, Gonatopoulos-Pournatzis and Cowling, 2014). It has 
been shown that a cytosolic enzymatically active mutant of RNMT is unable to 
rescue loss of cell viability caused by depletion of endogenous RNMT. Hence, 
the nuclear localisation of RNMT is necessary for its cellular functions (Shafer et 






Figure 1.3 The human mRNA cap methyltransferase complex 
The human mRNA cap methyltransferase complex consists of RNMT (which 
contains RNA cap methyltransferase activity) and its activating subunit RAM 
(RNMT-activating miniprotein). RNMT catalyses the transfer of a methyl group 
from SAM to the N-7 position of the guanosine cap. 
 
1.5 7-methylguanosine cap formation occurs co-
transcriptionally 
There is increasing evidence that formation of the cap occurs predominately, if 
not entirely, co-transcriptionally (Figure 1.4). Data suggest that nascent RNA is 
capped and subsequently methylated as soon as it emerges from RNA pol II 
(Furuichi and Shatkin, 2000). As described above, RNA pol II is recruited to 
genes with the CTD hypophosphorylated and it is phosphorylated during, or 
soon after, transcription initiation (Cadena and Dahmus, 1987, Laybourn and 
Dahmus, 1990, Lu et al., 1991). CTD serine 5 phosphorylation is associated 
with the initiation of transcription, whereas CTD serine 2 phosphorylation is 
primarily associated with transcription elongation (Marshall et al., 1996, 
Komarnitsky et al., 2000b, Trigon et al., 1998). Evidence suggest that the 
phosphorylated CTD acts as a binding platform for the mRNA capping 
enzymes, thereby recruiting these proteins to the nascent transcript 
(Komarnitsky et al., 2000b, Buratowski, 2009). Several studies have shown that 
the methyl cap is formed very early in transcription and it is thought that the 
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capping enzymes are recruited during, or soon after, transcription initiation 
(Rasmussen and Lis, 1993, Mandal et al., 2004b, Chiu et al., 2002, Glover-
Cutter et al., 2008a, Schroeder et al., 2000, Komarnitsky et al., 2000b). The fact 
that methyl cap formation is faster on RNA that is being actively transcribed, 
compared to RNA alone, suggests that mRNA capping and transcription 
initiation are functionally coupled (Moteki and Price, 2002). The CTD of RNA II 
plays an important role in the formation of the methyl cap. For example, it has 
been shown that RNA Pol II is essential for efficient mRNA capping and the 
phosphorylated CTD enhances the recruitment of the capping enzymes to 
nascent RNA. (McCracken et al., 1997). Moreover, the phosphorylated CTD of 
RNA Pol II has been demonstrated to interact with the triphosphatase and 
methyltransferase in yeast (McCracken et al., 1997, Cho et al., 1997) and the 
mammalian capping enzyme (Yue et al., 1997, Ho et al., 1998, Ghosh et al., 
2011, McCracken et al., 1997). A direct interaction between the mammalian cap 
methyltransferase and RNA Pol II remains controversial. Although it has been 
reported that RNMT does not interact directly with RNA Pol II (Shatkin and 
Manley, 2000, Pillutla et al., 1998b), recent experiments in our laboratory have 
demonstrated an interaction (Cowling, unpublished). Moreover, one study 
reported that RNMT, the human cap methyltransferase, associates with RNA 
Pol II via an interaction with the capping enzyme (Pillutla et al., 1998b). A recent 
study from our lab has demonstrated the N-terminus non-catalytic domain of 
RNMT mediates its recruitment to transcription initiation sites. It was observed 
that the recruitment of RNMT to chromatin is inhibited by 5,6-dichloro-1-beta-D-
ribofuranosylbenzimidazole (DRB), a RNA Pol II phosphorylation inhibitor, 
which suggests that RNMT interacts with RNA pol II at least indirectly (Aregger 
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and Cowling, 2013). The precise mechanisms by which RNMT is recruited to 
either transcription initiation sites, or to the transcripts, remains to be elucidated.  
 
Figure 1.4 7-methylguanosine cap formation occurs co-transcriptionally 
RNA pol II is recruited to genes with its CTD hypophosphorylated. Shortly after 
the initiation of transcription, TFIIH phosphorylates the CTD on Ser-5. It is 
thought that the capping enzymes (RNGTT and RNMT) associate with the 
phosphorylated CTD, thereby recruiting these enzymes to the 5’ end of nascent 
RNA. RNGTT (human capping enzyme) and RNMT-RAM (human mRNA cap 
methyltransferase complex). 
 
1.6 The regulation of mRNA cap methylation 
The formation of the methyl cap was long thought to be a constitutive process, 
however, emerging evidence indicates that it is regulated (Ho and Shuman, 
1999, Wen and Shatkin, 2000, Wen and Shatkin, 1999b, Schwer et al., 2000, 
Cowling and Cole, 2007, Fernandez-Sanchez et al., 2009a, Cole and Cowling, 
2009). For the purpose of this introduction only the regulation of mRNA cap 
methylation will be described further. During mRNA cap methylation, the RNA 
methyltransferase catalyses the transfer of a methyl group from the methyl 
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donor SAM to the N-7 position of the guanosine cap. Known regulators of 
mRNA cap methylation either increase the recruitment of the methyltransferase 
to the transcript, or increase the efficiency of the methyltransferase capping 
reaction (Cowling, 2009b).  
Since transcripts lacking the methylated cap accumulate under amino acid and 
glucose starvation in S. cerevisiae, it is possible that nutrient availability 
regulates mRNA cap methylation in yeast (Jiao et al., 2010). The human 
transcription factors E2F1 and c-Myc, which stimulate cell growth in response to 
growth factors, have been observed to increase cap methylation on specific 
human transcripts (Figure 1.5) (Fernandez-Sanchez et al., 2009b, Cole and 
Cowling, 2009, Cowling and Cole, 2007, Aregger and Cowling, 2012). The Myc 
proteins (c-Myc and N-Myc) are known to be essential for cell growth and 
proliferation. c-Myc is a well-established oncoprotein and its expression is 
deregulated in an estimated 70% of human cancers. The c-Myc proteins are 
transcription factors which regulate transcription in a gene-specific manner; 
typically they repress, or activate, genes by 1.5-2-fold (Dang, 2012, Felsher and 
Bishop, 1999, Cowling and Cole, 2006). Myc promotes the cap methylation of 
several transcripts; including most Myc transcriptionally regulated genes, as 
well as some non-transcriptionally regulated genes. Interestingly, the 
upregulation of mRNA cap methylation by c-Myc is independent of its ability to 
transcriptionally regulate genes (Cowling and Cole, 2007). As shown in Figure 
1.5, Myc upregulates cap methylation by two distinct mechanisms. The first 
mechanism involves an upregulation of RNA Pol II CTD phosphorylation (serine 
5). As described earlier, the kinase subunit of TFIIH phosphorylates the CTD of 
RNA Pol II at serine 5. It has been observed that Myc binds directly to TFIIH 
and enhances its recruitment to transcription initiation sites, thus increasing 
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serine 5 CTD phosphorylation and enhancing the recruitment of the capping 
enzymes. For the transcripts tested, this correlates with enhanced 7-
methylguanosine cap formation and protein translation (Cowling and Cole, 
2007). It is likely that any protein which upregulates serine 5 CTD 
phosphorylation will enhance the formation of the mRNA methyl cap.  
The second mechanism by which c-Myc upregulates cap methylation involves 
the increased expression of the enzyme S-adenosyl homocysteine hydrolase 
(SAHH). All methylation reactions convert SAM into S-adenosyl homocysteine 
(SAH), which inhibits methylation reactions (Chiang et al., 1996). Our laboratory 
discovered that Myc upregulates the expression of SAHH, an enzyme which 
catalyses the hydrolysis of SAH into adenosine and homocysteine, thus 
neutralising the inhibitory effect of SAH. The upregulation of SAHH by c-Myc is 
essential for Myc-induced mRNA cap methylation, protein synthesis, cell 
proliferation and cell transformation. These observations demonstrate that Myc-
induced methyl cap formation is a crucial function of Myc. Strikingly, it was 
observed that inhibition of cap methylation selectively inhibits the proliferation of 
cells with elevated c-Myc expression, suggesting that targeting mRNA cap 
methylation could be an effective strategy to inhibit upregulated c-Myc function 















Figure 1.5 Myc and E2F1 upregulate 7-methylguanosine cap formation 
The 7-methylguanosine cap is formed co-transcriptionally. Shortly after the 
initiation of transcription, TFIIH phosphorylates the CTD on Ser 5. It is thought 
the capping enzymes interact with the phosphorylated CTD, thereby recruiting 
these enzymes to the 5’ end of nascent RNA. Myc and E2F1 upregulate methyl 
cap formation by enhancing the recruitment of TFIIH. Myc can also promote 
methyl cap formation via a second mechanism, whereby Myc enhances the 
expression of SAHH, which removes the inhibitory by-product of cap 
methylation, SAH. SAH is hydrolysed into adenosine and homocysteine. 
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1.7 Functions of the 7-methylguanosine cap in gene 
expression 
The 7-methylguanosine cap structure at the 5’ end of mRNA is essential for cell 
viability and efficient gene expression. The methyl cap is known to promote 
several steps in the gene expression pathway. For example, the methyl cap is 
essential for the translation of most mRNAs and it is reported to protect mRNA 
from degradation and to enhance transcription, splicing, polyadenylation and 
mRNA nuclear export (Figure 1.6) (Furuichi and Shatkin, 2000). The functions 
of the methyl cap are mostly mediated by proteins which bind the mRNA methyl 
cap. The cap binding complex (CBC) and eukaryotic translation initiation factors 
4E (eIF4E) are the most well-characterised cap binding proteins (Topisirovic et 
al., 2011). Although, it is important to note that other cap binding proteins have 
been reported, such as poly(A)-specific ribonuclease and pumilio2 (Dehlin et al., 







Figure 1.6 Functions of the 7-methylguanosine cap in gene expression 
The 7-methylguanosine cap is essential for the translation of most mRNAs and 
for efficient gene expression and cell proliferation. This schematic illustrates the 
main functions of the 7-methylguanosine cap in gene expression. These 
functions include promoting RNA stability, mRNA transcription, pre-mRNA 
splicing, pre-mRNA 3’ end processing, mRNA export and mRNA translation. 
These functions of the cap are predominately mediated by two cap-binding 
proteins: eIF4E and CBC (described in detail in the text).  
 
1.7.1 The 7-methylguanosine cap stabilises RNA 
Soon after the discovery of the 7-methylguanosine cap it was shown that the 
methyl cap functions to stabilise RNA. Methyl capped RNA is more stable, 
compared to uncapped RNA, when microinjected into X. laevis, or incubated 
with wheat germ extracts (Furuichi et al., 1977, Green et al., 1983, Shimotohno 
et al., 1977). The mRNA methyl cap structure promotes RNA stability by acting 
as a blocking structure, thereby protecting the transcript from exoribonucleolytic 
degradation (Shimotohno et al., 1977, Inoue et al., 1989, Murthy et al., 1991).  
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Although the methyl cap has been shown to stabilise transcripts, this function is 
not observed in all cellular systems. It is likely that the role of the methyl cap in 
mRNA stability is species specific, or gene specific (Grudzien et al., 2006, 
Schwer et al., 2000, Furuichi et al., 1977, Fresco and Buratowski, 1996, Schwer 
and Shuman, 1996, Schwer et al., 1998). Moreover, the cap-binding proteins 
CBC and eIF4E function to further enhance the stability of RNA by competing 
with the decapping enzymes for binding to the methyl cap (Jiao et al., 2013, 
Grudzien et al., 2006, Gonatopoulos‑Pournatzis and Cowling, 2014, Schwartz 
and Parker, 2000).  
 
1.7.2 The cap-binding proteins 
1.7.2.1 The cap-binding complex 
The cap-binding complex (CBC) is a hetero-dimer composed of the subunits 
CBP20 and CBP80. The CBC was first purified from cell extracts on the basis of 
its ability to specifically bind the 7-methylguanosine cap at the 5’ end of mRNA 
(Izaurralde et al., 1994, Izaurralde et al., 1995). Although structural and 
mutational studies have demonstrated that the CBP20 subunit contains the 
methyl cap binding pocket, both subunits of the CBC are required for binding to 
the methyl cap at the 5’end of mRNA (Izaurralde et al., 1994, Izaurralde et al., 
1995, Kataoka et al., 1995, Calero et al., 2002, Mazza et al., 2001). The CBC 
binds to the methylated cap with greater affinity compared to the non-
methylated cap, which suggests that cap methylation is important for efficient 
binding of the methyl cap to CBC. It is known that the CBC is required for cell 
growth and promotes several steps in gene expression (Fortes et al., 1999, Das 
et al., 2000, Narita et al., 2007). Since several studies have observed that the 
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CBC recruits several pre-mRNA processing proteins to the transcript (Pabis et 
al., 2013, Narita et al., 2007, Merz et al., 2007, Flaherty et al., 1997), it is likely 
that the CBC complex predominately mediates its effect on gene expression 
through the recruitment of other proteins. As shown in Figure 1.7, several 
functions of the 7-methylguanosine cap are mediated by the CBC. 
 
1.7.2.2 The eukaryotic translation initiation factor 4E (eIF4E) 
The translation of most mRNAs is dependent on the 7-methylguanosine cap 
structure at the 5’ end of mRNA. As described above, the main regulatory step 
in cap-dependent translation initiation is the association of the 43S pre-initiation 
complex with the 7-methylguanosine cap. This association is mediated by the 
eIF4F complex which consists of (1) eIF4E, the cap-binding protein, (2) eIF4G, 
the scaffold protein and (3) eIF4A, the ATP-dependent RNA helicase 
(Sonenberg and Hinnebusch, 2009, Gingras et al., 1999). eIF4E is a 24kDa 
protein that specifically binds the methyl cap, thereby recruiting the eIF4F 
complex to the 5’ end of the mRNA. The structure of the mammalian eIF4E 
bound to the 7-GpppG cap analogue has been determined by X-ray 
crystallography and biophysical methods (Niedzwiecka et al., 2002, 
Marcotrigiano et al., 1997). The methyl cap binds to eIF4E with much higher 
affinity compared to the non-methylated cap, which indicates that cap 
methylation is important for the eIF4E-methyl cap interaction (Niedzwiecka et 
al., 2002, von der Haar et al., 2004).  
There is considerable evidence that expression of eIF4E is rate-limiting for cap-
dependent translation (De Benedetti et al., 1991, Duncan et al., 1987, Hiremath 
et al., 1985). The interaction between eIF4E and the methyl cap enhances 
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mRNA translation by promoting the recruitment of translation machinery to the 
5’ end of mRNA (Sonenberg et al., 1979, Sonenberg et al., 1980). eIF4E is an 
essential component of the translation machinery, but its overexpression only 
modestly increases global protein synthesis, while strongly enhancing the 
translation of a subset of eIF4E-dependent mRNAs (Koromilas et al., 1992, De 
Benedetti and Harris, 1999, Rosenwald et al., 1993, Shantz and Pegg, 1994, 
Kevil et al., 1995). Several studies have shown eIF4E overexpression to be 
oncogenic both in vitro and in vivo (Lazaris-Karatzas et al., 1990, De Benedetti 
and Rhoads, 1990, De Benedetti and Graff, 2004, Ruggero et al., 2004, Wendel 
et al., 2004b). As shown in Figure 1.7, eIF4E mediates several functions of the 
methyl cap. The regulation of eIF4E activity and the role of eIF4E in cancer will 








Figure 1.7 Cap-binding proteins mediate most of the functions of the 7-
methylguanosine cap 
Most of the functions of the 7-methylguanosine cap are mediated by two cap-
binding proteins: CBC and eIF4E. CBC (CBP20 and CBP80) promotes 
transcription, pre-mRNA splicing, pre-mRNA 3’ end processing and mRNA 
nuclear export. eIF4E binding to the 7-methylguanosine cap is essential for the 
translation of most mRNAs. eIF4E also promotes mRNA stability and nuclear 
export. The 7-methylguanosine cap structure itself stabilises RNA. 
 
1.7.3 The 7-methylguanosine cap is required for cap-dependent 
translation 
From yeast to humans, the methyl cap structure is essential for the translation 
of most mRNAs. Soon after the discovery of the methyl cap, in vitro 
experiments demonstrated that mRNA translation is dependent on the methyl 
cap structure (Muthukrishnan et al., 1975, Zan-Kowalczewska et al., 1977, 
Shimotohno et al., 1977). The methyl cap has also been shown to be essential 
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for mRNA translation in vivo. Methyl capped RNA injected into X. laevis oocytes 
are translated more efficiently compared to guanosine capped RNA and this 
effect was not due to increased transcript stability (Gillian-Daniel et al., 1998, 
Drummond et al., 1985).The binding of eIF4E to the methyl cap is essential for 
efficient cap-dependent translation (Sonenberg et al., 1978, Sonenberg et al., 
1979, Altmann et al., 1985, Altmann et al., 1987, Sonenberg et al., 1980). Since 
the methylation of the guanosine cap enhances eIF4E binding to the methyl 
cap, it is likely that cap methylation promotes mRNA translation. Indeed, the 
methylation of the guanosine cap is essential for the translation of mRNA in cell-
free systems (Both et al., 1975, Weber et al., 1977, Filipowicz, 1978). Moreover, 
inactivation of the RNA methyltransferase in yeast leads to a robust decrease in 
protein synthesis without a corresponding decrease in transcript stability 
(Schwer et al., 2000). Although it has been reported that depletion of cellular 
RNMT does not significantly impact global protein synthesis, it was found that a 
subset of mammalian transcripts are highly dependent on mRNA cap 
methylation for their translation (Cowling, 2009a). The full spectrum of mRNAs 
which are highly dependent on cap methylation for their translation remains to 
be elucidated.  
 
1.7.5 The 7-methylguanosine cap promotes transcription 
The transcription of eukaryotic genes is a multistep process in which there are 
multiple opportunities for regulation. RNA pol II pauses at promoter-proximal 
sites shortly after the initiation of transcription, and this pausing event is 
important for the control of transcription (Guenther et al., 2007, Rahl et al., 
2010). Since the recruitment of the capping enzymes coincide with this pausing, 
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transcription and the formation of the methyl cap are functionally linked. 
Experiments carried out in the yeast, or in vitro using human proteins, have 
observed that the capping enzyme promotes transcription and can interact with 
proteins that function in transcription (Pei and Shuman, 2002, Lindstrom et al., 
2003, Wen and Shatkin, 1999a, Mandal et al., 2004a). Several lines of evidence 
suggest that the RNA methyltransferase can influence transcription. For 
example, the cap methyltransferase in yeast has been shown to be required for 
the transcription of a subset of genes (Schroeder et al., 2004) and to recruit P-
TEFb to chromatin, which alleviates RNA pol II pausing on chromatin (Guiguen 
et al., 2007). In both yeast, and humans, the RNA methyltransferase co-
localises with paused RNA pol II, and is present both at gene promoters and 
throughout the gene body (Glover-Cutter et al., 2008b, Komarnitsky et al., 
2000a, Schroeder, 2000). Since cap methylation is not required for the 
transcription of a subset of genes in yeast, it is likely that cap methylation 
enhances transcription in a gene-specific manner (Schroeder et al., 2004). 
However, no studies to date, have established how RNMT, the human cap 
methyltransferase, affects the human transcriptome. 
In addition, the methyl cap has the potential to influence transcription via the 
CBC. The CBC, which is located at the 5’ ends of genes and throughout gene 
bodies, promotes transcription in both yeast and mammalian cells (Hossain et 







1.7.6 The 7-methylguanosine cap is required for efficient pre-mRNA 
splicing 
The incubation of in vitro transcribed methyl-capped or uncapped RNA with cell 
extracts demonstrated that the methyl cap is required for efficient splicing 
(Konarska et al., 1984, Edery and Sonenberg, 1985, Ohno et al., 1987, Patzelt 
et al., 1987, Izaurralde et al., 1994). In vivo experiments carried out in X. laevis 
have observed that microinjected methyl-capped RNA is spliced more efficiently 
than uncapped RNA. The splicing of the 5’ proximal intron is reported to be 
highly dependent on the methyl cap structure (Inoue et al., 1989, Ohno et al., 
1987). Extracts in yeast have shown that the methyl cap structure promotes 
splicing in a gene-specific manner (Fresco and Buratowski, 1996, Schwer and 
Shuman, 1996). Moreover, a recent study revealed that for human endogenous 
transcripts the methyl cap not only enhances the splicing of the 5’ proximal 
intron, but also promotes the splicing of subsequent downstream introns (Jiao et 
al., 2013). The full spectrum of mammalian endogenous genes that are 
dependent on the methyl cap for splicing remains to be determined.  
Incubation of in vitro transcribed RNA with the methyl-cap analogues m7Gppp 
and m7GpppG inhibited splicing more efficiently than the cap analogue GpppG, 
which indicates that the effect of the methyl cap on splicing is mediated by a 
methyl cap binding protein (Patzelt et al., 1987, Izaurralde et al., 1994). The 
CBC has been shown to mediate the effects of the methyl cap on splicing. Cell 
extracts depleted of CBC have reduced splicing activity (Izaurralde et al., 1994, 
Lewis et al., 1996, Izaurralde et al., 1995). Furthermore, inhibition of the 
interaction between the CBC and methyl capped RNA in X. laevis reduced 
splicing (Izaurralde et al., 1995).  
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1.7.7 The methylguanosine cap promotes pre-mRNA 3’ end processing 
The methyl cap influences 3’ end processing (which involves endonucleolytic 
cleavage at the poly(A) site followed by the addition of the poly(A) tail). 
Experiments in vitro and in X. laevis have shown that the methyl cap promotes 
endonucleolytic cleavage (Georgiev et al., 1984, Cooke and Alwine, 1996, 
Gilmartin et al., 1988). Furthermore, in mammalian cells, methyl capped RNA is 
cleaved at the poly (A) site much more efficiently than uncapped RNA (Jiao et 
al., 2010). Since the mammalian capping enzymes (RNGTT and RNMT) are 
found to be located at both the 5’ and the 3’ ends of genes, it is possible that the 
capping enzymes influence pre-mRNA 3’ end processing. The fact that a m7G 
cap analogue inhibits 3’ end processing, suggests that a cap binding protein is 
required for 3’ end processing (Glover-Cutter et al., 2008a). Indeed, the CBC is 
required for efficient 3’ pre-mRNA processing in mammalian cells (Flaherty et 
al., 1997), but the precise mechanism of this remains to be elucidated.  
 
1.7.8 The 7-methylguanosine cap promotes nuclear export of mRNA 
The effective nuclear export of microinjected mRNA and snRNA is dependent of 
the methyl cap structure and this effect is mostly mediated by the CBC 
(Izaurralde et al., 1992, Izaurralde et al., 1995, Cheng et al., 2006, Dargemont 
and Kuhn, 1992, Jarmolowski et al., 1994). eIF4E has been observed  to 
promote mRNA export in a gene-specific manner and eIF4E-mediated nuclear 
export of mRNA is dependent of the ability of eIF4E to bind the methyl cap 
(Culjkovic et al., 2005, Rousseau et al., 1996b, Cohen et al., 2001, Strudwick 
and Borden, 2002). The full spectrum of mammalian transcripts that are 
dependent on the methyl cap for nuclear export remains to be elucidated.  
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1.8 Breast cancer 
1.8.1 Introduction to cancer 
Cancers are diseases characterised by the uncontrolled expansion of clonal 
cells. In a landmark paper in 2000, Hanahan and Weinberg proposed that all 
human cancers acquire six hallmark capabilities during cancer development. 
These hallmarks include: sustaining proliferative signalling, evading growth 
suppressors, resisting cell death, activating invasion and metastasis, enabling 
replicative immortality and inducing angiogenesis (Hanahan and Weinberg, 
2000). Recently they proposed an additional two hallmark capabilities: 
reprogramming of energy metabolism and evading immune destruction 
(Hanahan and Weinberg, 2011). The eight hallmarks of cancer are shown in 
Figure 1.8. Although it is believed that cells must acquire these hallmarks to 
achieve a neoplastic state, cells will vary in the mechanism and ordering by 
which they acquire the hallmarks. For example, in some human cancers, the 
acquisition of one particular oncogenic genetic mutation may confer numerous 







Figure 1.8 The hallmarks of cancer 
The eight hallmarks of human cancers. Adapted from (Hanahan and Weinberg, 
2011, Hanahan and Weinberg, 2000). 
  
One of the fundamental properties of cancer cells is their ability to proliferate 
uncontrollably. The growth of normal cells is carefully controlled by the 
production and release of growth signals, which regulate the cell growth and 
division cycle. These growth signals bind to and activate cell-surface receptors 
such as receptor tyrosine kinases (RTKs). These activated receptors are then 
able to release signals via cellular signalling pathways, which regulate key 
cellular processes such as cell growth and cell division. Cancer cells are able to 
induce and sustain hyper-activated proliferative signalling via a number of 
different mechanisms. For example, they can evade growth factor control via 
autocrine signalling whereby they can produce growth factors themselves, thus 
self-activating their own receptors. Alternatively, mutations in components of the 
signalling pathway that are downstream of the receptor can lead to constitutive 
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pathway activation; thereby relieving the need to activate these growth 
pathways via receptor activation. Cancer cells also have mechanisms to evade 
tumour suppressor proteins, which negatively regulate cell proliferation 
(Hanahan and Weinberg, 2000, Hanahan and Weinberg, 2011). For example, 
several cancer genetic studies have shown that tumour suppressors proteins, 
such as TP53 and PTEN, are frequently mutationally inactivated in several 
types of human cancers, such as breast cancer (Sorlie et al., 2001, Carey et al., 
2006, Kan et al., 2010). 
The acquisition of the “hallmarks of cancer” is largely dependent on a 
succession of mutations in the cancer genome. The multistep development of 
cancer involves successive rounds of clonal expansion; with each round being 
triggered by the acquisition of a genetic mutation which confers a selective 
advantage (Lengauer et al., 1998, Hanahan and Weinberg, 2011). It is known 
that not all genetic mutations contribute to cancer development. In fact the 
progression of cancer is a complex interplay of advantageous “driver” 
mutations, neutral “passenger” mutations and deleterious mutations, as well as 
mutations which enhance the rate of mutational change (Stratton et al., 2009). 
Several types of genetic mutations have been identified in human cancers, 
including: subtle sequence changes (for example, base substitutions); 
alterations in chromosome number; chromosome translocations and gene 
amplifications (Lengauer et al., 1998). Clonal expansion may also be initiated by 
non-mutational epigenetic changes that alter gene expression and chromatin 
structure (Berdasco and Esteller, 2010, Hanahan and Weinberg, 2011). 
To ensure that an anti-cancer strategy is selectively toxic to cancer cells, it is 
important to target a unique property of cancer cells which is not shared by 
normal cells. Cancer cells possess genetic mutations that distinguish them from 
33 
 
normal cells. The concept of synthetic lethality can be exploited to specifically 
target cancer cells that contain genetic mutations not present in normal cells. 
Synthetic lethality is defined as a type of genetic interaction in which the 
combination of mutations in two genes results in lethality, but mutation of either 
gene alone has no effect on cell viability. The presence of one of these genetic 
mutations in cancer cells, but not in normal cells, creates an opportunity to 
selectively kill cancer cells by mimicking the effect of the second genetic 
mutation using targeted therapies. Since synthetic lethal targeting will only kill 
cells with the specific cancer associated mutation, this therapeutic strategy 
would most likely have less toxic side effects compared to standard 
chemotherapy strategies (McLornan et al., 2014, Luo et al., 2009, Chan and 
Giaccia, 2011). Significant effort is currently being made to identify synthetic 
lethal interactions for the development of novel targeted anti-cancer therapies. 
Interestingly, studies have revealed that mutations in the genes BRCA1 or 
BRAC2, which are associated with significant risk of breast cancer, display 
synthetic lethality with the DNA repair enzyme poly(adenosine diphosphate 
[ADP]-ribose) polymerase (PARP) (Bryant et al., 2005, Farmer et al., 2005). 
Clinical trials have shown that treatment of patients (whose breast tumours 
contain mutations in BRCA1 and BRCA2) with PARP inhibitors results in an 
anti-tumour response with limited off-target toxicities (Fong et al., 2009, Tutt et 
al., 2010, McLornan et al., 2014).  
Although a diverse range of genetic mutations contribute to the development 
and maintenance of cancer, several studies have shown that cancer cells often 
acquire an increased dependence on a single oncogenic signalling pathway, or 
oncoprotein, for their uncontrolled growth and survival. Strikingly, inactivation of 
the same signalling pathway, or protein, in normal cells causes minimal 
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damage. These experimental observations have led to the development of 
“molecular targeted therapies”, which aim to kill cancer cells by inhibiting the 
molecules selectively essential for cancer survival (Higgins and Baselga, 2011, 
Weinstein, 2002, Weinstein and Joe, 2006). 
 
1.8.2 Breast cancer subtypes  
Breast cancer is the most frequently diagnosed cancer in women worldwide, 
accounting for an estimated 23% (1.38 million) of new cancer cases each year. 
Although significant progress has been made in the diagnosis and treatment of 
breast cancer, the fact remains that it is still the leading cause of cancer death 
in women worldwide, accounting for an estimated 500,000 deaths worldwide 
each year (Jemal et al., 2010, Ferlay et al., 2010). 
Gene expression studies has revealed that breast cancers can be classified into 
the following four main subtypes: luminal A, luminal B, HER2+ (human 
epidermal growth factor receptor 2) and triple negative (TN) breast cancer (also 
known as basal like) (Sorlie et al., 2001, Sorlie et al., 2003, Perou et al., 2000, 
Network, 2012). These main subtypes are heterogeneous in terms of their 
mutational spectrum, prevalence rates, disease progression and response to 
treatment (Carey et al., 2006, van 't Veer et al., 2002, Polyak and Metzger Filho, 
2012). In additional to the four main subtypes, breast cancers can also be 
classified into several other subgroups (Bertos and Park, 2011, Network, 2012). 
Luminal A and B tumours, which represent an estimated 70% of breast cancer 
cases, often express progesterone and estrogen receptors and generally 
respond well to hormone therapy such as tamoxifen. Around 25% of breast 
tumours display amplification/ overexpression of the RTK HER2 and these are 
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classified as HER2+ (Polyak and Metzger Filho, 2012) (Bertos and Park, 2011). 
HER2+ breast cancer patients were previously reported have a poor prognosis, 
but the advent of HER2-targeted therapies, such as the anti-HER2 monoclonal 
antibody trastuzumab, has significantly improved the prognosis of HER2+ 
breast cancer patients (Smith et al., 2007, Carter et al., 1992, Carey et al., 
2006, Slamon et al., 1987, Sorlie et al., 2001). However, the emergence of 
resistance to HER2-targeted therapies is common (Arteaga et al., 2012). Triple 
Negative (TN) breast tumours (also known as basal like), which represent 10% 
of breast cancer cases, predominately lack HER2 overexpression and lack 
expression of the progesterone and estrogen receptors. Currently there are no 
effective therapies for the treatment of TN breast cancer and consequently this 
subtype is associated with poor clinical prognosis (Nielsen et al., 2004, Sorlie et 
al., 2003, Polyak and Metzger Filho, 2012, Sorlie et al., 2001). 
 
1.8.3 Genetic mutations found in breast cancer 
Comprehensive analyses of the breast cancer genome has revealed the most 
frequent genetic mutations found in breast cancer (Stephens et al., 2012, 
Banerji et al., 2012, Kan et al., 2010, Network, 2012, Polyak and Metzger Filho, 
2012). This mutational information has helped identify the key oncogenic 
signalling pathways in breast cancer, which has revealed several new 
therapeutic targets (Higgins and Baselga, 2011, Polyak and Metzger Filho, 
2012). A recent study by the Cancer Genome Atlas Network reported the most 
frequent alterations found in the four main breast cancer subtypes (Luminal A, 
Luminal B, HER2+ and TN) by analysing patient-derived breast tumours using 
exome sequencing, DNA methylation, genomic DNA copy number arrays, 
36 
 
messenger RNA arrays, microRNA sequencing and reverse-phase protein 
arrays (Network, 2012). The main findings from this study are summarised in 
Table 1.2. This study, as well as several others, observed that several 
components of the PI3K-Akt-mTOR signalling pathway (PIK3CA, PTEN, 
INPP4B) are frequency altered in breast tumours. In fact the PI3K pathway is 
the most frequently mutated pathway in breast cancer and an estimated 70% of 
breast tumours display hyper-activated PI3K signalling (Miller et al., 2011, 
Polyak and Metzger Filho, 2012, Network, 2012, Wood et al., 2007, Kan et al., 
2010, Banerji et al., 2012). The impact of PI3K pathway mutations on breast 






Table 1.2 Most common genetic alterations found in human breast 
tumours 
LuA= luminal A, LuB= luminal B, TN=triple negative, HER2= HER2 amplified 
Adapted from (Network, 2012). 
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1.9 Deregulation of mRNA translation in cancer 
The development of cancer involves the deregulation of processes that are 
essential for normal cell growth. The translation of RNA into protein (mRNA 
translation) is a tightly regulated process that is essential for cell growth and 
proliferation. One of the fundamental features of cancer cells is their ability to 
proliferate in a deregulated manner, and the increased proliferation of cancer 
cells is often associated with enhanced mRNA translation, either global or gene-
specific (Johnson et al., 1976, Blagden and Willis, 2011, Silvera et al., 2010). 
The rate-limiting step of mRNA translation is reported to be translation initiation; 
in which the 43S pre-initiation complex associates with the 7-methylguanosine 
(methyl cap) found at the 5’ end of mRNA. This association is mediated by the 
eIF4F complex which consists of: (1) eIF4E, an mRNA 5’ methyl cap binding 
protein, (2) eIF4G, a scaffold protein and (3) eIF4A, an ATP-dependent RNA 
helicase. Oncogenic signalling pathways stimulate mRNA translation through 
the regulation of eIF4F complex assembly and components of the eIF4F 
complex can become oncogenic when overexpressed. The deregulation of the 
eIF4F complex in cancer will be described in this subchapter (Blagden and 
Willis, 2011, Silvera et al., 2010, Gingras et al., 1999, Sonenberg and 
Hinnebusch, 2009).  
 
1.9.1 eIF4E 
eIF4E specifically binds to the mRNA methyl cap, thereby facilitating the 
recruitment of the 43S pre-initiation complex to the 5’ end of mRNA. The 
binding of eIF4E to the methyl cap is essential for mRNA translation. There is 
considerable evidence that expression of eIF4E is rate-limiting for eIF4F 
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complex formation and cap-dependent mRNA translation (De Benedetti et al., 
1991, Duncan et al., 1987, Hiremath et al., 1985). A numbers of studies have 
reported eIF4E to be oncogenic. Exogenous overexpression of eIF4E enhances 
cell proliferation and leads to cell transformation (Lazaris-Karatzas et al., 1990, 
De Benedetti and Rhoads, 1990, De Benedetti and Graff, 2004, Avdulov et al., 
2004). Conversely, depletion of eIF4E expression from cells impairs cell 
proliferation and reverses the eIF4E-mediated oncogenic phenotype (Soni et 
al., 2008). Moreover, mouse studies have observed that eIF4E overexpression 
is sufficient to induce tumorigenesis (Ruggero et al., 2004, Wendel et al., 
2004b). Data has demonstrated that the ability of eIF4E to stimulate mRNA 
translation is required for eIF4E-mediated oncogenesis. For example, 
overexpression of an eIF4E mutant which cannot bind the 5’ methyl cap is 
unable to promote lymphomagenesis in mice (Ruggero et al., 2004) and a 
reduction in the affinity of eIF4E for the methyl cap suppresses oncogenic 
transformation (Cohen et al., 2001). Moreover, overexpression of 4E-BP1, 
which inhibits eIF4E assembly into the eIF4F complex, reverses the eIF4E-
induced transformed phenotype in mammary epithelial cells and rodent 
fibroblasts (Rousseau et al., 1996a, Avdulov et al., 2004) and reduces the 
tumorigenicty of human breast cancer cells injected into nude mice (Avdulov et 
al., 2004). Data from several studies has revealed that eIF4E promotes cell 
proliferation and oncogenesis by enhancing the translation of several mRNAs 
which encode for proteins which stimulates cell growth (Koromilas et al., 1992, 
De Benedetti and Harris, 1999, Rosenwald et al., 1993, Shantz and Pegg, 
1994, Kevil et al., 1995). The full spectrum of these “eIF4E-dependent” mRNAs 
remains unknown, but mRNAs with complex secondary structures in their 5’ 
UTRs have been shown to be strongly dependent on eIF4E expression for their 
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translation (Graff et al., 2007, Koromilas et al., 1992, Kevil et al., 1995, 
Rousseau et al., 1996b). (De Benedetti and Harris, 1999). Moreover, 
overexpression of eIF4E enhances the nuclear export of specific mRNAs and 
this is known to be required for eIF4E-mediated oncogenesis (Rousseau et al., 
1996b, Culjkovic et al., 2005, Cohen et al., 2001, Strudwick and Borden, 2002). 
eIF4E expression is elevated in several types of human cancers such as: 
breast, head and neck, lung and prostate cancer (Li et al., 1998, De Benedetti 
and Harris, 1999, DeFatta et al., 1999, Nathan et al., 2004, Wang et al., 2009, 
Coleman et al., 2009). Since eIF4E overexpression in breast cancer correlates 
with poor clinical outcome and reduced patient survival it is likely that eIF4E 
contributes to human breast cancer (De Benedetti and Harris, 1999, Li et al., 
1997, Li et al., 1998, Scott et al., 1998, Kerekatte et al., 1995, Coleman et al., 
2009). However, eIF4E expression is not always found to be elevated in breast 
cancer (Avdulov et al., 2004). Several strategies to target eIF4E expression/ 
activity in human cancer are currently being explored and these will be 
described in section 1.10. 
 
1.9.2 eIF4G 
eIF4G acts as a scaffold protein and facilitates the recruitment of the 43S pre-
initiation complex to the mRNA via interactions with eIF3 and eIF4E (Gingras et 
al., 1999, Sonenberg and Hinnebusch, 2009). Although not as well studied as 
eIF4E-mediated oncogenesis, eIF4G has been reported to be oncogenic when 
overexpressed. Exogenous overexpression of eIF4G in NIH3T3 cells leads to 
anchorage independent growth and these cells form tumours when injected in 
nude mice (Fukuchi-Shimogori et al., 1997). Moreover, elevated expression of 
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eIF4G enhances tumour formation in a xenograft model of inflammatory breast 
cancer (Silvera et al., 2009). The majority of breast tumours derived from 
patients with advance stage breast cancer, or inflammatory breast cancer, 
exhibit elevated eIF4G expression (Braunstein et al., 2007, Silvera et al., 
2009).The reported overexpression of eIF4G in a subset of human cancers 
provides evidence to support an oncogenic role for eIF4G in human cancer 
(Braunstein et al., 2007, Silvera et al., 2009, Bauer et al., 2001). The interaction 
between eIF4E and eIF4G has been targeted for anti-cancer therapeutics and 
this is described in section 1.10.2. 
 
1.9.3 eIF4A 
eIF4A, an ATP dependent RNA helicase, unwinds the secondary structure in 
the 5’ UTR of mRNA allowing the efficient recruitment of the 43S pre-initiation 
complex to the mRNA (Rogers et al., 1999). An oncogenic role for eIF4A has 
not yet been established (Malina et al., 2012, Silvera et al., 2010), but eIF4A 
mRNA has been shown to be elevated in human melanoma cells and primary 
human hepatocellular carcinomas (Eberle et al., 1997, Shuda et al., 2000). 
Despite eIF4A having no established role in oncogenesis, inhibitors of eIF4A 
have potent anti-cancer activity and are currently in clinical development 






1.9.4 PI3K-Akt-mTOR signalling  
Most human cancers are caused by the hyper-activation of signalling pathways 
which regulate processes essential for cell growth, such as protein synthesis. 
The PI3K-Akt-mTOR signalling pathway is one of the most frequently mutated 
pathways in human cancers. A major downstream target of PI3K is the 
serine/threonine kinase mammalian target of rapamycin (mTOR) (Blagden and 
Willis, 2011, Silvera et al., 2010, Proud, 2007, Rajasekhar et al., 2003). mTOR, 
which is the target of the macrolide rapamycin, regulates cell growth and protein 
synthesis in response to cellular nutrient and energy levels  (Laplante and 
Sabatini, 2012, Sabatini et al., 1994, Sabers et al., 1995). mTOR forms two 
multisubunit complexes : mTORC1 and mTORC2. mTORC1 is known to be 
extremely sensitive to inhibition by rapamycin, whereas mTORC2 is only 
sensitive to chronic rapamycin treatment. mTORC1 can stimulate cap-
dependent translation via the regulation of eIF4F complex formation (Laplante 
and Sabatini, 2012, Ma and Blenis, 2009). 
The regulation of cap-dependent mRNA translation by the PI3K-Akt-mTOR 
signalling pathway is shown in Figure 1.9. The ability of the PI3K pathway to 
stimulate mRNA translation via the activation of mTORC1 is essential for its 
oncogenic capabilities (Hsieh et al., 2010, Skeen et al., 2006). The activation of 
RTKs by mitogenic signals (growth factors, cytokines, hormones) stimulates 
PI3K, which in turn, phosphorylates phosphatidylinositol 4,5 bisphosphate 
(PI(4,5)P2)  to produce phosphatidylinositol 3,4,5- trisphosphate (PI(3,4,5)P3). 
The catalytic activity of PI3K is antagonised by the tumour suppressor 
phosphatase and tensin homolog (PTEN), which dephosphorylates PI(3,4,5)P3 
to produce  PI(4,5)P2  (Myers et al., 1998, Maehama and Dixon, 1998). 
PI(3,4,5)P3 production leads to Akt recruitment and activation (Manning and 
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Cantley, 2007, Liu et al., 2009b). Activated Akt stimulates mTORC1 by two 
mechanisms: (1) inhibiting PRAS40, a negative regulator inhibitor of mTORC1 
activity (2) phosphorylating and inactivating the tuberous sclerosis complex 
(TSC) complex (Inoki et al., 2002, Kovacina et al., 2003, Sancak et al., 2007). 
The TSC complex, which consists of TSC1 and TSC2, functions as a GTPase-
activating protein, inhibiting the small G-protein Rheb. Inactivation of the TSC2 
complex by Akt-mediated phosphorylation allows Rheb-GTP activation, which in 
turn, activates mTORC1 (Inoki et al., 2002, Inoki et al., 2003a, Long et al., 
2005). AMP-activated protein kinase (AMPK) is an important energy and 
nutrient sensor kinase (Hardie et al., 2012). Activated AMPK is able to inhibit 
mTORC1 by phosphorylating and activating the TSC2 complex (Inoki et al., 
2003b). AMPK activity is regulated by the tumour suppressor kinase LKB1 
(Liver Kinase B1), which is frequently inactivated in cancer resulting in 
enhanced mTORC1 activity (Shaw et al., 2004, Woods et al., 2003). mTORC1 
signalling drives several cellular processes that regulate protein synthesis, such 
as mRNA translation and ribosome biogenesis (Guertin and Sabatini, 2007). 
Activated mTORC1 enhances cap-dependent translation by phosphorylating its 
downstream targets 4E-BPs and S6K (Pearson et al., 1995, Beretta et al., 1996, 
Gingras et al., 1998). The 4E-BPs bind to eIF4E, the methyl cap binding protein, 
and inhibit eIF4F complex formation by preventing eIF4E interacting with the 
eIF4G scaffold protein (Mader et al., 1995, Marcotrigiano et al., 1999, 
Haghighat et al., 1995). Phosphorylated 4E-BP is no longer able to interact with 
eIF4E, thereby permitting eIF4F complex formation and allowing cap dependent 
translation to proceed (Pause et al., 1994, Brunn et al., 1997, Gingras et al., 
1999). eIF4E-mediated mRNA translation is proposed to be one of the main 
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effector pathways that drives cell proliferation downstream of mTORC1 
(Laplante and Sabatini, 2013, Laplante and Sabatini, 2012, Populo et al., 2012). 
Activated mTORC1 also phosphorylates and activates S6K. Activated S6K then 
enhances cap-dependent translation by phosphorylating its downstream 
substrates, such as S6 ribosomal protein and eIF4B. The exact mechanisms by 
which these S6K-activated substrates mediate their effects on translation 
remain unresolved. However, studies have reported that the S6K-
phosphorylation of eIF4B enhances translation possibility by stimulating eIF4A 
helicase activity (Holz et al., 2005, Shahbazian et al., 2006). Furthermore, 
activated S6 kinase phosphorylates the CBP80 subunit of CBC, which 
enhances the affinity of the CBC for the 7-methylguanosine cap (Wilson et al., 
2000). As described above, the CBC promotes several steps in gene 
expression and mediates several functions of the methyl cap (Figure 1.7) (Ma et 
al., 2008). It is proposed that S6K-mediated phosphorylation of CBC stimulates 











Figure 1.9 The regulation of cap-dependent translation by the PI3K-Akt-
mTOR signalling pathway  
PI3K signalling stimulates cap-dependent translation via mTORC1 activation, as 
described in more detail in the text. Adapted from (Thomas, 2006, Silvera et al., 
2010, Laplante and Sabatini, 2012). 
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1.10 Therapeutic strategies to inhibit mRNA translation 
As discussed above, deregulated mRNA translation is associated with cancer. 
The assembly of the eIF4F complex is regulated by oncogenic pathways and 
components of the complex can become oncogenic. Therefore, there has been 
considerable effort into developing strategies to inhibit mRNA translation for 
cancer therapeutics.  
Most of the components of the eIF4F complex lack enzymatic activity, which 
has hindered the development of small molecule inhibitors against the complex. 
Nonetheless, a number of strategies have been developed to target the eIF4F 
complex and these are illustrated in Figure 1.10. These strategies include: (1) 
inhibition of eIF4E expression/activity, (2) blocking the interaction between 
eIF4E-eIF4G, (3) blocking the interaction between eIF4E and the mRNA 5’ 
methyl cap, (4) inhibition of eIF4A activity, or (5) inhibition of mTOR signalling 
(Silvera et al., 2010, Blagden and Willis, 2011, Malina et al., 2012).  
Although not exhaustive, strategies to therapeutically target cap-dependent 







Figure 1.10 Targeting cap-dependent mRNA translation in cancer 
Active mTORC1 stimulates cap-dependent translation by phosphorylating the 
4E-BPs, which allows eIF4E to bind eIF4G and facilitates eIF4F complex 
(eIF4A, eIF4E and eIF4G) formation. Binding of eIF4E to the 5’ mRNA methyl 
cap is essential for recruiting the eIF4F complex to the mRNA and this 
interaction is required for cap-dependent translation. PABP binds the 3’ end of 
mRNA and eIF4G leading to mRNA circulation. The eIF4F complex leads to the 
recruitment of the 43S pre-initiation (consisting of 40S ribosomal subunit, eIF2-
GTP-Met tRNA ternary complex, eIF3, eIF1, eIF1A and most likely eIF5) to the 
5’ of mRNA. The 43S pre-initiation complex scans the 5’UTR until it finds the 
initiation codon. Following the dissociation of several translation factors, the 60S 
ribosome joins to form the 80S translation initiation complex and cap-dependent 
mRNA translation initiates. Although not exhaustive, strategies to target cap-
dependent mRNA translation in cancer include directly targeting eIF4F complex 
components (4EGI-1, ribavirin, 4E-ASO and silvestrol) or inhibiting mTORC1 










Table 1.3 The strategies to therapeutically target mRNA translation in 
preclinical or clinical development 
Adapted from (Blagden and Willis, 2011, Malina et al., 2012, Wander et al., 




1.10.1 Inhibition of eIF4E expression 
eIF4E expression has been targeted using the antisense oligonucleotides 4E-
ASO, which inhibits eIF4E expression by binding the eIF4E gene. In breast and 
prostate xenograft models, treatment of 4E-ASO reduces tumour size while 
causing limited toxicity to normal tissue (Graff et al., 2007). This study 
demonstrated for the first time that tumour cells exhibit an enhanced 
dependency on eIF4E expression for survival, in comparison to normal cells. 
However, a phase II clinical trial testing the efficacy of 4E-ASO in patients with 
advanced cancer showed that despite an effective reduction in eIF4E 
expression, no significant changes in tumour size were observed (Hong et al., 
2011). Potential explanations for this include: (1) eIF4E does not function as an 
oncoprotein in these tumours and (2) the depletion of eIF4E expression was not 
sufficient enough to exert a potent anti-tumour effect. 
 
1.10.2 Blocking the eIF4E-eIF4G interaction 
The Wagner group identified a small molecule called 4EGI-1, that inhibits cap-
dependent translation by blocking the eIF4E-eIF4G interaction. Treatment of 
cells with 4EGI-1 preferentially reduced the expression of eIF4E-dependent 
oncogenic proteins, and inhibited the proliferation of lung cancer cell lines. 
Furthermore, 4EGI-1 was demonstrated to be selectivity toxic to transformed 
cells compared to non-transformed cells (Moerke et al., 2007). Although the 
results from this study indicated that 4EGI-1 is not potent enough for use as a 
single agent, the use of this drug as part of combination therapies is currently 




1.10.3 Blocking the eIF4E- 5’ mRNA methyl cap interaction 
Since the interaction between eIF4E and the 5’ methyl cap is essential for 
mRNA translation and eIF4E-mediated oncogenesis (Ruggero et al., 2004), it is 
likely that targeting the eIF4E-5’ methyl cap interaction is an effective anti-
proliferative strategy. The drug ribavirin, which is approved for the treatment of 
hepatitis C, is structurally similar to the mRNA 5’ methyl cap and it has been 
reported that ribavirin sequesters eIF4E away from the mRNA methyl cap 
(Malina et al., 2012). Strikingly, treatment with ribavirin was found to selectively 
inhibit the translation of eIF4E-dependent mRNAs and inhibit tumour growth in 
mice (Kentsis et al., 2004). A phase I clinical trial assessing the effect of 
ribavirin on patients with acute myeloid leukemia demonstrated that ribavirin 
treatment lead to significant reduction in eIF4E overexpressing tumours while 
causing limited toxic side effects (Assouline et al., 2009). This study provided 
the first clinical evidence that targeting the eIF4E-mRNA methyl cap interaction 
is an effective anti-cancer strategy in eIF4E overexpressing tumours. However, 
since two additional studies have been unable to detect an interaction between 
ribavirin and recombinant eIF4E, it remains controversial whether ribavirin 
inhibits the eIF4E-methyl cap interaction (Yan et al., 2005, Westman et al., 
2005). 
 
1.10.4 Inhibition of eIF4A  
 An oncogenic role for eIF4A has not yet been established. However, eIF4A 
inhibitors derived from nature such as paleamine A, hippuristanol and silvestrol 
exert powerful anti-proliferative effects and are therefore being investigated as 
therapeutic anti-cancer inhibitors (Malina et al., 2012, Blagden and Willis, 2011). 
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Silvestrol, which acts by removing eIF4A from the eIF4F complex, is the most 
clinically developed eIF4A inhibitor. In various cancer cell lines, as well as in 
mouse tumour xenograft models, treatment with silvestrol exerts anti-tumour 
activity (Cencic et al., 2009, Cencic et al., 2010). Preclinical studies have shown 
that silvestrol is particularly effective against B-cell leukemias and it is currently 
in clinical development for use against aggressive leukemias and lymphomas 
(Lucas et al., 2009, Lucas et al., 2010). 
 
1.10.5 Inhibition of mTOR signalling 
As discussed above, the PI3K-Akt-mTOR pathway stimulates mRNA translation 
via the regulation of mTORC1. PI3K-Akt-mTOR signalling is frequently hyper-
activated in cancer leading to deregulated protein synthesis. Thus, 
therapeutically targeting this pathway is an attractive anti-cancer strategy. 
Although inhibitors against several components of the PI3K pathway are in 
clinical development for the treatment of cancer, only mTOR inhibitors have 
been approved for use in the clinic (Silvera et al., 2010, Blagden and Willis, 
2011). Rapamycin and its derivatives, known as rapalogs, suppress mRNA 
translation by inhibiting mTORC1 and exert anti-tumour effects (Silvera et al., 
2010, Pedersen et al., 1997, Shor et al., 2008).The rapalogs temsirolimus, and 
everolimus are approved for the treatment of metastatic renal cell carcinoma but 
the anti-tumour effect of these drugs is often short term and resistance is 
frequent. The rapalogs are currently being explored in numerous clinical trials 
for use against several types of human cancers (Malina et al., 2012, Blagden 
and Willis, 2011, Meric-Bernstam and Gonzalez-Angulo, 2009). Data from 
clinical trials have shown that rapalogs are only effective against a subset of 
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human cancers. For example, rapalogs are effective as single therapy agents in 
patients with metastatic endometrial cancer and mantle cell lymphoma (Hess et 
al., 2009, Oza et al., 2008), but they have limited single agent activity in patients 
with metastatic breast cancer or small-cell lung cancer (Pandya et al., 2007, 
Chan et al., 2005). The long term clinical response to rapalogs is known to be 
limited by the activation of feedback mechanisms, as well as the activation of 
redundant signalling pathways (Carew et al., 2011).  This may be because 
rapamycin does not fully de-phosphorylate the 4E-BPs, thereby allowing cap-
dependent translation to persist in response to treatment (Choo et al., 2008, 
Thoreen et al., 2009). The fact that eIF4E expression confers resistance to 
mTOR inhibitors suggests that the combined inhibition of eIF4E expression/ 
activity with mTOR inhibitor treatment may synergise to reduce resistance 
(Wendel et al., 2004b, Cope et al., 2013, Sun et al., 2005). 
The activity of mTORC2 is only sensitive to chronic rapamycin treatment and 
resistance to rapalogs can occur by mTORC2-mediated feedback activation of 
the PI3K signalling pathway. These observations have led to the development 
of second generation mTOR kinase inhibitors (TORKinibs), which inhibit the 
catalytic activity of both mTORC1 and mTORC2. Several of these are currently 
in either preclinical, or clinical, development (Table 1.3) (Blagden and Willis, 
2011, Benjamin et al., 2011). TORKinibs have been shown to be superior to 
rapalogs in their ability to inhibit mTORC1-mediated 4E-BP phosphorylation and 
suppress cell growth and protein synthesis (Feldman et al., 2009, Thoreen et 
al., 2009). 
As well as mTOR inhibitors, several inhibitors against PI3K and Akt are in 
clinical trials and have shown significant anti-tumour effects  (Liu et al., 2009a, 
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Pal and Mandal, 2012). The therapeutic targeting of PI3K in cancer will be 
described in more detail in the introduction of chapter 5. 
 
1.11 mRNA cap methylation and cancer 
There is considerable evidence that eIF4E is oncogenic and eIF4E expression 
is often found to be elevated in several types of human cancers, including 
breast cancer (De Benedetti and Graff, 2004, De Benedetti and Harris, 1999, 
Gingras et al., 1999). The binding of eIF4E to the methyl cap has been reported 
to be essential for the translation of most mRNAs and is important for eIF4E-
mediated oncogenesis. These observations suggest that mRNA cap 
methylation has the potential to contribute to cancer (Ruggero et al., 2004, 
Cohen et al., 2001). Indeed, emerging evidence has shown that the mRNA 
methyl cap is associated with oncogenic transformation. For example, 
exogenous overexpression of RNMT in mammary epithelial cells promotes cell 
transformation (Cowling, 2009a). Moreover, the oncoprotein c-Myc upregulates 
cap methylation and this is essential for Myc-driven protein synthesis, cell 
transformation and cell proliferation (Fernandez-Sanchez et al., 2009a).  
Strikingly, inhibition of cap methylation is reported to be synthetic lethal with 
elevated c-Myc expression. The above observations lead us to the intriguing 
possibility that inhibition of cap methylation may be an effective anti-cancer 
strategy. Since the methyl cap is essential for the translation of most mRNAs, 
the inhibition of cap methylation has the potential to inhibit the action of any 
oncogene that deregulates gene expression. Thus, targeting RNMT would likely 
have wide efficacy and could be effective in tumours driven by different 
oncogenes. All of the above experiments were carried out in non-transformed 
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experimental cell lines and it is important to establish whether inhibition of cap 
methylation selectively supresses the proliferation of cancer cells. 
 
1.12 Summary and aims of this PhD thesis: 
Breast cancer is the leading cause of cancer death in women worldwide. 
Significant advances have been made in the treatment of breast cancer, but 
new therapeutic approaches are required. Protein synthesis is often found to be 
deregulated in cancer and there has been significant effort into developing 
strategies to inhibit protein synthesis for anti-cancer therapeutics. The 7-
methylguanosine cap structure found at the 5’ end of mRNA is essential for 
mRNA translation and it has been shown to promote several steps in gene 
expression. In humans, RNMT catalyses the methylation of the guanosine cap 
structure and RNMT expression is essential for mRNA cap methylation and 
efficient gene expression. Emerging evidence suggests that inhibition of cap 
methylation may be an effective therapeutic anti-cancer strategy. The aim of 
this thesis is to assess whether depletion of RNMT selectively inhibits the 








Chapter 2: Materials and Methods 
2.1 Materials 
 
2.1.1 Laboratory equipment  
Autoradiography cassette (Siemens), Automatic film processor (Konica 
Corporation), C1000 thermal cycler (Bio-Rad), Cell countess (Invitrogen), 
Centrifuge 5415-R (Eppendorf), CO2 incubators (Mackay + Lynn), Mini-
PROTEAN Tetra Cell (Bio-Rad), Mini-Sub Cell GT Cell (Bio-Rad), Mini-Trans-
Blot Cell (Bio-Rad), Nanodrop Spectrometer 1000 (Thermo Scientific), 
Phosphorimager FLA-500 (FujiFilm), Phosphor screen (FujiFilm), Pipettes 
(Greiner), Tissue culture safety cabinets (Medical Air technology), Versa Max 
microplate reader (Molecular Devices), X-Cell SureLock Mini-Cell (Life 
Technologies). 
 
2.1.2 Tissue culture reagents 
Antibiotic – Antimycotic (Anti-Anti) (Gibco, Life Technologies), Cryovials 
(Corning), Dulbecco’s phosphate buffered saline (DPBS) (Gibco, Life 
Technologies), Dimethyl sulfoxide (DMSO) (Sigma-aldrich), Dulbecco’s 
modified eagle medium nutrient mixture F-12 ham (Gibco, Life Technologies), 
Epidermal growth factor (EGF) (Sigma-aldrich), G-418 (ForMedium), HyClone 
fetal bovine serum (FBS) (Thermo Scientific), Insulin solution human (Sigma-
aldrich), L-Glutamine (Gibco, Life Technologies), Lipofectamine 2000 
transfection reagent (Life Technologies), Lipofectamine RNAiMax transfection 
reagent (Life Technologies), Nunc 25 cm2 and 75 cm2 flasks (Thermo 
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Scientific), NuPAGE (Novex) 4-12% Bis-Tris protein gels (Life Technologies), 
Polybrene (Sigma-aldrich), Petri dishes (Corning), RPMI 1640 Medium (Gibco, 
Life Technologies), Trypan blue solution (0.4%) (Gibco, Life Technologies), 
Trypsin-EDTA solution (Gibco, Life Technologies). 
 
2.1.3 Commercial reagents  
2-Mercaptoethanol (Sigma-aldrich), [35S] Protein labelling mix (2 mCi) (Perkin 
Elmer), 40% Acrylamide : Bis-acrylamide 29:1 (Flowgen Biosciences), 96-well 
hard-shell PCR frame Plate (Bio-Rad), [α-32P] guanonsine-5’ triphosphate 
(GTP) (500 µCi) (Perkin Elmer), Acetic acid (VWR International), Agarose (Life 
technologies), Ammonium sulphate (Sigma-aldrich), Aprotinin (Sigma-aldrich), 
BenchMark pre-stained protein ladder (Life technologies), Bio-Rad protein 
assay (Bio-Rad), Bovine serum assay (Bio-Rad), Bromophenol blue (Sigma-
aldrich), Dithiothreitol (DTT) (ForMedium), Dried skimmed milk (Marvel), 
Ethanol (VWR International), Ethylenediamine tetraacetic acid (EDTA) (Sigma-
aldrich), Ethylene glycol tetraacetic acid (EGTA) (Sigma-aldrich), GeneJET 
RNA Purification kit (Thermo Scientific), Glycerol (VWR International), 
Hydrochloric acid (VWR International), Immobilon transfer membrane 
(Millipore), iScript cDNA synthesis kit (Bio-Rad), Leupeptin hydrochloride 
(Sigma-aldrich), Magnesium chloride (MgCl2) (Sigma-aldrich), Methanol (VWR 
International), Microseal adhesive seals (BioRad), N,N,N′,N′-
Tetramethylethylenediamine (TEMED) (VWR International), NuPAGE® Novex® 
4-12% Bis-Tris protein gels (Life Technologies), NuPAGE® Novex® MES SDS 
running buffer (Life Technologies), NuPAGE® Novex® MOPS SDS running 
buffer (Life Technologies), P1 nuclease (Sigma-aldrich), PCR tubes (Axygen), 
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Pepstatin (Sigma-aldrich), Phosphatase inhibitor cocktail 2 (Sigma-aldrich), 
Phosphatase inhibitor cocktail 3 (Sigma-aldrich), Phenol:Chloroform: 
isoamylalcohol  (Ambion), Plasmid maxi kit (Qiagen), Potassium chloride (KCl) 
(Sigma-aldrich), QIAquick PCR purification kit (Qiagen), Recombinant RNasin 
ribonuclease inhibitor (rRNasin) (Promega), S-adenosyl-methionine (SAM)  
(Sigma-aldrich), SimplyBlue safe stain (Life technologies), Sodium acetate 
(Ambicon), Sodium chloride (NaCl) (VWR International), Sodium dodecyl sulfate 
(SDS) (Sigma), Sodium fluoride (NaF) (Sigma-aldrich), Sodium orthovanadate  
(Sigma-aldrich), Sodium pyrophosphate tetrabasic (Sigma-aldrich), Super signal 
west pico chemiluminescent substrate (Thermo Scientific), SYBR® Green 
FastMix TM (Quanta Biosciences), T7 RNA polymerase (Promega), TLC PEI 
cellulose sheets (Merck Millipore), Tris-Base (VWR International), Triton X-100 
(Sigma-aldrich), tRNA (Sigma-aldrich), Tween-20 (VWR International), X-ray 
films (Konica Minolta), Zinc chloride (ZnCl2) (Sigma-aldrich). 
 
 2.1.4 In-house regents 
LB agar plates (+ Ampicillin) and LB broth (+ Ampicillin) (Media Kitchen facility, 
College of Life Sciences, University of Dundee). GDC-0941, an inhibitor of class 
I PI3Ks (Folkes et al., 2008b), and Staurosporine (a broad spectrum kinase 
inhibitor) were produced by the Division of Signal Transduction Therapy 







All commercial antibodies used in this thesis are shown in Table 2.1 and were 
used at a 1:1000 dilution in 3% BSA in TBS-Tween. All in-house antibodies 
used were made by DSTT and were affinity purified on CH-Sepharose 
covalently coupled to the antigen. The details of the in-house antibodies used in 
this thesis are shown in Table 2.2. The working concentration and dilution 








































Table 2.2 Details of the in-house antibodies used in this thesis  
The host and antigen used to raise the antibodies and the antibody reference 
















Table 2.3 Working concentrations and dilution conditions used for all the 




2.1.6 Buffers and solutions 
F buffer (pH 7.05): 10 mM Tris (pH 7.05), 50 mM NaCl, 30 mM Na 
pyrophosphate, 50 mM NaF, 5 µM ZnCl2, 10% Glycerol, 0.5% Triton X-100, 1 
mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, (further supplemented 
with 0.1 TIU (trypsin inhibitor unit) aprotinin, 1 µM pepstatin, 10 µM leupeptin 
and 1 mM DTT immediately before use) 
SDS running buffer: 25 mM Tris, 250 mM glycine, 0.1% SDS 
Transfer buffer: 25 mM Tris, 192 mM glycine, 20% methanol 
TBS-Tween (pH 8.1):  25 mM Tris, 155 mM NaCl, 0.1% Tween-20 
Laemmli buffer (4x): 240 mM Tris (pH 6.8), 8% SDS, 40% glycerol, 
bromophenol blue (further supplemented with 10% DTT immediately before 
use) 
Methyltransferase assay buffer: 100 mM Tris (pH 8), 6 mM KCl, 1.25 mM MgCl2 





2.2.1 Transformation of E.coli and plasmid purification 
For each transformation, 30 µl of competent E.coli cells were mixed with 2 µg of 
plasmid DNA and incubated on ice for 20 min. To facilitate the uptake of DNA, 
cells were subject to heat-shock by incubating at 45˚C for 1 min followed by a 2 
min incubation on ice. For selection, cells were streaked on LB/ Amp agar 
plates and inverted plates were incubated overnight at 37˚C. A single isolated 
colony was then picked and incubated with 200 ml of LB (Amp) at 37˚C 
overnight, following which cells were pelleted by centrifugation at 3000 rpm for 
10 min. Plasmid DNA was purified using the Qiagen plasmid Maxi kit according 
to manufacturer’s instructions.  
 
2.2.2  DNA sequencing 
DNA sequencing was performed by DNA Sequencing & Services (MRCPPU, 
College of Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) 
using Applied Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems 
model 3730 automated capillary DNA sequencer. 
 
2.2.3  Cloning 
All constructs used in this thesis were cloned by Dr Simone Weidlich from the 
Division of Signal Transduction Therapy (DSTT) cloning team. All constructs 
employed in this thesis are shown in Table 2.4 and encode the human version 
of the gene. All constructs were used to retrovirally transduce cells to produce 





Table 2.4 All constructs employed in this thesis 
 
2.2.4 DNA concentration determination 
Concentration of DNA (resuspended in distilled water) was determined 
using a Nanodrop Spectrophotometer 1000, which was blanked using distilled 
water. The absorbance was measured at 260/280 nm according to the 
manufacturer’s instructions. 
 
2.2.5 Cell culture and maintenance 
Cells were grown in 75 cm2 flasks and maintained at 37 ˚C in a humidified 
incubator with 5% CO2. The cell lines and culture media used in this thesis are 
shown in Table 2.5. The breast cancer cell panel was purchased directly from 
the American Type Culture Collection (ATCC) and the key features (Subtype, 
source, clinical features) of the cell lines are shown in Table 2.6. The IMEC cell 
line was kindly provided to me by Dr James DiRenzo (Dartmouth Medical 
School). When the cells were passaged, each flask of cells was washed once 
with PBS and then 1 ml of Trypsin was added to the cells for 5 min to dissociate 
them from the flask. Cells were then resuspended in fresh culture media (Table 
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2.5) to inactivate trypsin and 1/5th of the cell suspension was seeded into a new 
flask. Trypsinised immortalised mammary epithelial cells (IMEC) were 
resuspended in RPMI culture media supplemented with 10% FBS to inactivate 
trypsin and centrifuged for 3 min at 1,700 rpm. The resultant cell pellet was 
resuspended in DMEM F-12 Ham media (supplemented with 2 mM L-glutamine, 
5 mg/ml Insulin, 10 ng/ml EGF, 0.5 µg/ml hydrocortisone and 1% Anti-Anti) and 
1/5th of the cell suspension was seeded into a new flask. IMECs were used for 
experiments up to passage number 18 and all other cell lines were used for 
experiments up to passage number 30. IMEC and ZR.75.1 cells stably 
expressing wild-type, or activating mutants, of PI3K p110α were used for 
experiments up to passage number 60. 
When cells were required for the immunoblot analysis of phosphorylated 







































Table 2.6 Features of the breast cancer cell lines studied in this thesis 
Subtype, source and clinical features of the breast cancer cell lines used in this 
thesis are indicated. Information on the cell lines was obtained from the 




2.2.6 Freezing/ thawing of cell lines 
Cells were grown in a 75 cm2 flask until 70% confluent and were trypsinised (as 
described above) and resuspended in RPMI media supplemented with 10% 
FBS to inactivate trypsin. The cell suspension was then centrifuged at 1700 rpm 
for 3 min and the resultant cell pellet was resuspended in 4 mls of 90% FBS/ 
10% DMSO and transferred into a cyro vial (1 ml aliquots per 1.5 ml cyro vial). 
The cyro vials were stored in a Mr Frosty at -80 ˚C for 24-48 hr prior to long 
term storage in liquid nitrogen. Frozen cells were thawed at room temperature 
for 5 min and resuspended in 10 ml of relevant culture media (Table 2.5) and 
the cell suspension was then transferred into a 25 cm2 flask. 
 
2.2.7 Cell counting 
Cell suspension was mixed 1:1 with trypan blue (0.4%) and cells were then 
counted using a Countess cell counter (Life technologies) according to the 
manufacturer’s instructions. 
 
2.2.8 Cell growth assays 
The effect of short interfering RNA (siRNA)-mediated RNMT depletion on the 
proliferation of cells was established by seeding cells at equivalent density (2.5 
X 105 cell/ well in a 6 well plate) and immediately transfecting cells with 3 
independent siRNAs targeting RNMT, or a non-targeting siRNA. Cells were 
counted in triplicate on four consecutive days (1, 2, 3, 4 days post-
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seeding/siRNA transfection) using a cell counter. Culture media was 
replenished 48 hr post-plating/siRNA transfection.  
 
2.2.9 Cell doubling time 
The cell doubling time for each cell line was established by plating cells at 
equivalent density (2.5 X 105 cell/ well in a 6 well plate) and cells were counted  
in triplicate on four consecutive days (1, 2, 3, 4 days post-plating) using a cell 
counter and the cell doubling time (hr) was calculated. 
 
2.2.10 siRNA transfection 
siRNA-mediated RNA-Interference (RNAi) was used to deplete RNMT 
expression levels throughout this thesis. All cells were transfected with siRNA 
using Lipofectamine RNAiMax transfection reagent according to the 
manufacturer’s instructions. For a 6 cm dish, 0.45 nmol of siRNA was 
transfected with 9 µl of Lipofectamine RNAiMax and 480 µl serum-free DMEM 
media. For a well in a 6 well dish, 0.16 nmol of siRNA was transfected with 3 µl 
of Lipofectamine RNAiMax and 200 µl serum-free DMEM media. All siRNAs 
used in this thesis are shown in Table 2.7. 
All cell lines used were seeded at 2.5 X 105 cells per well/ 6 well dish, or 6 X 105 
per 6 cm dish, and were immediately transfected with siRNA. For experiments 
requiring longer than 48 hr siRNA transfection, media was replenished at 48 hr 





Table 2.7 siRNAs used in this thesis 
 
2.2.11 DNA transfection using lipofectamine 2000 
Phoenix cells were transiently transfected with DNA vectors using lipofectamine 
2000 according to the manufacturer’s instructions. For a 10 cm dish, 5 µg of 
DNA was transfected with 15 µl of lipofectamine 2000 and 500 µl of serum-free 
DMEM media. Cells were seeded at 5 X 105/ 10 cm dish and left to adhere for 
24 hr prior to DNA transfection. Media was replenished with culture media 6 hr 
post-DNA transfection. 
 
2.2.12 Treatment of cells with inhibitors 
The inhibitors used in this thesis (GDC-0941 and Staurosporine) were produced 
by the DSTT and were dissolved in DMSO. For different concentrations of 
inhibitors, the 10 mM stock was diluted further with DMSO and added to the cell 
culture media. For the control treatment, an equal volume of DMSO was added 
to the culture media. 
To assess the combined effect of siRNA-mediated RNMT depletion and 
pharmacological PI3K inhibition on the proliferation of T47D cells, cells were 
seeded at 2.5 X 105 cells/ well (in a 6 well dish) and transfected with siRNA 
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targeting RNMT, or non-targeting siRNA. 4 hr post-siRNA transfection, cells 
were treated with GDC-0941 (0.05 µM), or an equal volume of DMSO. 72 hr 
post-siRNA transfection, cells were counted using a cell counter, or protein 
extracted for Immunoblot analysis.  
As a positive control for the cleaved-PARP Immunoblot experiments, cells were 
treated with 0.1 µM straurosporine for three hours prior to cell lysis. Cells were 
then lysed and cell lysates subject to immunoblot analysis.  
 
2.2.13 Generation of stable cell lines 
HCC-1806, ZR.75.1 and IMEC cells were stably transfected using the retroviral 
transduction method. Firstly, Phoenix cells were transfected with DNA vectors 
using lipofectamine 2000 according to the manufacturer’s instructions to 
generate infectious retroviruses. 48 hr post-transfection, 10 ml of virus-
containing media was passed through a 45 micron filter and supplemented with 
5 µg/ ml of polybrene and this was then used to infect a 10 cm dish of cells. 
Successfully transduced cells were selected for using 0.5 mg/ml of Geneticin.   
 
2.2.14 Rescue of siRNA-mediated RNMT depletion 
A siRNA-resistant full-length RNMT construct was made by introducing several 
silent mutations which alter the nucleotide sequence, but do not alter the amino 
acid sequence, into a GFP-tagged full-length RNMT construct (Table 2.4). Then 
HCC-1806 cells were retrovirally transduced to stably express either wild-type, 




2.2.15 Cell lysis 
Cell lysis was performed at 4 ˚C to avoid protein degradation. Culture media 
was removed and cells were washed once with ice-cold PBS. Cells were lysed 
with ice-cold F buffer. For Immunoblot analysis of phosphorylated proteins, the 
lysis buffer was further supplemented with Phosphatase inhibitors (cocktail 
mixture 2 + 3) to avoid dephosphorylation of proteins. Cell lysates were 
collected by scraping and the soluble fraction collected following 13,000 rpm for 
10 min at 4˚C. Protein concentration was determined using the Bradford 
method. 
 
2.2.16 Protein concentration determination 
Protein concentration was determined using the Bradford method (Bradford, 
1976). To generate a standard curve, dilutions of BSA standard (0.5, 1, 1.5 µg 
of BSA) were made in F-buffer and 2 µl of the BSA dilutions, or F-buffer only 
(blank), were added to 200 µl of 1X Bradford Protein assay reagent in a 96-well 
plate. Absorbance was measured at 595 nm using a plate reader. A standard 
curve was obtained by plotting the absorbance reading against the 
concentration of BSA and a line equation determined. To determine the protein 
concentration of samples, samples were diluted in water and analysed the 
same as described above. The linear equation of the standard curve was used 
to establish the protein concentration of the sample. All Bradford measurements 




2.2.17 Immunoprecipitation (IP) 
All IP steps were performed at 4˚C to avoid protein degradation. For all Myc-
tagged exogenously expressed proteins, 1.5 mg of protein lysates were pre-
cleared with agarose beads for 30 min on a rotating wheel. The agarose beads 
were then pelleted by centrifugation at 3000 rpm for 1 min. The pre-cleared 
supernatant was transferred to a new eppendorf tube and incubated with 1.5 µg 
of anti-E910 (Myc tag) antibody for 2 hr on a rotating wheel. Agarose beads 
were then added to the mixture for an additional 30 min. The IPs were pelted by 
centrifugation at 3000 rpm for 1 min, the supernatant discarded and the beads 
washed 3 times with 1 ml of F buffer. Immunoprecipitated proteins were eluted 
in 50 µl of 1X Loading dye and 15 µl were analysed by SDS-PAGE. Loading 
dye was also added to the IP inputs, which were analysed along with the IPs by 
SDS-PAGE. 
 
2.2.18 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Each resolving gel contained 400 mM Tris (pH 8.8), 0.1% SDS, 0.1% APS and 
8-15% acrylamide. The amount of protein lysate analysed and the percentage 
of acrylamide used in the resolving gels for the immunoblot analysis of specific 
proteins is shown in Table 2.8.  
Each stacking gel contained 400 mM Tris (pH 6.8), 0.1% SDS, 0.1% APS and 
5% acrylamide. 0.01% TEMED was added to initiate the polymerisation 
reaction. Homemade gels were resolved in a Mini-PROTEAN Tetra cell (Bio-
Rad) using SDS Running buffer. 
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4-12% NuPAGE Novex gradient gels were used for some experiments and the 
use of these gels are indicated in the figure legends. NuPAGE Novex gels were 
resolved in a X-Cell SureLock Mini-Cell (Life Technologies). MOPS running 
buffer (Novex) was used for resolving proteins larger than 30 kDa, whereas 
MES running buffer (Novex) was used for smaller proteins. 
 
 
Table 2.8 Proteins analysed by immunoblotting in this thesis.  
 
Protein samples were denatured in 1X Laemmli sample buffer at 95˚C for 5 min 
and centrifuged 13000 rpm for 2 min at room temperature. Protein samples (5-
20 µg of total protein) (Table 2.8), or 15 µl of immunoprecipitate, were loaded 
per lane and 4 µl of protein standards, which have apparent molecular weights 
of 180, 115, 82, 64, 49, 37, 26, 19, 15 kDa, were loaded in the first lane of each 





2.2.19 Transfer of proteins to PVDF membrane 
Proteins separated by SDS-PAGE were transferred onto PVDF membrane by 
electro-transfer. The gel was placed on PVDF (which had been pre-activated by 
incubation with methanol for 5 min), which was then packed between 3 mm 
Wattman filter papers and sponges all submerged in transfer buffer. The 
sandwich was loaded into a mini-Trans-blot cell with the gel facing the cathode, 
and the PVDF membrane facing the anode, to ensure the transfer of the 
negatively charged proteins onto the PVDF membrane. The electro-transfer 
was carried out at 68 V for 1.5 hr. 
 
2.2.20 Immunoblotting 
Membranes were blocked with 5% milk, or 3% BSA, /TBS-Tween for 1 hr at 
room temperature to prevent non-specific binding of primary antibody. 
Membranes were incubated with primary antibody diluted in either 5 % milk, or 
3% BSA, /TBS-Tween overnight at 4˚C. All commercial antibodies were diluted 
in 3 % BSA/ TBS-Tween and the antibody dilution conditions used for in-house 
antibodies are shown in Table 2.3. Membranes were then incubated with HRP- 
conjugated secondary antibody diluted in 5 % milk/ TBS-Tween for 1 hr at room 
temperature and membranes were subsequently washed 3 times in TBS-
Tween. Finally, the membranes were incubated with Super Signal West Pico 
Chemiluminescent substrate for 2 min and signal exposed to x-ray film for 




2.2.21 [35S]-amino acid labelling   
Cells were incubated for 20 min at 37˚C with pre-warmed media containing 11 
µCi/ ml protein labelling mix (containing 35S-methionine and 35S-cysteine). 
Cells were washed once with ice-cold PBS and lysed in F-buffer. Protein lysates 
were then resolved by SDS-PAGE in a 10% polyacramide gel. A polyacramide 
gel loaded with 6 µg of protein was stained with Simply Blue stain and used to 
assess equal loading of protein in each lane. In order to quantify the 
incorporation of [35S]-labelled amino acids into nascent proteins, a 
polyacramide gel loaded with 12 µg of protein was desiccated and then 
underwent autoradiography. 
 
2.2.22 Coomassie staining of polyacrylamide gels 
Following SDS-PAGE, gels were washed 3 times in distilled water and stained 
with SimplyBlue stain for 30 min. After staining, gels were washed in distilled 
water until the gel background was distained. 
 
2.2.23 Desiccation of polyacrylamide gels 
For [35S]-amino acid labelling experiments, gels were placed on 2 sheets of 
pre-wetted Whatman 3mm filter paper and covered with cellophane wrap. The 





The radioactive signal was recorded on to a phosphor screen and an image of 
the radioactive signal was created using a phosphorimager. The AIDA imager 
analyser software was used to obtain quantitative measurement of the 
radioactive signal. 
 
2.2.25 Phenol/chloroform extraction of RNA 
Phenol/ chloroform extraction was used to remove contaminating proteins and 
DNA from RNA solutions. Phase partitioning of nucleic acids is dependent on 
the pH of the phenol: at pH ≤ 7, the DNA moves into the organic phase and 
interphase, whereas the RNA remains in the aqueous phase. Phenol (pH 6.6) 
was used for phenol/chloroform extraction in this thesis to ensure the selective 
purification of RNA. An equal volume of phenol/ chloroform was added to the 
DNA/ RNA/ protein solution and vortexed for 10 sec to mix the phases. The 
aqueous and organic phases were separated by centrifugation at 13000 rpm for 
10 min at 4˚C. The aqueous phase containing the RNA solution was then 
transferred to a new tube. 
 
2.2.26 RNA precipitation 
Following phenol/chloroform extraction, the aqueous phase was combined with 
2 volumes of 100% ethanol containing 0.5 µM ammonium acetate, and then 
incubated overnight at 20˚C. The precipitate was then pelted by centrifugation 
at 13000 rpm for 1 hr. The RNA pellet was washed twice with 70% ETOH and 
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left to air dry for 1 hr. Finally, the RNA pellet was resuspended in 50 µl of 
DEPC-treated H2O. 
 
2.2.27 In vitro cap methyltransferase assay 
 
pGEM CEM was linearised using EcoRI and then purified using a Qiagen PCR 
purification column according to the manufacturer’s instructions. T7 RNA 
polymerase (Promega) was used according to the manufacturer’s instruction to 
in vitro transcribe RNA from pGEM CEM. Briefly, 500 ng of linerased pGEM 
CEM was incubated with T7 RNA polymerase, 250 mM NTPs and Promega 
transcription buffer. The in vitro transcribed RNA was then purified using phenol 
chloroform and the ethanol-precipitated pellet resuspended in 50 µl of DEPC-
treated H2O. The in vitro transcription steps described above were performed by 
Thomas Gonatopoulous-Pournatzis, a previous PhD student in the Cowling 
laboratory. 
To add a [α-32P]- labelled guanosine cap to the 5’ end of RNA, 200 ng of RNA 
in vitro transcribed from pGEM CEM was incubated with 20 µCi of [α-32P]- 
guanosine 5’-triphosphate (GTP), 2 µg recombinant RNGTT (human capping 
enzyme), 10% RNGTT buffer and 40 U RNasin at 37˚C for 1 hr. The in vitro 
transcribed capped RNA was purified using phenol chloroform and the ethanol-
precipitated pellet resuspended in 50 µl of DEPC-treated H2O. 
For the in vitro cap methylation reaction, protein lysates (0.25 µg, 0.5 µg or 1 
µg) prepared by F buffer protein extraction were incubated with 2 mM SAM, 20 
U RNasin, 1% MT buffer and 1/100th of purified in vitro transcribed capped RNA 
at 37˚C for 10 min. The resultant RNA was purified using Phenol Chloroform 
and the ethanol-precipitated pellet was resuspended in 4 µl of 50 mM Na 
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Acetate (pH 5.5). The RNA was subsequently incubated with 20% P1 nuclease 
at 37˚C for 1 hr to cleave guanosine cap (GpppG), or methyl guanosine cap 
(m7GpppG), from the transcript. [α-32P]-labelled GpppG, or [α-32P]-labelled 
m7GpppG, were resolved by Thin layer chromatography (TLC) (using PEI 
cellulose plates in 0.4 M ammonium sulphate). The TLC was visualised using 
autoradiography and quantified using AIDA imager analyser. 
The concentration of methyl capped (m7GpppG) RNA was calculated based on 
an input of 200ng of RNA into the [α-32P]-GTP capping reaction and assuming 
a 100% [α-32P]-GTP capping efficiency and a 100% recovery of RNA at the 
subsequent phenol chloroform and ethanol precipitation steps.  
 
2.2.28 Statistical analysis 
Statistical significance was assessed by one way analysis of variance (ANOVA) 
followed by Dunnett’s, or Tukey’s, multiple comparison tests using GraphPad 
Prism 5.0. P-value ≤ 0.05 was considered to a significant difference; P-value ≤ 
0.05 is denoted with *; P-Value ≤ 0.01 is denoted with **;  P-Value ≤ 0.001 is 









Chapter 3: A subset of breast cancer cell lines 
exhibit enhanced dependency on RNMT for 
survival 
3.1 Introduction 
Eukaryotic RNA polymerase II (RNA Pol II) transcripts are uniquely modified at 
the 5’ terminus with the addition of a 7-methylguanosine cap (methyl cap) 
structure. From yeast to humans, the methyl cap is required for efficient gene 
expression and cell viability. The methyl cap is necessary for the translation of 
most mRNAs and it has also been shown to promote transcription, splicing, 
polyadenylation, and nuclear export of mRNAs (Cowling, 2009b, Furuichi and 
Shatkin, 2000).  
Formation of the methyl cap occurs predominantly, if not entirely, co-
transcriptionally. Synthesis of the methyl cap is dependent on the sequential 
enzymatic activities of an RNA triphosphatase, RNA guanylyltransferase and 
RNA methyltransferase. The RNA triphosphatase removes the terminal 
phosphate of the transcript and the RNA guanylyltransferase catalyses the 
addition of guanosine monophosphate (GMP) to form the cap structure. To 
finalise the methyl cap structure, the RNA methyltransferase methylates the 
guanosine cap at the N-7 position (Cowling, 2009b, Furuichi and Shatkin, 
2000).  
The human cap methyltransferase, RNMT, catalyses the methylation of the 
guanosine cap (Pillutla et al., 1998b) and our laboratory has recently 
discovered that RAM (RNMT activating mini-protein), a novel interacting 
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protein of RNMT, is essential for RNMT expression and activity 
(Gonatopoulos-Pournatzis et al., 2011). Several recent studies have 
demonstrated that mRNA cap methylation is a regulated process (Fernandez-
Sanchez et al., 2009a, Cole and Cowling, 2009, Jiao et al., 2010).  
Deregulated mRNA translation is associated with cancer. Despite being 
essential for cell viability, emerging data suggest that targeting mRNA 
translation initiation is an effective anti-cancer strategy (Blagden and Willis, 
2011, Silvera et al., 2010). In this thesis, I set out to investigate the suitability of 
RNMT as a therapeutic target in breast cancer. Expression of the human mRNA 
cap methyltransferase, RNMT, is rate-limiting for efficient mRNA translation and 
cell proliferation (Cowling, 2009a, Chu and Shatkin, 2008). Intriguingly, several 
lines of evidence from our laboratory suggest there is strong biological rationale 
to explore RNMT as a therapeutic target in breast cancer. Firstly, the oncogene 
c-Myc can upregulate cap methylation in mammary epithelial cells and this 
process is required for c-Myc-driven protein synthesis and cell proliferation. 
Secondly, inhibition of cap methylation is synthetic lethal with elevated c-Myc 
expression (Fernandez-Sanchez et al., 2009b). Thirdly, experimental 
overexpression of RNMT is sufficient  to transform mammary epithelial cells 
(Cowling, 2009a). However, it remains unknown whether cancer cells exhibit an 
enhanced dependency on RNMT for proliferation, in comparison to non-
cancerous cells. To assess RNMT as a therapeutic target in breast cancer, the 
initial aim of this project was to investigate the effect of RNMT depletion on the 
proliferation of breast cancer cells and non-transformed mammary epithelial 
cells. It is important to note that the inhibition of an effective therapeutic target 





3.2.1 siRNA-mediated RNMT depletion does not significantly impair the 
proliferation of non-transformed mammary epithelial cells 
I first sought to establish whether RNMT depletion affected the proliferation of 
immortalised mammary epithelial cells (IMECs). The IMEC cell line was 
originally established by overexpressing the catalytic subunit of human 
telomerase in primary human mammary epithelial cells. In addition, IMECs 
have previously been shown to be immortalised, but non-transformed 
(DiRenzo et al., 2002). When this project was initiated there were no specific 
inhibitors against RNMT activity, therefore, I explored whether RNMT 
expression could be depleted in IMECs using siRNA-mediated RNA-
Interference. Cells were transfected with three independent siRNAs targeting 
RNMT, or a non-targeting siRNA. 72 hr post-siRNA transfection, cells were 
lysed and protein lysates were immunoblotted with antibodies against RNMT 
and RAM to assess their expression. RNMT and RAM antibodies have 
previously been shown to be specific against endogenous RNMT and RAM 
protein expression, respectively (Gonatopoulos-Pournatzis et al., 2011). As 
shown in Figure 3.1A, the three independent siRNAs reduced endogenous 
RNMT protein expression. It has previously been reported that expression of 
RAM protein is dependent on RNMT protein expression, and vice and versa 
(Gonatopoulos-Pournatzis et al., 2011). Consistent with this, an efficient 
reduction in RNMT protein also caused a depletion of RAM protein using the 
three independent siRNAs (Figure 3.1A). It should be noted that detectable 




In order to investigate the effect of RNMT depletion on the ability of IMECs to 
proliferate, cells were transfected with three independent siRNAs targeting 
RNMT, or a non-targeting siRNA, and then counted on four consecutive days. 
Strikingly, as shown in Figure 3.1B, RNMT depletion did not significantly affect 
the proliferative capacity of IMECs. Reassuringly, each of the three 

























Figure 3.1 The proliferative capacity of IMECs is not significantly affected 
by siRNA-mediated RNMT depletion 
(A) Cells were transfected with 3 independent siRNAs targeting RNMT (1, 2, 3), 
or a non-targeting siRNA (-), for 72 hr. Protein lysates were analysed by 
immunoblotting with the indicated antibodies. Actin serves as loading control. 
(B) Equal number of cells were plated and transfected with siRNAs targeting 
RNMT (1, 2, 3) (day 0), or a non-targeting siRNA, and cells were counted on 4 
consecutive days (day 1, 2, 3, 4) using a cell counter. Error bars indicate SD. 
Result is representative of two independent biological replicates. 
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3.2.2 RNMT depletion impairs the proliferation of a subset of breast cancer 
cells 
To further assess the suitability of RNMT as a therapeutic target in breast 
cancer, I next investigated whether siRNA-mediated RNMT depletion impaired 
the proliferation of a panel of eight breast cancer cells lines (MCF7, HCC-1806, 
JIMT-1, T47D, CAMA-1, BT-549, MDA-MB-231, ZR.75.1). The key features 
(subtype, source, clinical features) of the breast cancer cell panel are shown in 
Table 7.1 in the appendix. Cells were transfected with three independent 
siRNAs targeting RNMT, or a non-targeting siRNA, and lysed 72 hr post-siRNA 
transfection. Protein lysates were then immunoblotted with antibodies against 
RNMT, and RAM, to assess RNMT depletion. As shown in Figure 3.2, 
transfection of three RNMT siRNAs, resulted in a reduction of RNMT 
expression in all the breast cancer cells tested. As observed in IMECs (Figure 
3.1A), transfection of RNMT siRNA resulted in a reduction in RAM expression. 
The immunoblots in Figure 3.2, show that both RNMT and RAM are depleted 
to similar levels across the different breast cancer cell lines. It should be noted 
that on longer immunoblot exposures, endogenous RNMT and RAM was 
detectable for all the breast cancer cell lines tested.  
To investigate the impact of RNMT depletion on the proliferation of the breast 
cancer panel, cells were transfected with three independent siRNAs targeting 
RNMT, or a non-targeting siRNA, and were then counted on four consecutive 
days (Figure 3.3). Interestingly, RNMT depletion was found to impair the 
proliferation of four breast cancer cell lines (MCF7, HCC-1806, JIMT-1 and 
T47D), whereas not significantly affecting the others (CAMA-1, BT-549, MDA-
MB-231 and ZR.75.1). For the following cell lines: T47D, CAMA-1, BT-549, 
MDA-MB-231 and ZR.75.1, transfection of the three independent RNMT 
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siRNAs produced a similar effect on the proliferation of each cell line (Figure 
3.3.). However, RNMT siRNA 2 was not as efficient at reducing cellular 
proliferation as RNMT siRNA 1 and 3 (Figure 3.3) for the following cell lines: 


















Figure 3.2 RNMT protein levels are effectively and equivalently depleted 
using siRNA-mediated RNA Interference in breast cancer cells  
Cells were transfected with 3 independent siRNAs targeting RNMT (1, 2, 3), or 
a non-targeting siRNA (-), for 72 hr. Protein lysates were analysed by 
immunoblotting with the indicated antibodies. Tubulin, or Actin, serve as 
loading controls. The cell lines tested are indicated below the loading controls. 















Figure 3.3 RNMT depletion impairs the proliferation of a subset of breast 
cancer cell lines 
Equal number of cells were plated and transfected with siRNAs targeting RNMT 
(1, 2, 3) (day 0), or a non-targeting control siRNA, and cells were counted in 
triplicate on 4 consecutive days (day 1, 2, 3, 4) using a cell counter. Graph 
shows the mean cell number against days of growth and SD. Result is 
representative of two independent biological experiments. 
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3.2.3 A subset of the breast cancer cell lines tested exhibit enhanced 
dependency on RNMT for survival 
If the depletion of RNMT can selectively inhibit the proliferation of breast 
cancer cells, it would provide the first evidence to suggest that RNMT would 
make a good therapeutic target in breast cancer. The afore-mentioned 
experiments (Figure 3.1 and Figure 3.3) showed that equivalent RNMT 
depletion impaired the proliferation of four breast cancer cell lines (MCF7, 
HCC-1806, JIMT-1 and T47D), whereas it did not significantly affect the 
proliferation of the other four breast cancer cell lines tested (CAMA-1, BT-549, 
MDA-MB-231 and ZR.75.1) and non-transformed mammary epithelial cells 
(IMECs). In an attempt to directly compare the ability of RNMT depletion to 
inhibit the proliferation of the breast cancer panel (MCF7, HCC-1806, JIMT-1, 
T47D, CAMA-1, BT-549, MDA-MB-231, ZR.75.1) and IMECs, cells were 
transfected with siRNA targeting RNMT, or a non-targeting siRNA, and cells 
were counted 96 hr post-siRNA transfection (Figure 3.4). It should be noted 
that previous experiments had shown that RNMT could be efficiently depleted 
in all the cell lines tested (Figure 3.1A and Figure 3.2). MCF7, HCC-1806, 
JIMT-1 and T47D exhibit a significant decrease in cell number in response to 
RNMT depletion, relative to IMECs (P ≤ 0.001, ANOVA followed by Dunnett’s 
multiple comparison test). Thus, I concluded these four cell lines were 
“sensitive to RNMT depletion” (Figure 3.4). In contrast, CAMA-1, BT-549, 
MDA-MB-231 and ZR.75.1 exhibit no significant decrease in cell number in 
response to RNMT depletion (P > 0.05, ANOVA followed by Dunnett’s multiple 
comparison test). Thus, I concluded these four cell lines were “insensitive to 
RNMT depletion (Figure 3.4). These results show that targeting RNMT can 
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selectively inhibit the proliferation of a subset of breast cancer cells, in 
comparison to non-transformed mammary epithelial cells. 
During the comparison of sensitivity to RNMT depletion, a key issue was 
whether the differential dependency of breast cancer cells on RNMT for 
proliferation (Figure 3.3 and Figure 3.4) was simply due to differences in 
RNMT depletion levels between the cells “sensitive to RNMT depletion” and 
those cells “insensitive to RNMT depletion”. To directly compare RNMT 
depletion levels between the two groups of cells, two representative cell lines 
from each group were transfected (MCF7, HCC-1806, BT-549 and ZR.75.1) 
with siRNA targeting RNMT, or a non-targeting siRNA, for 48 hr. Immunoblot 
analysis was then performed on protein lysates using antibodies that detect 
RNMT and RAM. This revealed that depletion of RNMT protein was relatively 
equivalent across the four cell lines tested. Furthermore, consistent with an 
equivalent reduction in RNMT levels, the depletion of RAM protein was also 
relatively equivalent across the four cell lines tested (Figure 3.5). These 
observations indicate that RNMT depletion is comparable in the breast cancer 



















Figure 3.4 A subset of breast cancer cell lines are significantly more 
dependent on RNMT for proliferation in comparison to IMECs 
Cells were transfected with siRNA RNMT 1, or non-targeting control siRNA, for 
96 hr and counted using a cell counter. Bar chart depicts mean number of 
RNMT siRNA transfected cells relative to non-targeting siRNA transfected cells. 
SD for 3 independent biological replicates are indicated. Statistical significance 
was assessed by ANOVA followed by Dunnett’s multiple comparison test using 
GraphPad Prism 5.0. ns P > 0.05, no significance difference compared to IMEC; 






















Figure 3.5 siRNA-mediated depletion of RNMT is relatively equivalent 
between the breast cancer cell lines tested 
Cells were transfected with siRNA targeting RNMT (+) or a non-targeting siRNA 
(-), for 48 hr. Resulting cell lysates were analysed by immunoblotting with the 
indicated antibodies. Actin blot serves as loading control. Result is 
representative of 2 independent biological replicates. The sensitivity of breast 
cancer cells to RNMT depletion is indicated. 
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3.2.4 Rescue of the proliferative defect induced by RNMT depletion 
To establish whether the impaired proliferation induced by RNMT depletion 
(Figure 3.3 and Figure 3.4) was specifically due to a reduction in RNMT 
expression, or was simply a consequence of siRNA off target effects, a 
“rescue” experiment was carried out. A siRNA-resistant RNMT-GFP construct 
was made by introducing several silent point mutations which altered the 
nucleotide sequence, but did not alter the amino acid sequence, into a GFP-
tagged full-length RNMT construct. For use in the rescue experiment, HCC-
1806 cells stably expressing siRNA-resistant RNMT-GFP, or vector control, 
were made by retroviral transduction. To determine RNMT and RAM 
expression levels in response to endogenous RNMT depletion, cells were 
transfected with siRNA targeting RNMT, or a non-targeting siRNA, for 72 hr 
and an immunoblot analysis was carried out using antibodies against RNMT 
and RAM (Figure 3.6A). This revealed that endogenous RNMT was depleted 
equivalently in cells expressing RNMT-GFP, or vector control, and there was a 
corresponding reduction in endogenous RAM protein in cells expressing vector 
control. I was able to demonstrate that expression of exogenous RNMT-GFP 
maintained RAM expression in spite of endogenous RNMT depletion (Figure 
3.6A). To test whether exogenous expression of RNMT-GFP could rescue the 
proliferative defect induced by endogenous RNMT depletion, cells were 
transfected with siRNA targeting RNMT, or non-targeting siRNA, and counted 
72 hr post-siRNA transfection (Figure 3.6B). Consistent with previous 
experiments (Figure 3.3 and Figure 3.4), depletion of endogenous RNMT 
significantly inhibited the cell number by approximately 40%, in comparison to 
cells transfected with non-targeting siRNA (P ≤ 0.001, ANOVA followed by 
Tukey’s multiple comparison test). Importantly, cells expressing RNMT-GFP 
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had no significant decrease in cell number in response to endogenous RNMT 
depletion, in comparison to cells transfected with non-targeting siRNA (P > 
0.05 ANOVA followed by Tukey’s multiple comparison test). Thus, expression 
of exogenous RNMT-GFP rescued the reduction in cell number of RNMT 
depleted cells. It should be noted that, in comparison to cells expressing vector 
control, exogenous expression of RNMT-GFP did not alter the proliferation rate 
of HCC-1806 cells (P > 0.05 ANOVA followed by Tukey’s multiple comparison 
test) (Figure 3.6B). Overall these results show that the impaired proliferation of 
RNMT depleted cells is indeed due to a reduction in RNMT expression, and is 














Figure 3.6 Exogenous expression of RNMT can rescue the proliferative 
defect induced by siRNA-mediated RNMT depletion  
HCC-1806 cells stably expressing RNMT-GFP (RNMT-GFP), or vector control 
(control), were plated in equal numbers and transfected with siRNA targeting 
RNMT (siRNA RNMT 1) (+), or non-targeting control (-), for 72 hr. (A) Protein 
lysates were analysed by immunoblotting with the indicated antibodies. Result 
is representative of two independent biological replicates. Actin serves as 
loading control. (B) Cell counts relative to control (i.e. control cells transfected 
with non-targeting siRNA) and SD for three independent biological replicates 
are indicated. Statistical significance was assessed using ANOVA followed by 
Tukey’s multiple comparison test using GraphPad Prism 5.0. ns P > 0.05, no 
significance difference compared with control cells treated with non-targeting 
siRNA; *** P ≤ 0.001. 
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3.2.5 RNMT depletion induces apoptosis in a subset of breast cancer cells 
Apoptosis is the process of programmed cell death and apoptosis could 
contribute to the reduced cell proliferation of cell lines “sensitive to RNMT 
depletion” (Evan and Vousden, 2001, Thompson, 1995). Interestingly, two 
studies have previously reported that a reduction in RNMT expression induces 
apoptosis in HeLa cells, a cervical cancer cell line (Chu and Shatkin, 2008, 
Gonatopoulos-Pournatzis et al., 2011). Therefore, I investigated the ability of 
RNMT depletion to induce apoptosis in breast cancer cells “sensitive” (MCF7 
and HCC-1806) and “insensitive” (MDA-MB-231 and ZR.75.1) to RNMT 
depletion. A well-characterised indicator of apoptosis is the cleavage of the 
poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) protein from 
112 kDa to 89 kDa. Thus, the induction of apoptosis in response to RNMT 
depletion was assessed by detecting PARP cleavage using immunoblot 
analysis. Cells were transfected with 3 independent siRNAs targeting RNMT, 
or a non-targeting siRNA, for 96 hr. The breast cancer cells were treated with 
straurosporine, a broad spectrum kinase inhibitor which is well-characterised 
inducer of apoptosis (Zhang et al., 2004). This served as a positive control for 
the immunoblot experiments. As shown in Figure 3.7 and Figure 3.8, for the 
four cell lines tested (MCF-7, HCC-1806, MDA-MB-231 and ZR.75.1), RNMT 
was efficiently depleted using each of the three independent RNMT siRNAs. 
Treatment of the cells with straurosporine induced the cleavage of PARP from 
112 kDa to 89 kDa. The immunoblot experiments revealed that RNMT 
depletion, with all three independent siRNAs, induced PARP-cleavage in 
MCF7 and HCC-1806 cells, whereas it did not significantly induce PARP-
cleavage in MDA-MB-231 and ZR.75.1 cells. These results show that RNMT 
depletion induces apoptosis in MCF7 and HCC-1806 cells, whereas it does not 
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significantly induce apoptosis in MDA-MB-231 and ZR.75.1 cells (Figure 3.7 
and Figure 3.8). Taken together, these results show that RNMT depletion can 
























Figure 3.7 Apoptosis is detected in MCF7 and HCC-1806 cells depleted of 
RNMT 
Cells were plated and transfected with 3 independent siRNAs targeting RNMT 
(1, 2, 3), or non-targeting control siRNA (-) for 96 hr. As a positive control for 
apoptosis, cells were treated with control siRNA for 72 hr followed with 1µM 
straurosporine (STA) (+) for 3 hr. Protein lysates were extracted and analysed 
by immunoblotting with the indicated antibodies. Actin serves as a loading 







Figure 3.8 Apoptosis is not significantly detected in MDA-MB-231 and 
ZR.75.1 cells depleted of RNMT 
Cells were plated and transfected with 3 independent siRNAs targeting RNMT 
(1, 2, 3), or non-targeting control siRNA (-) for 72 hr. As a positive control for 
apoptosis, cells were treated with control siRNA for 72 hr followed with 1µM 
straurosporine (STA) (+) for 3 hr. Protein extracts were analysed by 
immunoblotting with the indicated antibodies. Actin serves as a loading control. 




3.3 Discussion  
3.3.1 RNMT: a potential target in breast cancer? 
Deregulated mRNA translation is a characteristic of cancer and there has been 
considerable effort into developing strategies to target mRNA translation 
initiation for cancer therapeutics (Blagden and Willis, 2011, Silvera et al., 2010). 
From yeast to humans, the mRNA methyl cap is essential for efficient gene 
expression and cell viability (Furuichi and Shatkin, 2000). In humans, RNMT 
catalyses the methylation of the guanosine cap at the N-7 position. RNMT 
expression is essential for cellular cap methylation and efficient gene 
expression (Cowling, 2009a, Cowling, 2009b). Emerging evidence suggests 
that there is strong biological rationale to explore RNMT as a therapeutic target 
in breast cancer (Cowling, 2009a, Fernandez-Sanchez et al., 2009a, Cole and 
Cowling, 2009). An effective therapeutic target should reduce the proliferation of 
cancerous cells, but cause limited toxicity to non-cancerous cells.  
RNMT has previously been shown to be rate-limiting for efficient cell 
proliferation (Chu and Shatkin, 2008, Aregger and Cowling, 2013, 
Gonatopoulos-Pournatzis et al., 2011). However, there are no published data 
exploring whether inhibition of RNMT supresses the proliferation of all cells, or 
has selectivity for cancer cells. Therefore, in this thesis I set out to explore the 
suitability of RNMT as a therapeutic target in breast cancer. The data presented 
in this chapter has demonstrated for the first time that that RNMT depletion 
selectively inhibits the proliferation of breast cancer cells, in comparison to 
immortalised mammary epithelial cells. These data strongly suggest that RNMT 
should be explored as a therapeutic target in breast cancer. My findings add to 
the increasing body of data that has shown that targeting mRNA translation 
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initiation can selectively inhibit the growth of cancer cells (Silvera et al., 2010, 
Blagden and Willis, 2011, Graff et al., 2007, Moerke et al., 2007). 
 
3.3.2 RNMT depletion selectively inhibits the proliferation of a subset of 
breast cancer cell lines 
When targeting an essential process such as mRNA methyl cap synthesis, a 
major question is whether it will be significantly toxic to non-cancerous cells. 
Results in this chapter have shown that RNMT depletion does not significant 
affect the proliferation of immortalised mammary epithelial cells (IMECs). This 
suggests that non-transformed cells are less dependent on RNMT expression in 
comparison to certain cancer cells. Since detectable levels of RNMT expression 
remained in response to siRNA transfection, it is not possible to conclude that 
IMECs do not require RNMT for proliferation. It is likely that the low levels of 
RNMT expression that remained are enough to maintain cell proliferation. In 
future, it would be of interest to explore the effects of RNMT depletion in a 
different breast-derived non-transformed cell line, such as MCF10A, to fully 
establish the validity of the results. 
These observations demonstrate that a subset of breast cancer cells are 
significantly more dependent on RNMT expression for proliferation, in 
comparison to IMECs. Since three independent siRNAs targeting RNMT 
produced a similar effect and exogenous expression of siRNA-resistant RNMT 
rescued the impaired proliferation of RNMT depleted cells, it is likely that the 
observed proliferative defects of RNMT depleted cells is not simply due to 
siRNA off-target effects. Although our laboratory is currently screening for 
specific RNMT inhibitors in collaboration with the Drug Discovery Unit (College 
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of Life Sciences, University of Dundee), at present there are no specific 
inhibitors for RNMT. To establish the validity of my findings, it would be 
desirable to investigate the effects of an RNMT inhibitor on the breast cancer 
cell panel.  
It has been reported that RNMT exists in a complex with RAM (RNMT-activating 
mini protein). RAM enhances RNMT activity in vitro up to 5-fold and RAM 
expression is essential for cellular cap methylation and efficient gene 
expression (Gonatopoulos-Pournatzis et al., 2011). It has previously been 
reported that the expression of RAM protein is dependent on RNMT expression, 
and vice a versa (Gonatopoulos-Pournatzis et al., 2011). Consistent with this, 
for all the cell lines tested in this present study, a reduction in RNMT expression 
lead to a corresponding decrease in RAM protein expression. Thus, it is 
possible that RAM loss contributes to the reduced proliferative capacity of the 
“RNMT depletion sensitive” breast cancer cells.  
It is possible that the differential dependency of breast cancer cells on RNMT 
for proliferation is simply due to differences in RNMT depletion levels between 
cells “sensitive to RNMT depletion” and those cells “insensitive to RNMT 
depletion”. Western blot analysis, which can only be considered semi-
quantitative, of two representative cell lines from each group revealed that 





3.3.3 RNMT depletion induces apoptosis in a subset of breast cancer cells 
The observed reduction in cell number in RNMT depleted breast cancer cells 
could result from either a reduction in cell growth, or an increase in the rate of 
apoptosis (Evan and Vousden, 2001, Thompson, 1995). For the breast cancer 
cell lines “sensitive to RNMT depletion”, I observed that there was a substantial 
increase in the number of floating cells in the petri dish in response to RNMT 
depletion. Two previous studies have shown that RNMT depletion induces 
apoptosis in HeLa cells, a cervical cancer cell line (Chu and Shatkin, 2008, 
Gonatopoulos-Pournatzis et al., 2011). Measuring PARP cleavage using 
immunoblot analysis confirmed that RNMT depletion induces apoptosis in 
breast cancer cells “sensitive to RNMT depletion” but does not in those 
“insensitive to RNMT depletion”. These results suggest that apoptosis 
contributes to the reduction in cell number of breast cancer cells “sensitive to 
RNMT depletion”. The ability of RNMT to induce apoptosis in a subset of breast 
cancer cells provides evidence to suggest that targeting RNMT could be a 
suitable therapeutic target in a subset of breast cancer. However, in the future, 
it will be important to investigate whether RNMT depletion selectively induces 
apoptosis in breast cancer cells, in comparison to IMECs.  
A number of methods exist to detect apoptotic cells and it would be important to 
use several independent approaches to confirm the validity of my findings. For 
example, activated caspase-3, which an indicator of apoptosis could be 
measured using enzyme-linked immunosorbent assay (ELISA), or fluorescence 
activated cell sorting (FACS). Moreover, DNA fragmentation, which occurs 
during apoptosis, could be measured using terminal deoxynucleotidyl 
transferase nick end labelling (TUNEL).  
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In addition, it would be important to investigate the mechanisms by which 
RNMT depletion induces apoptosis in breast cancer cells. The mRNA methyl 
cap is essential for efficient cap-dependent translation and RNMT expression is 
rate-limiting for a subset of mRNAs (Cowling, 2009a). The balance of cellular 
pro- and anti-apoptotic proteins determines cell fate. It is possible that RNMT 
depletion inhibits the expression of certain anti-apoptotic proteins, but does not 
significantly affect the expression of pro-apoptotic proteins. If so, RNMT 
depletion may induce apoptosis by tipping the balance of cellular pro- and anti-
apoptotic proteins in favour of pro-apoptotic ones. Interestingly, several proteins 
which induce apoptosis, such as c-Myc and p53, are translated via a cap-
independent mechanism and expression of these proteins would likely be 
maintained in response to RNMT depletion (Hoffman and Liebermann, 1998, 
Spriggs et al., 2005, Yang et al., 2006, Ray et al., 2006, Liwak et al., 2012). It 
would therefore be of interest to investigate whether c-Myc and p53 are 
mediating the apoptotic effects observed in RNMT depleted cells. 
The reduced proliferation observed in cells depleted of RNMT may be caused 
completely by apoptosis, or it may be caused by the combined effect of 
apoptosis and growth arrest. Z-VAD.FMK is a caspase inhibitor that inhibits 
cellular apoptosis (Slee et al., 1996). To investigate whether the reduced 
proliferation of cells is completely dependent on apoptosis, the combined effect 
of Z-VAD.FMK and siRNA RNMT on the proliferation of breast cancer cells 
should be explored. If the above experiments indicate that growth arrest 
contributes to the reduced proliferation of RNMT depleted cells, it would be of 
interest to explore whether RNMT depletion affects cell cycle progression. This 
could be assessed by monitoring cellular DNA content using DNA staining 
followed by FACS. 
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3.3.4 Potential mechanisms of RNMT dependency in breast cancer cells 
The methyl cap is essential for efficient mRNA translation and it has been 
shown to promote several steps in gene expression (Furuichi and Shatkin, 
2000). It is likely that the breast cancer cells which are “sensitive to RNMT 
depletion” have an enhanced dependency on the methyl cap for survival. Since 
the methyl cap is essential for the translation of most mRNAs, inhibition of cap 
methylation has the potential to inhibit the actions of any oncogene that 
deregulates gene expression. Thus, targeting RNMT could be effective in a 
wide range of tumours driven by different oncogenes. However, the molecular 
mechanisms that render breast cancer cells dependent on RNMT expression 
for proliferation are unclear, and this is investigated in chapter 4 and chapter 5. 
eIF4E binds the mRNA methyl cap and eIF4E expression is rate-limiting for 
mRNA translation. There is a large body of data that suggests eIF4E is an 
effective therapeutic target in cancer (De Benedetti and Graff, 2004). Since the 
methylation of the guanosine cap is essential for efficient binding of eIF4E to the 
methyl cap (Niedzwiecka et al., 2002, von der Haar et al., 2004), it is possible 
that targeting RNMT could inhibit eIF4E function in cancer cells. It is possible 
that the breast cancer cells which are “sensitive to RNMT depletion” may have 
an enhanced dependency on eIF4E activity. This issue should be investigated 







Overall, the results presented in this chapter show that a subset of breast 
cancer cells have an enhanced dependency on RNMT for survival in 
comparison to immortalised mammary epithelial cells. These findings strongly 
suggest that RNMT should be perused as a therapeutic target in breast cancer. 
Furthermore, my findings have demonstrated for the first time that targeting 















Chapter 4: Investigating cellular sensitivity to 
RNMT depletion 
4.1 Introduction 
The results in chapter 3 demonstrated that RNMT depletion impairs the 
proliferation of a subset of breast cancer cell lines, but does not significantly 
affect the proliferation of immortalised mammary epithelial cells (IMECs).  
Many cancer therapies aim to exploit the fact that cancer cells exhibit 
enhanced dependence on a signalling pathway by targeting that pathway. 
Since a subset of breast cancer cells are more dependent on RNMT for 
survival, in comparison to IMECs, targeting RNMT may be an effective anti-
cancer strategy in a subset of breast cancers. However, it is important that we 
understand the molecular mechanisms that render breast cancer cells 
dependent upon RNMT for proliferation and survival. 
Therefore, I decided to explore the factors that determine cellular sensitivity to 
RNMT depletion. In this chapter, I investigate whether there is a correlation 
between various cellular parameters and cellular sensitivity to RNMT depletion 









4.2.1 RNMT protein is expressed at comparable levels across the breast 
cancer cell line panel 
The observation that experimental overexpression of RNMT is sufficient to 
transform mammary epithelial cells indicates that elevated RNMT expression 
could have the potential to contribute to breast cancer. This raises the 
possibility that breast cancer cells with elevated RNMT expression may exhibit 
an enhanced dependency on RNMT for survival. A search of ONCOMINE (a 
web-based microarray database) revealed that RNMT expression is not higher 
in breast cancer tissue in comparison to non-cancerous tissue. Moreover, no 
studies to date have examined RNMT protein expression in breast cancer. In 
order to test whether there was a relationship between RNMT expression and 
cellular sensitivity to RNMT depletion, I compared RNMT protein levels in the 
previously used eight breast cancer cell lines and in IMECs using immunoblot 
analysis with anti-RNMT and anti-RAM antibodies. As shown in Figure 4.1, 
RNMT expression levels were fairly comparable across all cell lines tested. As 
mentioned in the previous chapter, RNMT and RAM protein expression are co-
dependent (Gonatopoulos-Pournatzis et al., 2011). Consistent with an 
equivalent expression of RNMT, the expression of RAM protein was also fairly 
equivalent across the cell lines tested (Figure 4.1). However, it should be 
noted that between multiple biological replicates, I observed slight fluctuations 
in RNMT and RAM levels, which made it difficult to confidently conclude that 
RNMT and RAM were equivalently expressed across the cell lines panel. In an 
attempt to address this issue, I quantified the intensity of RNMT and RAM 
immunoblot bands from four independent biological replicates using Image J 
software (Figure 4.1B).This analysis revealed that there was no significant 
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difference in the protein expression levels of either RNMT or RAM across the 
cell panel (P > 0.05, one-way ANOVA). In order to help compare RNMT 
expression levels between the breast cancer cell lines “sensitive” and 
“insensitive” to RNMT depletion, the breast cancer cells in Figure 4.1, are 
arranged in order of decreasing sensitivity to RNMT depletion (from left to 
right). It is important point out that this order is used for several subsequent 
figures in this chapter (Figure 4.4, Figure 4.5, Figure 4.6, Figure 4.7 and Figure 
4.8). Overall these results show that expression of RNMT and RAM is not 
higher in breast cancer cells, in comparison to non-transformed mammary 
epithelial cells. Furthermore, RNMT and RAM protein is not differentially 
expressed between breast cancer cells “sensitive” (MCF7, HCC-1806, JIMT-1 
and T47D) and “insensitive” (CAMA-1, BT-549, MDA-MB-231 and ZR.75.1) to 
RNMT depletion (Figure 4.1). These results indicate that RNMT protein 













Figure 4.1 RNMT and RAM expression levels are similar across the cell 
line panel 
A) Protein lysates were analysed by immunoblotting with the indicated 
antibodies. Actin serves as a loading control. Result is representative of four 
biological replicates. The sensitivity of the breast cancer cells to RNMT 
depletion are indicated. B) RNMT and RAM immunoblot band intensities were 
quantified using Image J software. Bar chart depicts the mean band intensity 
quantification. SD for four independent biological replicates is indicated. 
Statistical significance was assessed by ANOVA using GraphPad Prism 5. For 
both RNMT and RAM expression, there was no significant difference in the 
















4.2.2 Cellular mRNA cap methyltransferase activity levels does not 
correlate with cellular sensitivity to RNMT depletion 
Cellular mRNA cap methyltransferase activity is dependent on RNMT 
expression (Cowling, 2009a). However, previous experiments in our laboratory 
have demonstrated that RNMT enzymatic (cap methyltransferase) activity can 
be regulated by phosphorylation (Aregger, unpublished). Therefore, despite 
RNMT expression levels being similar across the cell panel (Figure 4.1) the 
enzymatic activity could be different and may correlate with cellular sensitivity 
to RNMT depletion. To address this, I next sought to establish the mRNA cap 
methyltransferase activity levels across the cell panel. Cellular cap 
methyltransferase activity can be determined using an in vitro assay, which 
was established by the Shuman lab (Mao et al., 1995). This assay was 
performed as previously described in section 2.2.27 (Figure 4.2). To be able to 
accurately measure cap methyltransferase activity across the cell panel, it was 
important to first determine the linear range of the assay for each cell line. 
Therefore, protein lysates were extracted from the cell panel and the in vitro 
cap methyltransferase assay was performed using a titration of protein lysates 
from 0.25 µg to 1 µg. For all the cell lines tested (IMEC, MCF7, HCC-1806, 
JIMT-1, T47D, BT-549, CAMA-1, MDA-MB-231 and ZR.75.1), the assay was 
found to be linear between 0.25 µg to 1 µg of protein lysate (Figure 4.3). 
Therefore, I decided to use 0.5 µg of protein lysates for each reaction to 
compare the RNMT activity levels across the cell panel. As shown in Figure 
4.4, it was observed that two of the breast cancer cell lines (HCC-1806 and 
CAMA-1) have significantly lower RNMT activity levels, compared to IMECs (P 
≤ 0.5, ANOVA, followed by Dunnett’s multiple comparison test). Whereas, the 
RNMT activity levels between the remaining six breast cancer cell lines 
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(MCF7, JIMT-1, T47D, BT-549, MDA-MB-231 and ZR.75.1) and IMECs are not 
significantly different (P > 0.05, ANOVA followed by Dunnett’s multiple 
comparison test). It should be noted that IMECs and MCF7 cells have the 
highest RNMT activity levels of all the cell lines tested (Figure 4.4). The above 
results show that, except for MCF7 cells, breast cancer cells generally have 
lower RNMT activity levels compared to IMECs. Furthermore, as shown in 
Figure 4.4, there is no significant difference in the cap methyltransferase levels 
between the breast cancer cells “sensitive” (MCF7, HCC-1806, JIMT-1, T47D) 
and “insensitive” (CAMA-1, MDA-MB-231, ZR.75.1 and BT-549) to RNMT 
depletion. On the basis of these findings, I concluded that cap 
methyltransferase activity levels of the cell panel do not correlate with cellular 
sensitivity to RNMT depletion. 
Although it was shown that RNMT depletion levels are comparable in the breast 
cancer cells “sensitive” and “insensitive” to RNMT depletion (Figure 3.5), it was 
possible that there could be differences in the cap methyltransferase levels. 
Therefore, I next sought to measure cap methyltransferase levels in the RNMT 
depleted cell line panel. Cells were transfected with siRNA targeting RNMT, or a 
non-targeting siRNA, for 48 hr and the in vitro cap methyltransferase assay was 
performed on cell lysates. This revealed that there is approximately a two-fold 
decrease in cap methyltransferase levels in all the cell lines (Figure 4.5). Thus, 
it can be concluded that cap methyltransferase levels are equivalently depleted 






















Figure 4.2 Schematic of the in vitro cap methyltransferase assay 
The schematic illustrates the major steps of the assay and a typical 
autoradiography exposure is shown. Negative control without protein (-) and 
protein extract (RNMT) is indicated. To determine cellular cap 
methyltransferase levels, protein extracts were incubated with 32P-labelled 
capped in vitro transcribed RNA and the methyl donor S-adenosyl methionine 
(SAM). The resultant RNA was subsequently incubated with P1 nuclease to 
release the cap structures (GpppG and m7GpppG), which were then resolved 
by thin layer chromatography (TLC.) The conversion of cap (GpppG) to methyl 

























Figure 4.3 Optimisation of the in vitro cap methyltransferase assay for use 
with the cell panel  
Protein lysates were extracted from cells and the in vitro cap methyltransferase 
assay was performed using 0.25, 0.5 and 1 µg of protein lysates, or without 
lysates as a negative control, in the presence of in vitro transcribed [32-P]-
capped RNA and S-adenosyl-methionine. GpppG and m7GpppG were resolved 
using thin layer chromatography. [32-P] signal was detected using a 
phosphorimager and quantified using AIDA Image analyser. Each graph depicts 
the linear regression for each cell line between protein extract (µg) and the 
concentration of methyl capped RNA (pg) for one biological replicate carried out 
in duplicate. The linear regression coefficient (R2) was determined using 









Figure 4.4 mRNA cap methyltransferase activity levels in IMECs and 
breast cancer cells do not correlate with cellular sensitivity to RNMT 
depletion 
Protein lysates were extracted from cells and the in vitro cap methyltransferase 
assay was performed using 0.5 µg of total protein, or without lysate as a 
negative control, in the presence of in vitro transcribed [32P]-capped RNA and 
S-adenosyl-methionine. GpppG and m7GpppG were resolved using thin layer 
chromatography. [32P] signal was detected using a phosphorimager and 
quantified using AIDA Image analyser. Bar chart depicts the mean concentration 
of m7GpppG RNA (pg). SD for four biological replicates is indicated. Statistical 
significance was assessed using ANOVA followed by Dunnett’s multiple 
comparison test using GraphPad Prism 5.0. ns, P > 0.05 no significant 













Figure 4.5 mRNA cap methyltransferase activity levels are equivalently 
depleted in IMECs and breast cancer cells using siRNA-mediated RNMT 
depletion 
Cells were transfected with siRNA targeting RNMT or a non-targeting siRNA, for 
48 hr. The in vitro cap methyltransferase assay was performed using 1 µg of 
protein lysate, or without lysate as a negative control, in the presence of in vitro 
transcribed [32P]-capped RNA and S-adenosyl-methionine. GpppG and 
m7GpppG were resolved using thin layer chromatography. [32P] signal was 
detected using a phosphorimager and quantified using AIDA Image analyser. 
Bar chart depicts the mean concentration of m7GpppG RNA (pg) in RNMT 
depleted cells relative to cells transfected with non-targeting siRNA. SD for 
three biological replicates is indicated. Statistical significance was assessed by 
ANOVA using GraphPad Prism 5. There was no significant difference in the cap 
methyltransferase activity levels across the cell line panel (P > 0.05).  
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4.2.3 Global protein synthesis rates do not correlate with cellular 
sensitivity to RNMT depletion 
The increased proliferation of cancer cells is often dependent upon 
upregulated mRNA translation (Blagden and Willis, 2011, Johnson et al., 
1976). The efficient translation of most mRNAs is dependent upon the 
methylation of the mRNA methyl cap (Muthukrishnan et al., 1975, Schwer et 
al., 2000, Drummond et al., 1985). This raises the question whether cells with 
heightened protein synthesis rates exhibit an enhanced dependency on RNMT 
for proliferation. To test whether there was a relationship between the rate of 
global protein synthesis and cellular sensitivity to RNMT depletion, I measured 
the incorporation of 35S-labelled amino acids into proteins in the cell panel. As 
shown in Figure 4.6, compared to IMECs, 35S incorporation was significantly 
higher in four breast cancer cell lines (JIMT-1: P ≤ 0.001; HCC-1806: P ≤ 
0.001; ZR.75.1: P ≤ 0.001; CAMA-1: P ≤ 0.5; ANOVA followed by Dunnett’s 
multiple comparison test), whereas the 35S incorporation between IMECs and 
the remaining four breast cancer cell lines was not significantly different 
(MCF7, T47D, BT-549 and MDA-MB-231: P > 0.5; ANOVA, followed by 
Dunnett’s multiple comparison test; Figure 4.6). Overall these experiments 
show that a subset of breast cancer cells (HCC-1806, JIMT-1, CAMA-1 and 
ZR.75.1) exhibit an enhanced rate of global protein synthesis compared 
IMECs. However, this includes breast cancer cell lines which are “sensitive” 
(HCC-1806 and JIMT-1) as well as those “insensitive” (CAMA-1 and ZR.75.1) 
to RNMT depletion. The above findings suggest that an enhanced rate of 










Figure 4.6 Basal rate of global protein synthesis in IMECs and breast 
cancer cells does not correlate with cellular sensitivity to RNMT depletion 
Cells were incubated with media containing [35S]-labelled Met/Cys. [35S]-signal 
was detected using a phosphorimager and quantified using AIDA Image 
analyser. For each biological replicate, samples were labelled at duplicate and 
the bar chart depicts the mean CPM per µg of protein. SD for three independent 
biological replicates is shown. Statistical significance was assessed using 
ANOVA followed by Dunnett’s multiple comparison test using GraphPad Prism 
5.0. ns P > 0.05, no significant difference compared to IMEC; * P ≤ 0.05; ** P ≤ 




4.2.4 RNMT depletion does not significantly affect the rate of global 
protein synthesis   
The mRNA methyl cap is essential for efficient protein translation and RNMT 
expression has been shown to be rate-limiting for the translation of a subset of 
proteins (Cowling, 2009a). Therefore, the differential sensitivity of cells to 
RNMT depletion could be a due to a differential decrease in global protein 
synthesis. To test this hypothesis, IMECs and five breast cancer cell lines 
(MCF7, HCC-1806, JIMT-1, MDA-MB-231 and BT-549) were transfected with 
siRNA targeting RNMT, or non-targeting siRNA, and 40-48hr post-siRNA 
transfection and the global rate of protein synthesis was measured using 35S-
incorporation into proteins. This revealed that for MCF7 cells, RNMT depletion 
modestly reduced 35S incorporation by 25% (Figure 4.6). However, the effect 
of RNMT depletion on 35S incorporation between IMECs and all five breast 
cancer cell lines was not found to be significant (MCF7, HCC-1806, JIMT-1, 
MDA-MB-231 and BT-549) (P < 0.05; ANOVA, followed by Dunnett’s multiple 
comparison test). These results indicate that RNMT depletion does not 
significantly impact the rate of global protein synthesis in non-transformed 
mammary epithelial cells (IMEC) and in breast cancer cells “sensitive” (MCF7, 
HCC-1806 and JIMT-1) or “insensitive” (BT-549 and MDA-MB-231) to RNMT 
depletion. Taken together these results suggest that cellular sensitivity to 














Figure 4.7 RNMT depletion does not significantly affect the rate of protein 
synthesis in IMECs and breast cancer cells 
Cells were seeded and transfected with siRNA targeting RNMT, or non-targeting 
control siRNA, for 40-48 hr and then incubated with media containing [35S]- 
labelled Met/Cys. The [35S]-labelled signal was detected using a 
phosphorimager and was quantified using AIDA image analyser. For each 
biological replicate, samples were labelled at duplicate. Bar chart depicts the 
normalised mean CPM per µg of protein. SD for three independent biological 
replicates is indicated. Statistical significance was assessed using ANOVA 
followed by Dunnett’smultiple comparison test using GraphPad Prism 5.0. ns P 
> 0.05, no significant difference compared to IMEC. The sensitivity of breast 
cancer cells to RNMT depletion is indicated. 
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4.2.5 The rate of proliferation does not correlate with cellular sensitivity to 
RNMT depletion 
Previous publications have shown that RNMT expression is important for 
efficient cell proliferation (Aregger and Cowling, 2013, Gonatopoulos-
Pournatzis et al., 2011). Therefore, I investigated whether there was a 
correlation between proliferation rates and cellular sensitivity to RNMT 
depletion. To test this hypothesis, I compared the proliferation rate of the 
different cell lines in the panel. Cell number was established every 24 hr for a 
96 hr period post-seeding and the cell doubling time was calculated using the 
growth curve. As shown in Figure 4.8, the doubling time of the cell lines ranged 
from 23 hr to 33 hr. It was observed that three breast cancer cell lines (HCC-
1806, JIMT-1, T47D) have faster proliferation rates in comparison to IMECs 
(Figure 4.8). Whereas five breast cancer cell lines (MCF7, CAMA-1, BT-549, 
MDA-MB-231, ZR.75.1) have similar proliferation rates in comparison to 
IMECs. Interestingly, the fastest proliferating cells (HCC-1806, JIMT-1, T47D) 
are “sensitive” to RNMT depletion. However, as described in the previous 
chapter, the breast cancer cell line MCF7, which was found to be the cell line 
most dependent on RNMT for survival (Figure 3.3 and Figure 3.4), displayed 
the slowest proliferation rate of the cell lines tested. Therefore, from the small 
number of cell lines investigated here, there is no apparent correlation 















Figure 4.8 Proliferation rate of IMECs and breast cancer cells does not 
correlate with cellular sensitivity to RNMT depletion 
Cells were plated and counted every 24 hr for 96 hr using a cell counter. For 
each independent biological replicate, the cells were counted in triplicate and 
the mean cell doubling time established. Bar chart depicts the mean cell 
doubling time for each cell line and mean SD for two independent biological 
replicates. The sensitivity of breast cancer cells to RNMT depletion is indicated. 
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4.2.6 c-Myc protein expression does not correlate with cellular sensitivity 
to RNMT depletion 
The c-Myc onco-protein is deregulated in an estimated 70% of human cancers, 
and despite significant efforts, there are currently no therapeutic strategies to 
inhibit Myc function in cancer (Dang, 2012). A study from our lab demonstrated 
that inhibition of cap methylation selectively kills cells with elevated c-Myc 
expression (Fernandez-Sanchez et al., 2009a). Taken together these 
observations raise the possibility that breast cancer cells with elevated c-Myc 
expression may exhibit an enhanced dependency on RNMT for survival. To 
investigate whether there was a relationship between c-Myc expression and 
cellular sensitivity to RNMT depletion in the breast cancer cell panel, I 
determined c-Myc protein levels across the cell panel using immunoblot 
analysis with an anti-c-Myc antibody. Previous experiments have shown that 
the anti-c-Myc antibody is able to specifically detect c-Myc protein in 
immunoblot experiments (data not shown). In agreement with previous 
observations in our laboratory, IMECs have undetectable levels of c-Myc 
(Figure 4.8). The immunoblot experiment also revealed that c-Myc is 
differentially expressed across the breast cancer panel (Figure 4.9). It was 
found that breast cancer cells have either high (HCC-1806, JIMT-1, T47D and 
CAMA-1), intermediate (BT-549 and ZR.75.1), or low (MCF7 and MDA-MB-
231) c-Myc protein expression. However, no correlation between c-Myc protein 




















Figure 4.9 c-Myc protein expression in IMECs and breast cancer cell panel 
does not correlate with cellular sensitivity to RNMT depletion 
Protein extracts were analysed by immunoblotting with the indicated antibodies. 
Actin serves as loading control. Result is representative of two independent 





The results presented in this chapter demonstrated that cellular sensitivity to 
RNMT depletion does not correlate with cellular RNMT expression, RNMT 
enzymatic activity, global protein synthesis levels, basal cell proliferation rate 
and c-Myc protein expression.  
 
4.3.1 RNMT protein expression  
RNMT was not found to be expressed to higher levels in our breast cancer cell 
line panel, compared to immortalised mammary epithelial cells (IMECs). 
Moreover, RNMT was not observed to be differentially expressed between 
breast cancer cells “sensitive” and those “insensitive” to RNMT depletion. 
These results suggest that the enhanced dependency of breast cancer cells on 
RNMT for survival is not due to elevated RNMT expression. Consistent with 
my findings, a search of the ONCOMINE (a web based microarray database) 
revealed that RNMT mRNA expression is not higher in breast tumour tissue, in 
comparison to non-cancerous tissue. However, since experimental 
overexpression of RNMT has previously been shown to transform mammary 
epithelial cells, it is possible that elevated RNMT expression could contribute to 
breast cancer (Cowling, 2009a). In future, it could be important to examine 
RNMT protein expression in patient derived breast tumours, and to explore 






4.3.2 RNMT enzymatic activity 
RNMT catalyses the methylation of the guanosine cap and cellular mRNA cap 
methyltransferase levels are dependent on RNMT expression (Cowling, 
2009b). In this chapter it was revealed that the RNMT activity (cap 
methyltransferase) levels in the cell line panel do not correlate with cellular 
sensitivity to RNMT depletion. Moreover, it was observed that breast cancer 
cells generally have lower RNMT activity levels in comparison to IMECs. 
Surprisingly, this suggests that RNMT activity levels are lower in breast cancer 
cells, in comparison to non-transformed cells. However, it is important to note 
that the cap methyltransferase assay uses a single piece of in vitro transcribed 
RNA to measure cap methylation, and this may not accurately reflect the in 
vivo situation. Moreover, although demethylation of the mRNA methyl cap has 
not previously been described, it is possible that a cap demethylase exists in 
human cells and this would likely influence the cellular cap methyltransferase 
levels independent of RNMT activity. 
The fact that cap methyltransferase levels are equivalently reduced in the cell 
line panel suggests that siRNA-mediated RNMT depletion is comparable in 
these cell lines. Despite efficient depletion of RNMT expression in all the cell 
lines, only a two-fold decrease in cellular cap methyltransferase activity was 
detected. There are several possibilities which may explain why significant cap 
methyltransferase levels remain in RNMT depleted cells. Firstly, it is possible 
that RNMT activity is upregulated in response to RNMT depletion. Secondly, it 
is possible that the cap methyltransferase activity that remains results from 
another, as yet unidentified, cellular cap methyltransferase. However, since 
RNMT depletion results in a two-fold decrease in cap methyltransferase levels, 
130 
 
there is no other cellular cap methyltransferase that can fully compensate for 
the loss of RNMT activity/ function.  
 
4.3.3 Cellular proliferation rate 
Cellular proliferation rate was found not to correlate with cellular sensitivity to 
RNMT depletion. Several breast cancer cell lines were shown to have similar 
proliferation rates in comparison to IMECs. This indicates that, at least in 
culture conditions, breast cancer cells do not always proliferate faster than 
non-cancerous cells. However, breast cancer cells may have a selective 
advantage in vivo which confers a faster proliferation rate. 
 
4.3.4 Protein synthesis rate 
The enhanced proliferation of cancer cells is often dependent on the 
deregulation of mRNA translation (Blagden and Willis, 2011, Johnson et al., 
1976) and the translation of most mRNAs are dependent on the methyl cap 
structure (Furuichi and Shatkin, 2000). This chapter demonstrated that cells 
with heightened protein synthesis levels do not display an enhanced 
dependency on RNMT for survival. It has been reported the methyl cap is rate-
limiting for the translation of a subset of mRNAs. These mRNAs are termed as 
“methyl cap sensitive” mRNAs (Cowling, 2009a, Cole and Cowling, 2009). It 
remains unknown whether a correlation exists between the translation of 
“methyl cap sensitive” mRNAs and cellular sensitivity to RNMT depletion, and 
this is an issue that should be explored further.  
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It has been previously been shown that methyl capped RNA is translated more 
efficiently compared to capped RNA (Gillian-Daniel et al., 1998, Drummond et 
al., 1985). It remains a possibility that the differential cellular dependency on 
RNMT for survival is due to a differential ability to translate capped or methyl 
capped RNA. I did not explore this issue due to time restrictions, but in the 
future it would be of interest to compare the rate of translation of capped and 
methyl capped RNA in the cell line panel. 
The data presented in this chapter demonstrated that cellular sensitivity to 
RNMT depletion is not due to a differential reduction in global protein synthesis. 
Consistent with my findings, Cowling et al reported that RNMT depletion does 
not significantly impact global protein synthesis (Cowling, 2009a). Detectable 
levels of RNMT expression remain following siRNA transfection and it is 
possible that the low levels of RNMT that remain may be enough to maintain 
efficient protein synthesis. Thus, it cannot be concluded from this data that 
RNMT expression is not required for efficient protein synthesis. Moreover, it is 
possible that another enzyme exists which is functionally redundant with RNMT 
and is able to support protein synthesis by promoting mRNA cap methylation in 
response to RNMT depletion. To explore this issue further, the levels of mRNA 
cap methylation on endogenous transcripts should be measured by performing 
anti-methyl cap antibody immunoprecipitations on cellular RNA followed by real-
time PCR.  
 
Furthermore, it is important to note that the 35S technique used to measure 
global protein synthesis is not sensitive enough to detect a reduction in the 
translation of a small subset of mRNAs. Thus, the differential dependency of 
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cells on RNMT for survival could be due to a differential reduction in the 
translation of a small subset of mRNAs. This issue should be explored in the 
future. 
 
4.3.5 eIF4E, the mRNA cap binding protein 
The eIF4E-methyl cap interaction is essential for mRNA translation. Studies 
have shown that eIF4E depletion has limited effects on global protein 
synthesis, while specifically reducing the translation of “eIF4E-dependent” 
mRNAs (De Benedetti and Graff, 2004, Graff et al., 2007, Rinker-Schaeffer et 
al., 1992). These mRNAs generally encode for proteins that are known 
regulators of cell growth and survival, including oncogenic proteins  (Mamane 
et al., 2004, De Benedetti and Graff, 2004, Koromilas et al., 1992, Rosenwald 
et al., 1993, Kevil et al., 1995). Since eIF4E binding to the methyl cap is 
essential for eIF4E-mediated mRNA translation, it is possible that a reduction 
in cellular cap methylation (RNMT expression) will specifically reduce the 
translation of oncogenic “eIF4E-dependent mRNAs” (Sonenberg et al., 1979, 
Sonenberg et al., 1980). The differential response of breast cancer cells to 
RNMT depletion may be related to a differential dependency on “eIF4E-
dependent” proteins for cell survival. eIF4E is a c-Myc-transcriptional target 
gene and it has previously been shown that c-Myc increases the expression of 
eIF4E (Jones et al., 1996, Schmidt, 2004). Moreover, it has previously been 
reported that Myc upregulates the cap methylation of the eIF4E transcript 
(Cole and Cowling, 2009). Thus, it is likely that eIF4E protein expression is 
sensitive to changes in the levels of cellular mRNA cap methylation (RNMT 
expression levels). It would therefore be of interest to explore whether there is 
133 
 
a relationship between eIF4E expression and RNMT dependency in breast 
cancer cells.  
 
4.3.6 c-Myc protein expression 
Expression of the oncoprotein c-Myc is frequently deregulated in human 
cancers and no therapeutic strategies currently exists to target c-Myc function 
in cancer (Dang, 2012). It has previously been shown that c-Myc upregulates 
mRNA cap methylation and this is essential for c-Myc-driven protein synthesis, 
cell transformation and proliferation (Fernandez-Sanchez et al., 2009a, Cole 
and Cowling, 2009). Moreover, it has been reported that the inhibition of cap 
methylation selectively kills cells with elevated c-Myc expression (Fernandez-
Sanchez et al., 2009a). However, the data in this chapter demonstrated that 
there was no correlation between c-Myc protein expression and cellular 
sensitivity to RNMT depletion. This suggests that the differential sensitivity of 
breast cancer cells to RNMT depletion is not due to differences in c-Myc 
expression. It must be noted that c-Myc expression in the breast cancer cell 
lines panel does not correlate with the rate of proliferation and therefore c-Myc 
is not likely to be a driving force in the associated tumours.  
 
4.3.7 Summary 
In summary, the data presented in this chapter did not reveal any cellular 
parameters that determine cellular sensitivity to RNMT depletion. These results 
suggest that RNMT depletion only affects the translation of a subset of 
proteins since the global translation rates remains unchanged. It remains 
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unknown whether particular genetic mutations in breast cancer cells confer 




















Chapter 5: Investigation of the relationship 
between the PI3K pathway and RNMT  
5.1 Introduction 
In the third chapter I demonstrated that RNMT depletion impaired the 
proliferation of a subset of breast cancer cells, but did not significantly affect the 
proliferation of immortalised mammary epithelial cells (IMECs). The fact that a 
subset of breast cancer cells are more dependent on RNMT for survival, in 
comparison to non-transformed cells, suggests that therapeutically targeting 
RNMT could be an effective anti-cancer strategy for a subset of breast tumours.  
The efficacy of a targeted cancer therapy is often dependent on selecting the 
most receptive patient population. Therefore, in an attempt to understand why 
only certain breast cancer cells are sensitive to RNMT depletion, I explored 
whether basic cellular parameters correlated with cellular sensitivity to RNMT 
depletion. The results presented in the fourth chapter, found no relationship 
between RNMT expression, RNMT activity, protein synthesis rate, basal 
proliferation rate or cellular sensitivity to RNMT depletion.  
This current chapter focuses on exploring the genetic determinants of sensitivity 
to RNMT depletion. Specifically, I investigate whether the presence of an 
activating mutation in the gene phosphoinositide 3 kinase catalytic alpha 
(PIK3CA), which encodes the p110α catalytic subunit of PI3K, sensitises cells to 
RNMT depletion. Moreover, I explore whether activation of the PI3K pathway 
correlates with cellular sensitivity to RNMT depletion. 
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5.1.1 The PI3K pathway 
Protein kinases are key regulatory enzymes that can change the properties of a 
substrate by attaching a phosphate group to serine, threonine, or tyrosine 
resides. Phosphoinositide 3-kinases (PI3Ks) are a family of heterodimeric lipid 
kinases that, upon stimulation, catalyse the production of the second 
messenger phosphatidylinositol 3,4,5- trisphosphate (PI(3,4,5)P3), which in turn 
activates downstream kinases, such as 3-phosphoinositide dependent kinase 1 
(PDK1) and AKT. The three different classes of PI3K are classified according to 
their structure and substrate specificity. Only class I PI3Ks are able to produce 
(PI(3,4,5)P3) from the substrate phosphatidylinositol 4,5 bisphosphate 
(PI(4,5)P2) (Vanhaesebroeck et al., 2012, Vanhaesebroeck et al., 2010, Fruman 
and Rommel, 2014). Since only class I PI3Ks have been implicated in cancer 
pathogenesis this chapter introduction focuses on class I PI3Ks only.  
Class I PI3Ks are receptor regulated kinases that consist of a regulatory subunit 
and catalytic subunit. Four distinct isoforms of the catalytic subunit (p110α, 
p110β, p110γ and p110δ) have been identified in mammals and each of these 
are able to combine with different regulatory subunits (Vanhaesebroeck et al., 
2010, Zhao and Vogt, 2008b, Vanhaesebroeck et al., 2012). The different 
catalytic and regulatory subunits of mammalian class I PI3Ks are shown in 
Figure 5.1. 
Although the four p110 isoforms have identical catalytic activities, they have 
distinct and non-redundant biological functions. p110α and p110β expression is 
ubiquitous but p110γ and p110δ expression is predominately leukocyte-specific. 
Studies have shown that knockout of p110α or p110β in mice is embryonic 
lethal, whereas knockout of p110γ or p110δ in mice is non-lethal but results in 
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defective immune responses (Vanhaesebroeck et al., 2012, Vanhaesebroeck et 
al., 2010, Zhao and Vogt, 2008b). There is increasing evidence that p110α 
contributes to human cancer development and progression. For example, 
activating mutations in PIK3CA, the gene encoding the p110α catalytic subunit, 
are frequently found in cancer and several studies have shown these mutations 
to be oncogenic (Samuels et al., 2004a, Isakoff et al., 2005, Ikenoue et al., 
2005, Bader et al., 2006, Kang et al., 2005). Although the genes encoding the 
non-α p110 isoforms are not found to be mutated in cancer, the wild-type non-α 
p110 proteins are oncogenic when overexpressed in cells (Zhao and Vogt, 

















Figure 5.1 The catalytic and regulatory subunits of mammalian class I 
PI3Ks 
Class I PI3Ks consist of a regulatory subunit and a catalytic subunit. In 
mammals, four isoforms (p110α, p110β, p110δ and p110γ) of the p110 catalytic 
subunit have been identified. The catalytic subunits p110α, p110β and p110δ 
associate with the regulatory subunits p50α, p55α, p55γ, p85α and p85β. The 
p110γ subunit associates with the regulatory subunits p101 and p87. All Class I 
PI3Ks catalytic subunits consist of a PI3K core subunit that consists of a C2 
domain, a helical domain and a catalytic domain. The p110α, p110β and p110δ 
subunits also contain a p85-binding domain and a Ras-binding domain. The 
p110γ subunit contains a Ras-binding domain. All p85, p55 and p50 regulatory 
subunits have two SH2 domains and a p110 binding domain. The p101 and p87 
have no identifiable domains and lack homology to other known proteins. The 
functions of the individual p85 regulatory subunits are unknown. The functions 
of the individual catalytic subunits are described in the text. Adapted from 
(Vanhaesebroeck et al., 2010). 
 
5.1.2 Canonical PI3K signalling  
PI3K signalling regulates key cellular processes such as cell proliferation, 
growth and survival. A summary of PI3K-Akt signalling is shown in Figure 5.2. 
The binding of ligands to receptor tyrosine kinases (RTKs), such as human 
epidermal growth factor (HER2), initiates a cascade of events that ultimately 
lead to PI3K activation. Ligand binding to the receptor results in receptor 
dimerization and auto-phosphorylation of tyrosine residues, followed by the 
recruitment of src homology 2 (SH2) domain containing proteins to the plasma 
membrane–bound receptor. PI3K is one such protein that is recruited. The SH2-
domain of the p85 subunit of PI3K physically associates with the activated 
RTKs via the phospho-tyrosine residues (Liu et al., 2009a, Zhao and Vogt, 
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2008b). Alternatively, p85 can be recruited via an interaction with adaptor 
proteins, such as insulin receptor substrate 1, which interacts with the RTKs 
(Sun et al., 1991). Furthermore, PI3K can also associate with the plasma 
membrane via activated G protein coupled receptors (Stephens et al., 1994). 
The recruitment of PI3K to the activated receptor abolishes the suppressive 
effect of p85 on the catalytic activity of p110α, as well as enabling PI3K to co-
localise with its plasma membrane-bound substrate, PI(4,5)P2 (Yu et al., 1998). 
Furthermore, an association between p110α, the catalytic subunit of PI3K, and 
the small G-protein Ras enhances PI3K activation (Rodriguez-Viciana et al., 
1994).  Activated PI3K is then able to phosphorylate PI(4,5)P2  to produce 
PI(3,4,5)P3. The catalytic activity of PI3K is antagonised by the tumour 
suppressor phosphatase and tensin homolog (PTEN), which dephosphorylates 
PI(3,4,5)P3 to produce  PI(4,5)P2  (Myers et al., 1998, Maehama and Dixon, 
1998). The plasma membrane-bound PI(3,4,5)P3 is then able to recruit proteins, 
such as the serine-threonine kinase Akt (James et al., 1996, Burgering and 
Coffer, 1995) and its activating kinase PDK1 (Alessi et al., 1997a), to the 
plasma membrane via an interaction with their pleckstrin homology (PH)-
containing domains. Upon recruitment of Akt to PI(3,4,5)P3, a conformational 
change occurs in Akt which enables PDK1 to phosphorylate Akt at Thr 308 
(Alessi et al., 1997b, Milburn et al., 2003). Although phosphorylation of Akt at 
Thr 308 leads to a substantial increase in Akt activity, maximal Akt activity 
requires further phosphorylation of Akt at Ser 473, which is mediated by 
mTORC2 (Sarbassov et al., 2005). Following phosphorylation and activation, 
Akt translocates from the membrane to the nucleus where it is able to 
phosphorylate a diverse range of substrates (Manning and Cantley, 2007). 
Through the activation of these substrates, Akt is able to regulate a host of 
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cellular processes such as transcription, protein synthesis and cell growth 
(Manning and Cantley, 2007, Hers et al., 2011). For example, Akt regulates 
protein synthesis by signalling through the TSC complex, Rheb and mTORC1 to 
the downstream effectors 4E-BP and S6K1 (Laplante and Sabatini, 2012). In 
addition, Akt promotes cell proliferation by phosphorylating several proteins 
involved in the regulation of the cell cycle (Manning and Cantley, 2007). For 
example, phosphorylation of p27(Kip1) by Akt prevents p27(Kip1)-mediated cell 
cycle arrest, which results in  sustained cell proliferation (Liang et al., 2002, 











Figure 5.2 An overview of PI3K-Akt signalling 
Schematic illustrates a simplified version of PI3K-Akt signalling. Ligand (such as 
growth factor or hormone) binding activates RTKs, which in turn activates PI3K. 
PI3K consists of a p85 regulatory subunit and a p110 catalytic subunit. PI3K 
phosphorylates the membrane bound PI(4,5)P2 and produces PI(3,4,5)P3. This 
reaction is reversed by PTEN. PI(3,4,5)P3 stimulates the activation of Akt by 
PDK1 and mTORC2. PDK1 phosphorylates Akt on Thr 308, mTORC2 
phosphorylates Akt on Ser 473 . Activated Akt phosphorylates several 
downstream targets which lead to the activation of several of cellular processes 
such as cell growth, cell survival, cell proliferation and metabolism. PI3K 
signalling is described in detail in the text. 
 
5.1.3 Activating mutations in PIK3CA 
As mentioned above, class I PI3Ks are heterodimers consisting of a p85 
regulatory and a p110 catalytic subunit. PIK3CA is the gene coding for the 
p110α catalytic subunit of PI3K. Genetic cancer studies have demonstrated that 
PIK3CA mutations frequently occur in most human cancers (Samuels and 
Waldman, 2010, Samuels et al., 2004b) and PIK3CA somatic mutations are 
found in an estimated 18-40% of breast tumours (Bachman et al., 2004, 
Campbell et al., 2004, Lee et al., 2005, Levine et al., 2005, Saal et al., 2005, 
Network, 2012, Banerji et al., 2012, Stephens et al., 2012). The variation in the 
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reported frequency of PIK3CA mutations most likely reflects experimental 
differences across the studies; such as differences in the patient populations, 
tissue preparation and sample size. It remains controversial whether PIK3CA 
mutations in breast cancer patients correlate with clinical prognosis. Some 
studies have shown that breast cancer patients with PIK3CA mutations have a 
poor prognosis (Lai et al., 2008, Mangone et al., 2012, Barbareschi et al., 
2007), whereas other have reported an improved prognosis in patients with 
PIK3CA mutations (Kalinsky et al., 2009, Barbareschi et al., 2007, Dumont et 
al., 2012).  
Somatic mutations in PIK3CA are single nucleotide substitutions, and 80% of 
the PIK3CA mutations in human cancers are found in one of three “hot spot” 
mutations (E542K, E545K, H1047R), however, numerous rare cancer 
associated mutations have also been reported (Zhao and Vogt, 2008b). 
Exogenous overexpression of the hotspot p110α mutant proteins in various cell 
lines has shown that these mutations are oncogenic (Bader et al., 2006, 
Ikenoue et al., 2005, Isakoff et al., 2005, Zhao et al., 2005). Moreover, 
exogenous overexpression of most of the rare cancer-associated mutant p110α 
proteins is also sufficient to induce cell transformation (Gymnopoulos et al., 
2007). In addition, several transgenic mice studies have shown that expression 
of the p110α hot spot mutants (E545K and H1047R) result in mammary tumour 
formation, but the precise mechanisms of PIK3CA-induced mammary 
tumorigenesis have not yet been established (Adams et al., 2011, Meyer et al., 
2013, Liu et al., 2011, Koren and Bentires-Alj, 2013). A significant number of 
studies have shown that exogenous expression of PIK3CA activating mutants 
result in increased PI3K lipid kinase activity and constitutive Akt activation 
(Ikenoue et al., 2005, Kang et al., 2005, Isakoff et al., 2005, Gymnopoulos et al., 
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2007). Data from several independent laboratories have suggested that 
mutations in different regions of p110α have different mechanisms by which 
they increase PI3K activity (Huang et al., 2008, Gymnopoulos et al., 2007, Miled 
et al., 2007, Zhao and Vogt, 2008a). Furthermore, a transgenic mouse study 
showed that hotspot mutations in either the helical or kinase domain of p110α 
lead to mammary tumour formation (Meyer et al., 2013).  
Although, it is well established that exogenous expression of oncogenic PIK3CA 
results in constitutive Akt activation (Ikenoue et al., 2005, Gymnopoulos et al., 
2007, Isakoff et al., 2005), a correlation between endogenous activating 
PIK3CA mutations and Akt activation in breast cancer has not been established. 
For example, two studies found no relationship between PIK3CA activating 
mutations and enhanced Akt signalling in breast cancer cells (Dan et al., 2010, 
Stemke-Hale et al., 2008). Despite minimal Akt activation in breast cancer cells 
with oncogenic PIK3CA mutations, evidence suggests that activating mutants of 
p110α contributes to the survival of these cells. For example, the presence of 
an activating PIK3CA mutation can sensitise breast cancer cells to certain 
inhibitors of the PI3K pathway (Serra et al., 2008b, Sanchez et al., 2011, 
Weigelt et al., 2011a, Lehmann et al., 2011, Brachmann et al., 2009a, O'Brien 
et al., 2010, Tanaka et al., 2011, Brachmann et al., 2009b). Moreover, a study 
from the Bardelli laboratory showed that the knockin of activating mutations 
(E545K or H1047R) into wild-type PI3KCA in human immortalised breast 
epithelial cells, as well as non-cancerous MCF10A breast cells, results in cell 
transformation and can sensitise cells to everolimus, an mTORC1 inhibitor (Di 




5.1.4 Balance of PTEN and PI3K signalling in the cell 
Since PI3K and PTEN have opposing catalytic activities, it is tempting to equate 
a gain of PI3K function, to a PTEN loss of function. However, the fact that 
PIK3CA and PTEN mutations have been found to co-occur in breast cancer, 
indicates that these mutations may have different (or at least additive) functional 
effects in breast cancer (Stemke-Hale et al., 2008, Perez-Tenorio et al., 2007). 
Furthermore, it has been reported that a gain of PI3K induces cellular changes 
that are different from those conferred by PTEN loss of function. For example, 
several studies have shown that PTEN loss correlates with enhanced Akt 
activation in a range of human cancer cells, but no relationship exists between 
PIK3CA activating mutations and Akt activation (Dan et al., 2010, Stemke-Hale 
et al., 2008, Vasudevan et al., 2009b). Interestingly, a study showed that breast 
cancer cells with oncogenic mutations in PIK3CA, which also exhibit minimal 
Akt activation, have a reduced dependency on Akt signalling for tumorigenicity. 
These findings suggest that PIK3CA mutations may contribute to oncogenesis 
at least partly via Akt-independent mechanisms. For example, breast cancers 
cells with activating PIK3CA mutations can display an enhanced dependence 
on PDK1 and serum and glucocorticoid regulated protein kinase 3 (SGK3) for 
survival. (Vasudevan et al., 2009b). It is important to note that the catalytic 
antagonism of PTEN and PI3K is not the only determinant of the balance 
between cellular PTEN and PI3K signalling. It is likely that the different cellular 
localisation of PTEN and PI3K, as well as their interactions with different 
proteins, could influence the balance between PI3K and PTEN signalling in the 
cell (Zhao and Vogt, 2008b). 
The fact that breast cancer cells with oncogenic PIK3CA can display different 
drug sensitises from those with loss of PTEN function, provides strong evidence 
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that a gain of PI3K and loss of PTEN activities contribute to cancer 
pathogenesis differently. A large body evidence from preclinical and clinical 
studies shows that gain of PIK3CA function correlates with PI3K pathway 
inhibitor response in breast cancer (Serra et al., 2008b, Sanchez et al., 2011, 
Weigelt and Downward, 2012, Weigelt et al., 2011b, Lehmann et al., 2011, 
Brachmann et al., 2009b, O'Brien et al., 2010, Tanaka et al., 2011, Janku et al., 
2011). However, whilst loss of PTEN is known to be a robust activator of PI3K 
signalling (Stemke-Hale et al., 2008), the relationship between PTEN loss and 
PI3K pathway inhibitor response in breast cancer is not as clear (Sanchez et al., 
2011, Weigelt et al., 2011a, Lehmann et al., 2011, Tanaka et al., 2011, 
Brachmann et al., 2009a, O'Brien et al., 2010, Weigelt and Downward, 2012). It 
is important to note that one study demonstrated that the mutational status of 
the PI3K pathway did not predict the sensitivity of a panel of 39 cancer cell lines 
to 25 inhibitors of the PI3K pathway (Dan et al., 2010). Cancers are highly 
heterogeneous and it likely that the response to inhibitors of different 
components of the PI3K pathway may be limited to those tumours whose 
survival is dependent the targeted oncogenic protein.  
 
5.1.4 Hyper-activation of PI3K signalling in breast cancer 
The PI3K pathway is frequently mutated in a wide range of human cancers 
resulting in hyper-activation of PI3K signalling (Wood et al., 2007, Liu et al., 
2009a, Thomas et al., 2007) and a number of studies have demonstrated a role 
for PI3K hyper-activation in cancer development and progression (Chang et al., 
1997, Vogt et al., 2010, Sugimoto et al., 1984, Bader et al., 2006, Gymnopoulos 
et al., 2007, Kang et al., 2006). As discussed in section 1.9.4, the PI3K-Akt-
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mTOR pathway regulates mRNA translation. It has been shown that the 
deregulation of mRNA translation by hyper-activated PI3K signalling is essential 
for PI3K-mediated oncogenesis (Hsieh et al., 2010, Skeen et al., 2006). The 
PI3K pathway is the most frequently mutated pathway in breast cancer and an 
estimated 60% of breast tumours display hyper-activated PI3K signalling (Miller 
et al., 2011, Polyak and Metzger Filho, 2012, Network, 2012, Wood et al., 
2007). The most commonly observed mechanisms of PI3K signalling hyper-
activation found in breast cancer include: loss of PTEN or inositol 
polyphosphate-4-phosphatase function; activating mutation, or overexpression, 
of the p110α catalytic subunit of PI3K, Akt or Ras; inactivating mutation of p85α 
and the amplification of RTKs such as HER2 and fibroblast growth factor 
receptor (Miller et al., 2011). It is important to note that activating mutations in 
the gene PIK3CA, which encodes for the p110α catalytic subunit of PI3K, is one 
the most frequently mutated genes found in breast cancer (Wood et al., 2007, 
Banerji et al., 2012, Stephens et al., 2012, Polyak and Metzger Filho, 2012, 
Network, 2012). 
 
5.1.5 Therapeutic targeting of the PI3K pathway 
Since the PI3K pathway is frequency mutated in human cancers and is a key 
regulator of processes essential for cancer growth it is not surprising that 
components of the PI3K pathway are viewed as attractive therapeutic targets in 
cancer. In recent years there have been significant efforts to develop specific 
inhibitors against several components of the PI3K pathway for use in anti-
cancer therapy and several inhibitors of this pathway are currently in clinical 
trials (Weigelt and Downward, 2012, Liu et al., 2009a, Rodon et al., 2013). 
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Emerging data from clinical studies show that inhibitors of the PI3K pathway 
have limited anti-cancer effects when used as single agents, and the 
emergence of drug resistance is frequent. In an attempt to improve the efficacy 
of therapeutic PI3K inhibitors, there is significant effort to identify combination 
therapies of PI3K inhibitors with other anti-cancer therapies and to establish the 
















5.2.1 PI3K pathway mutations found in the breast cancer panel 
Previous results have shown that four breast cancer cells lines are sensitive to 
RNMT depletion (MCF7, HCC-1806, JIMT-1 and T47D), whereas four breast 
cancer cells are insensitive to RNMT depletion (CAMA-1, BT-549, MDA-MB-231 
and ZR.75.1) (Figure 3.3 and Figure 3.4). However, the mechanism of cellular 
sensitivity to RNMT depletion remains undetermined. In an attempt to identify 
genetic mutations that may confer cellular sensitivity to RNMT depletion, the 
Catalog of Somatic Mutations In Cancer (COSMIC) database was used to 
identify the cancer-associated somatic mutations found in the breast cancer cell 
panel (Forbes et al., 2010) (Figure 5.2). It was found that three out of the four 
breast cancer cell lines which are sensitive to RNMT depletion (MCF7, T47D, 
JIMT-1) have activating mutations (E545K, H1047R and C420R, respectively) in 
the gene PIK3CA, which encodes the p110α catalytic subunit of PI3K. These 
mutations in PIK3CA result in single amino acid substitutions. Studies have 
shown that exogenous expression of these p110α mutants results in PI3K 
activation and oncogenesis (Bader et al., 2006, Ikenoue et al., 2005, Isakoff et 
al., 2005). E545K and H1047R are hot spot mutations, whereas C420R is a rare 
cancer associated mutation (Zhao and Vogt, 2008b). In addition, HCC-1806 
cells, which are also sensitive to RNMT depletion, have an LKB1 deletion. Loss 
of LKB1 function has previously been shown to result in enhanced mTORC1 
activity (Shaw et al., 2004). Moreover, it was found that three out of four the 
breast cancer cell lines (CAMA-1, BT-549 and ZR.75.1) which are insensitive to 
RNMT depletion have mutations that lead to loss of PTEN function. As 
discussed in section 5.1.4, both loss of PTEN and gain of PIK3CA are 
commonly found in breast tumours and result in hyper-activation of PI3K 
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signalling (Miller et al., 2011). Overall these findings show that the breast 
cancer cells which are sensitive to RNMT depletion have either a PIK3CA 































Figure 5.3 Known gene mutations in the breast cancer cell lines studied in 
this thesis 
Mutational information was obtained from the online Catalogue Of Somatic 
Mutations In Cancer (COSMIC) database 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) or the references 
indicated. Only genes that are defined by COSMIC as being cancer associated 
have been listed here. 
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5.2.2 PI3K-Akt-mTOR pathway activation in the cell panel 
Mutations in the PI3K pathway that lead to deregulated PI3K signalling can 
render breast cancer cells sensitive to certain therapeutic inhibitors of the PI3K 
pathway (Weigelt and Downward, 2012). Since the breast cancer cells studied 
in this project were found to harbour mutations that have the potential to 
deregulate PI3K-Akt-mTOR signalling (Figure 5.3), an obvious question was 
whether PI3K pathway activation correlated with cellular sensitivity to RNMT 
depletion. To assess PI3K-Akt-mTOR pathway activation in the panel of breast 
cancer cells, and immortalised mammary epithelial cells (IMECs), the levels of 
phosphorylated forms of Akt (Ser 473 and Thr 308), S6K (Thr 389) and 4E-BP1 
(Thr 37/46 and Thr 70) were assessed using immunoblot analysis (Figure 5.3). 
The activation of Akt was determined by assessing Akt phosphorylation levels 
at Ser 473 and Thr 308. This revealed that all the breast cancer cell lines 
“insensitive” to RNMT depletion (CAMA-1, BT-549, MDA-MB-231 and ZR.75.1), 
one of the breast cancer cell lines “sensitive” to RNMT depletion (JIMT-1) and 
IMECs all displayed enhanced levels of Akt phosphorylation (Ser 473). In 
contrast, three out the four breast cancer cell lines “sensitive” to RNMT 
depletion had undetectable levels of Ser 473 Akt phosphorylation. This result 
indicates that breast cancer cells which are sensitive to RNMT inhibition 
generally have lower Akt phosphorylation levels at Ser 473. In contrast, it was 
found that cells displayed either high (BT-549 and IMECs), intermediate (JIMT-
1, CAMA-1 and ZR.75.1), or low (MCF7, HCC-1806, T47D and MDA-MB-231) 
levels of Thr 308 Akt phosphorylation. Strikingly, the levels of Thr 308 Akt 
phosphorylation across the cell panel did not appear to correlate with cellular 
sensitivity to RNMT depletion (Figure 5.4).  
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The activation of mTORC1 was assessed by monitoring the phosphorylation 
levels of S6K and 4E-BP1. Similar levels of S6 protein and S6 phosphorylation 
(Thr 389) was detected in all the cell lines, except for MCF7, which displayed 
substantially higher levels of S6 protein expression and S6K phosphorylation. 
This result is consistent with previously observations that S6K protein 
expression is upregulated in MCF7 cells due to gene amplification (Bärlund et 
al., 2000). In addition, similar levels of 4E-BP phosphorylation at Thr 37/46 and 
Thr 70 were detected in all the cell lines, apart from BT-549 which had 
increased phosphorylation at both Thr 37/46 and Thr 70. Protein expression 
levels of 4E-BP were variable across all the cell lines tested. Overall, there did 
not appear to be any correlation between cellular sensitivity and mTORC1 
activity (Figure 5.4). 
Taken together, these results show that breast cancer cells which are sensitive 
to RNMT inhibition generally display lower levels of phosphorylation of Akt at 
Ser 473. However, there seems to be no correlation between cellular 
sensitivity to RNMT depletion and global Akt phosphorylation at Ser 308, or 












Figure 5.4 Immunoblot analysis of PI3K-Akt-mTOR pathway activation in 
IMECs and breast cancer cells 
Protein lysates were analysed by immunoblotting with the indicated antibodies. 
Actin serves as loading control. Results are representative of two independent 
biological replicates. Sensitivity to RNMT depletion is indicated. 
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5.2.3 Expression of PI3K p110α activating mutants increase PI3K 
signalling in ZR.75.1 cells 
As discussed above, the gene PIK3CA is frequently mutated in breast tumours 
(Network, 2012, Polyak and Metzger Filho, 2012). These PIK3CA mutants are 
oncogenic and the presence of activating PIK3CA mutations can sensitise 
breast cancer cells to certain inhibitors of the PI3K pathway (Serra et al., 2008a, 
Sanchez et al., 2011, O'Brien et al., 2010, Weigelt et al., 2011b, Brachmann et 
al., 2009a, Tanaka et al., 2011). It was observed that three out the four breast 
cancer cell lines (MCF7, HCC-1806 and JIMT-1) which are “sensitive” to RNMT 
depletion have activating mutations in PIK3CA (E545K, H1047R and C420R, 
respectively) (Figure 5.3), whereas none of the breast cancer cell lines which 
are “insensitive” to RNMT depletion have oncogenic mutations in PIK3CA. This 
raises the possibility that activating mutations in PIK3CA may contribute to 
cellular sensitivity to RNMT depletion. To test this, I investigated whether 
exogenous expression of p110α activating mutants in an “RNMT depletion 
insensitive” cell line can render the cell line “RNMT depletion sensitive”. 
Previous experiments showed ZR.75.1 breast cancer cells to be insensitive to 
RNMT depletion (Figure 3.3 and Figure 3.4). Thus, I generated ZR.75.1 cells 
stably expressing Myc-tagged wild-type, or oncogenic activating mutants 
(E545K, H1047R, C420R), of p110α, or vector control using retroviral 
transduction. I was unable to detect expression of the exogenous p110α 
proteins using immunoblotting alone (data not shown). Therefore, to assess 
expression of the exogenous constructs, cell lysates were immunoprecipitated 
and immunoblotted using an anti-9E10 antibody that detects the Myc tag. This 
revealed that p110α wild-type, and activating mutants (C420R, E545K, 
H1047R) were expressed to similar levels (Figure 5.4A). Moreover, RNMT 
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expression levels were unaffected by exogenous expression of wild-type, or 
activating mutants, of p110α (Figure 5.5A). 
Activation of Akt is essential for PI3K signalling and Akt activation has been 
shown to be dependent on the Akt phosphorylation at the sites Ser 473 and Thr 
308 (Alessi et al., 1997b, Milburn et al., 2003, Sarbassov et al., 2005). To 
determine the effects of the p110α activating mutants on PI3K signalling, I 
assessed the levels of Akt phosphorylation by immunoblotting protein lysates 
with antibodies that detect Akt protein and the phosphorylated forms of Akt (Thr 
308 and Ser 473). Despite similar expression levels of Akt protein, cells 
exogenously expressing the p110α mutants (C420R, E545K, H1047R) 
displayed increased Akt phosphorylation at both Ser 473 and Thr 308, 
compared with cells expressing wild-type p110 (Figure 5.5B). Overall these 
results show that although wild-type, and the three activating mutants, of p110α 
are expressed to similar levels (Figure 5.5A), the mutants are more effective at 













Figure 5.5 Expression of PI3K p110α activating mutants increase Akt 
phosphorylation in ZR.75.1 cells  
Cells stably expressing Myc-tagged wild-type (WT), activating mutants (C420R, 
E545K, H1047R) of PI3K p110α, or vector control were lysed. (A) 1.5 mg of 
protein lysates were immunoprecipitated with anti-9E10 antibody and 
immunoblot analysis performed on immunoprecipitates using anti-c-Myc (9E10) 
antibody and on IP inputs using the anti-Actin and anti-RNMT antibodies. Actin 
serves as loading control. Result is representative of two independent biological 
experiments. (B) Protein lysates were analysed by immunoblotting with the 
indicated antibodies. Actin serves as loading control. Result is representative of 
two independent biological replicates. 
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5.2.4 Expression of PI3K p110α mutants sensitise ZR.75.1 cells to RNMT 
depletion 
I next sought to establish whether exogenous expression of the activating 
p110α mutant proteins can render ZR.75.1 cells sensitive to RNMT depletion. It 
was first important to assess whether exogenous expression of oncogenic 
p110α mutant proteins (C420R, E545K and H1047R) affected RNMT depletion 
levels. Therefore, cells were transfected with siRNA targeting RNMT, or a non-
targeting siRNA, for 72 hr and protein lysates were then immunoblotted with 
antibodies against RNMT, Akt and the phosphorylated form of Akt (Ser 473). 
This revealed that RNMT protein was equivalently depleted in cells expressing 
wild-type, or the activating mutants, of p110α (Figure 5.6). This result was also 
produced using an independent siRNA targeting RNMT (siRNA RNMT 3) (data 
not shown). Consistent with the previous result (Figure 5.5B), there was a 
substantial increase in Akt phosphorylation (Ser 473) in cells expressing mutant 
p110α ,compared to cells expressing wild-type p110α (Figure 5.6). In addition, 
RNMT depletion resulted in reduced Akt phosphorylation (Ser 473) levels in 
cells expressing vector control, p110α wild-type and the p110α C420R mutant. 
To determine whether exogenous expression of activating p110α mutants can 
render ZR.75.1 cells sensitive to RNMT depletion, I assessed whether RNMT 
depletion preferentially inhibited the growth of cells expressing p110α activating 
mutants, compared to cells expressing wild-type p110α. Cells were transfected 
with siRNA targeting RNMT, or a non-targeting siRNA, and were counted on 
three consecutive days. Consistent with previous observations (Figure 3.3 and 
Figure 3.4), RNMT depletion does not affect the proliferation of ZR.75.1 cells 
(Figure 5.7A). Strikingly, it was revealed that RNMT depletion resulted in a 
greater decrease in proliferation in cells expressing the p110α mutants, 
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compared to cells expressing p110 wild-type, or vector control. Exogenous 
expression of each of the three oncogenic p110α mutants (C420R, E545K and 
H1047R) resulted in a similar reduction in proliferation in response to RNMT 
depletion. It is important to note that there was no difference in the basal 
proliferation rate of ZR.75.1 cells expressing wild-type, or the p110α mutants 
(data not shown).   
To further expand on the above findings, cells were transfected with an siRNA 
targeting RNMT, or a non-targeting siRNA, and cells were counted 72 hr post-
siRNA transfection. As shown in Figure 5.7B, RNMT depletion resulted in a 
significant decrease in proliferation in cells expressing mutant p110α, compared 
to cells expressing wild-type p110α, or vector control (P ≤ 0.01, ANOVA 
followed by Dunnett’s multiple comparison test). As expected, a similar result 
was produced when RNMT was depleted using an additional siRNA targeting 
RNMT (Figure 5.7C) (P ≤ 0.001, ANOVA followed by Dunnett’s multiple 
comparison test). 
Overall these results demonstrate that exogenous expression of the p110α 
mutants (E545K, C420R and H1047R) in ZR.75.1 cells result in increased PI3K 
signalling and leads to an enhanced dependence on RNMT for proliferation. 
These results support the notion that breast cancer cells harbouring activating 
mutations in the gene PIK3CA have enhanced sensitivity towards RNMT 
depletion, which suggests that PIK3CA mutations and enhanced PI3K signalling 
























Figure 5.6 RNMT is equivalently depleted using siRNA in ZR.75.1 cells 
expressing either wild-type, or activating mutants, of PI3K p110α  
Cells stably expressing wild-type (WT), activating mutants (C420R, E545K, 
H1047R) of PI3K p110, or vector control (control), were transfected with siRNA 
targeting RNMT (siRNA RNMT 1) (+), or non-targeting siRNA (-), for 72 hr and 
then lysed. Protein lysates were analysed using immunoblotting with the 



























Figure 5.7 Expression of PI3K p110α activating mutants in ZR.75.1 cells 
result in an enhanced dependence on RNMT for proliferation 
Cells stably expressing wild-type (WT), activating mutants (C420R, E545K, 
H1047R) of PI3K p110α, or vector control (control), were seeded. (A) Cells were 
transfected with siRNA targeting RNMT (RNMT 3), or non-targeting siRNA, and 
were counted at triplicate on three consecutive days (day 1, 2, 3) using a cell 
counter. Graph shows mean cell number against days of growth and SD. 
(B) Cells were transfected with siRNA targeting RNMT (siRNA RNMT 1) (+), or 
a non-targeting siRNA (-), for 72 hr and were counted using a cell counter. Each 
bar chart depicts mean relative cell number and SD for three independent 
biological replicates. Statistical significance was assessed using ANOVA 
followed by Dunnett’s multiple comparison test using GraphPad Prism 5.0. ns P 
> 0.05, no significant difference compared to control cells transfected with 
siRNA RNMT; ** P ≤ 0.01; *** P ≤ 0.001. (C) same as (B) except cells 















5.2.5 Expression of PI3K p110α activating mutants in IMECs increase PI3K 
signalling  
It has previously been shown that exogenous overexpression of oncogenic 
p110α in MCF10A non-transformed breast cells results in constitute Akt 
activation and leads to transformation (Isakoff et al., 2005). Furthermore, 
“knockin” of hot spot mutations into the gene PIK3CA (E545K and H1047R) in 
MCF10A cells can sensitise them to everolimus, an mTORC1 inhibitor (Di 
Nicolantonio et al., 2008, Di Nicolantonio et al., 2010). Previous experiments 
have shown that RNMT depletion does not significantly affect the proliferation of 
immortalised mammary epithelial cells (IMECs) (Figure 3.1 and Figure 3.4). To 
further explore whether activating mutations in PIK3CA can contribute to cellular 
sensitivity to RNMT depletion, I assessed whether exogenous expression of 
activating p110α mutants in IMECs can sensitise cells to RNMT depletion. To 
do this, I generated IMECs stably expressing Myc-tagged wild-type p110α, or 
activating mutants (C420R, E545K and H1047R) using retroviral transduction. I 
was unable to detect expression of the p110α constructs by immunoblotting 
alone (data not shown). To assess the expression of the exogenous constructs, 
cell lysates were immunoprecipitated and immunoblotted using an anti-9E10 
antibody that detects the Myc tag. Despite equal IP protein input, as judged by 
similar actin levels, the p110α mutants E545K and H1047R were expressed to 
lower levels in comparison to wild-type p110α, or the C420R mutant (Figure 
5.8A). Furthermore, RNMT expression levels were not shown to be affected by 
exogenous expression of wild-type, or oncogenic mutants, of p110α protein 
(Figure 5.8A). To determine the effects of activating mutants of p110α on the 
activation of the PI3K signalling, I assessed the levels of Akt phosphorylation 
(Ser 473 and Thr 308) by immunoblotting protein lysates with antibodies that 
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detect Akt protein and the phosphorylated forms of Akt (Ser 473 and Thr 308). It 
was found that cells expressing exogenous p110α mutants (C420R, H1047R, 
E545K) displayed increased Akt phosphorylation at both sites, compared with 
cell expressing wild-type p110α, or vector control (Figure 5.8B). Despite lower 
expression of the p110α mutants E545K and H1047R, the three p110α mutants 
display a similar increase in the levels of Akt phosphorylation. Overall these 
results show that exogenous expression of the p110α mutants (C420R, 





















Figure 5.8 Expression of PI3K p110α activating mutants increase Akt 
phosphorylation in IMECs  
Cells stably expressing Myc-tagged wild-type (WT), activating mutants (C420R, 
E545K, H1047R) of PI3K p110α, or vector control were lysed. (A) 1.5 mg of 
protein lysates were immunoprecipitated with anti-9E10 antibody and 
immunoblot analysis performed on immunoprecipitates using anti-c-Myc (9E10) 
antibody and on inputs using the anti-Actin and anti-RNMT antibodies. Actin 
serves as loading control. Result is representative of two independent biological 
replicates. (B) Protein lysates were analysed by immunoblotting with the 
indicated antibodies. Actin serves as loading control. Result is representative of 
two biological replicates. 
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5.2.6 Expression of p110α activating mutants can sensitise IMECs to 
RNMT depletion 
I next sought to establish whether exogenous expression the activating p110α 
mutants (C420R, E545K and H1047R) can render IMECs sensitive to RNMT 
depletion. It was first important to assess whether exogenous expression of 
p110α in IMECs affected RNMT depletion levels. Therefore, cells were 
transfected with siRNA targeting RNMT, or a non-targeting siRNA, for 72 hr and 
protein lysates were immunoblotted with antibodies against RNMT, Akt and the 
phosphorylated forms of Akt (Ser 473). It was found that expression of the 
exogenous constructs did not affect RNMT depletion levels. Consistent with a 
previous result (Figure 5.8B), exogenous expression of the p110α oncogenic 
mutants resulted in a substantial increase in Akt phosphorylation. Moreover, 
RNMT depletion resulted in reduced Akt Ser473 phosphorylation levels in cells 
exogenously expressing the C420R and E545K p110α mutants. To assess 
whether RNMT depletion preferentially inhibited the growth of IMECs 
expressing p110α activating mutants, compared to cells expressing wild-type 
p110α. Cells were transfected with a siRNA targeting RNMT, or a non-targeting 
siRNA, and were counted 72 hr post-siRNA transfection. Consistent with 
previous results (Figure 3.1 and Figure 3.4), RNMT depletion did not 
significantly affect the proliferation of IMECs (Figure 5.10). Strikingly, RNMT 
depletion resulted in a significantly greater decrease in proliferation in cells 
expressing mutant p110α, compared to cells expressing wild-type p110α, or 
vector control (P ≤ 0.5, ANOVA followed by Dunnett’s multiple comparison test). 
It is important to note that exogenous expression of wild-type p110α, or the 




Overall these results show that exogenous expression of p110α mutants in non-
transformed mammary epithelial cells lead to hyper-activation of PI3K signalling 
and result in an enhanced dependence on RNMT for proliferation. These results 
support the notion that activating mutations in the gene PIK3CA and enhanced 





































Figure 5.9 RNMT is equivalently depleted in IMEC expressing either wild-
type, or activating mutants, of PI3K p110α  
IMECs stably expressing wild-type (WT), activating mutants (C420R, E545K, 
H1047R) of PI3K p110α, or vector control (control), were seeded and 
transfected with siRNA targeting RNMT (siRNMT 3) (+), or non-targeting siRNA 
(-), for 72 hr. Protein lysates were analysed using immunoblotting with the 

















Figure 5.10 Expression of PI3K p110α activating mutants in IMECs result 
in an enhanced dependence on RNMT for proliferation 
Cells stably expressing wild-type (WT), activating mutants (C420R, E545K, 
H1047R) of PI3K p110, or vector control (control), were transfected with siRNA 
targeting RNMT (siRNA RNMT 3) (+), or a non-targeting siRNA (-), for 72 hr and 
were counted using a cell counter. Each bar chart depicts mean relative cell 
number and SD for three independent biological replicates. Statistical 
significance was assessed using ANOVA followed by Dunnett’s multiple 
comparison test using GraphPad Prism 5.0. ns P > 0.05, no significant 
difference compared to control cells transfected with siRNA RNMT; * P ≤ 0.5. 
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5.2.7 Pharmacological inhibition of PI3K reverses the sensitivity of T47D 
cells to RNMT depletion 
The results presented above demonstrated that exogenous overexpression of 
p110α mutants in both ZR.75.1 cells, and IMECs result in constitutive PI3K 
signalling (Figure 5.5 and Figure 5.8) and lead to an enhanced dependency on 
RNMT for proliferation (Figure 5.7 and 5.10). These results suggest that 
enhanced PI3K signalling may contribute to cellular sensitivity to RNMT 
depletion. Thus, I hypothesised that downregulation of PI3K signalling in cells 
which are sensitive to RNMT depletion should reverse the sensitivity. To test 
this hypothesis, I assessed the combined effect of RNMT depletion and 
pharmacological inhibition of PI3k on the proliferation of T47D cells. Previous 
experiments have shown T47D cells to be sensitive to RNMT depletion (Figure 
3.3 and Figure 3.4). Cells were treated with 0.05 µM of GDC-0941 (Folkes et 
al., 2008a), a selective inhibitor of all four isoforms of class I PI3K, and were 
transfected with siRNA targeting RNMT, or a non-targeting siRNA. 72 post-
treatment, cells were either counted, or lysed for immunoblot analysis. I decided 
to used 0.05 µM of GDC-0941 on the basis of findings from a study which 
showed that treatment of T47D cells with 0.05 µM resulted in PI3K inhibition but 
did not significantly affect cellular proliferation (O'Brien et al., 2010). 
Immunoblotting of cell lysates with antibodies against RNMT, Akt and the 
phosphorylated form of Akt (Ser 473) revealed that treatment of cells with 
GDC0941 decreased Akt phosphorylation (Ser 473) to undetectable levels. In 
addition, it was found that RNMT protein expression was depleted to equivalent 
levels in the presence of GDC-0941, or DMSO (Figure 5.11A). Consistent with 
previous observations (Figure 3.3 and Figure 3.4), it was revealed that RNMT 
depletion in T47D cells resulted in a statistically significant two-fold decrease in 
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cell number, compared to cells transfected with non-targeting siRNA (P ≤ 0.001, 
ANOVA followed by Tukey’s multiple comparison test) Strikingly, RNMT 
depletion in the presence of GDC-0941 did not result in a significant decrease in 
cell number, compared to cells transfected with non-targeting siRNA (P > 0.05, 
ANOVA followed by Tukey’s multiple comparison test) Moreover, RNMT 
depletion in the presence of GDC-0941 resulted in a significant decrease in cell 
number, compared to cells treated with DMSO (P ≤ 0.01, ANOVA followed by 
Tukey’s multiple comparison test) (Figure 5.11B). Overall these results show 
that pharmacological inhibition of PI3K signalling desensitises T47D cells to 
RNMT depletion. Thus, the above findings support that hypothesis that 
enhanced PI3K signalling may contribute to the sensitivity of breast cancer cells 














Figure 5.11 Pharmacological inhibition of PI3K reverses the RNMT-
depletion induced proliferation defect of T47D cells 
Cells were seeded and transfected with siRNA targeting RNMT (RNMT 3) (+), 
or non-targeting control siRNA (-). 4 hr post-siRNA transfection, cells were 
treated with 0.05 µM of GDC-0941, or equal volume of DMSO control (-). 
(A) 72 hr post-siRNA transfection, protein lysates were extracted and analysed 
by immunoblotting with the indicated antibodies. Actin serves as loading control. 
Result is representative of two independent biological replicates. (B) 72 hr post 
siRNA transfection, cells were counted at triplicate using a cell counter. Bar 
chart depicts mean normalised cell number and SD for three independent 
biological replicates. Statistical significance was assessed using ANOVA 
followed by Tukey’s multiple comparison tests using GraphPad Prism 5.0. ns P 




5.3.1 PIK3CA activating mutations 
Results presented in chapter 3 demonstrated that RNMT depletion impairs the 
proliferation of a subset of breast cancer cell lines, in comparison to non-
transformed mammary epithelial cells. However, the mechanism of cellular 
sensitivity to RNMT depletion remained undetermined. In this chapter it was 
revealed that three out of the four breast cancer cell lines which are sensitive to 
RNMT depletion (MCF7, T47D, JIMT-1) have activating mutations (E545K, 
H1047R and C420R, respectively) in the gene PIK3CA, which encodes the 
p110α catalytic subunit of PI3K. It was demonstrated that exogenous 
expression of p110α activating mutants in cells increases PI3K signalling and 
leads to an enhanced dependence on RNMT for proliferation. This does not 
exclude the possibility that other genetic mutations may also contribute to 
RNMT dependency in breast cancer cells. To fully establish the validity of my 
results, it will be important to explore the effects of RNMT depletion on the 
proliferation of a larger breast cancer cell line panel and perform mechanistic 
studies.  
My findings support the idea that targeting RNMT would be most suitable for 
breast cancer patients harbouring mutations in PIK3CA. The efficacy of a 
targeted cancer therapy is often dependent on selecting the most receptive 
patient population. Since an estimated 18-40% of breast tumours harbour 
mutations in PIK3CA, these findings could have important therapeutic 
implications. The mechanisms by which PIK3CA activating mutations enhance 
dependence on RNMT expression for proliferation are currently unclear. It is 
possible that breast cancer cells with activating mutations in PIK3CA are highly 
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dependent on a subset of proteins for survival and mRNA cap methylation 
(RNMT) is required to facilitate the translation of these cancer survival proteins. 
Moreover, it is also possible that the PI3K pathway influences the translation of 
specific proteins by directly modulating RNMT activity/ target specificity. In 
future, it would therefore be of interest to explore the mechanisms of RNMT 
dependence in breast cancer cells. 
 
5.3.2 PI3K signalling and sensitivity to RNMT depletion 
The three activating p110α mutants used (E545K, H1047R and C420R) in this 
study each have single amino acid substitutions in different regions of the 
p110α protein (helical, kinase and C2, respectively). Data from several studies 
has shown that mutations in different regions of p110α enhance PI3K activity by 
differing mechanisms (Huang et al., 2008, Gymnopoulos et al., 2007, Miled et 
al., 2007, Zhao and Vogt, 2008a). It was demonstrated that each of the p110α 
mutants were shown to enhance PI3K signalling equivalently, which is 
consistent with results from previous studies (Ikenoue et al., 2005, 
Gymnopoulos et al., 2007). Moreover, the three p110α activating mutants were 
equally able to enhance cellular sensitivity to RNMT depletion. These 
observations may indicate that enhanced PI3K signalling contributes to the  
Inhibition of PI3K signalling in a breast cancer cell line which is sensitive to 
RNMT depletion reversed the sensitivity. This provides additional evidence to 
suggest that RNMT dependency in breast cancer is related to PI3K activity/ 
signalling. It remains unknown whether this effect is specific to PI3K activity, or 
is an effect of downstream PI3K pathway signalling. It would therefore be of 
interest to explore whether inhibitors of other components of the PI3K signalling 
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pathway (such as mTOR or Akt) are able to reverse the sensitivity of breast 
cancer cells to RNMT depletion. Furthermore, there are four isoforms of p110 
(p110α, p110β, p110δ, p110γ) and it would be on interest to explore whether 
p110 isoform specific inhibitors can reverse the sensitivity of breast cancer cells 
to RNMT depletion. 
The data presented in this chapter shows that RNMT depletion reduces Akt 
phosphorylation levels (Ser 473) in cells expressing p110α wild-type and the 
C420R and E545K activating mutants. However, RNMT depletion does not 
reduce Akt phosphorylation levels (Ser 473) in cells expressing the H1047R 
activating mutant. Since RNMT depletion equivalently reduces the proliferation 
of cells expressing each of the three p110α activating mutants (C420R, E545K 
and H1047R), it is likely that changes in Akt phosphorylation levels (Ser 473) 
are not mediating the proliferative defect induced by RNMT depletion. This may 
suggest that activating mutations in PIK3CA lead to an enhanced dependency 
on RNMT via Akt-independent mechanisms. Vasudevan et al, reported that a 
subset of breast cancer cells with PIK3CA activating mutations have reduced 
dependency on Akt signalling for survival, in comparison to cells with PTEN loss 
(Vasudevan et al., 2009a), and instead rely on other signals including PDK1 
and SGK3.Thus, it is an intriguing possibility that the differential response of 
breast cancer cells to RNMT depletion could be due to a dependence on PDK1 





5.3.3 Mutations in PTEN and PI3K 
PI3K activating mutations and PTEN inactivating mutations in cancer cells both 
increase PI(3,4,5)P3 levels. Therefore, it was surprising that our breast cancer 
cells with activating PIK3CA mutations were sensitive to RNMT depletion, 
whereas the cells with loss of PTEN were not. However, emerging evidence has 
shown that a gain of PI3K function has different biological effects to the loss of 
PTEN (Zhao and Vogt, 2008b, Blanco-Aparicio et al., 2007). Moreover, several 
studies have reported that breast cancer cells with PIK3CA activating mutations 
have different drug sensitises from those cells with loss of PTEN, (Serra et al., 
2011, Sanchez et al., 2011, Weigelt et al., 2011a, Weigelt and Downward, 
2012, Brachmann et al., 2009b, O'Brien et al., 2010, Janku et al., 2011, 
Lehmann et al., 2011, Tanaka et al., 2011). Several studies have reported that 
PTEN loss in breast cancer correlates with Akt activation, whereas PIK3CA 
activating mutations do not correlate (Dan et al., 2010, Stemke-Hale et al., 
2008, Vasudevan et al., 2009a). These observations are consistent with my 
findings that Akt Ser 473 phosphorylation levels are higher in breast cancer 
cells with PTEN loss, in comparison to those cells with activating mutations in 
PIK3CA. 
It has previously been observed that certain transcripts are more dependent on 
the methyl cap for their translation (Cowling, 2009a). Thus, it is possible that 
breast cancer cells with activating mutations in PIK3CA have an enhanced 
dependency on the translation of these transcripts for cancer survival, and this 
issue should be explored further. For example, it is possible that RNMT 




5.3.4 Targeting RNMT and mTOR for combinational therapies  
Several studies have shown that breast cancer cells with activating PIK3CA 
mutations have enhanced sensitivity to therapeutic PI3K pathway inhibitors, 
such as mTOR inhibitors (Weigelt et al., 2011a). However, emerging data has 
shown that inhibitors of the PI3K pathway have limited anti-tumour effects when 
used as single agents and the emergence of drug resistance in common. 
Upregulation of eIF4E expression has been shown to be a mechanism of 
resistance to mTOR inhibitors in cancer (Sun et al., 2005, Wendel et al., 2004a, 
Cope et al., 2013). Since eIF4E binding to the methyl cap is essential for eIF4E-
mediated translation and eIF4E-mediated oncogenesis, it may be of interest to 
explore whether inhibition of RNMT in combination with mTOR inhibitor 
treatment synergises to reduce resistance in cancer. It is possible that inhibition 
of RNMT also synergises with other anti-cancer treatments, and this is an issue 
that should be explored.  
 
5.3.5 The non-alpha P110 isoforms 
The four isoforms of p110 (p110α, p110β, p110δ, p110γ) have identical 
enzymatic activates, but experimental evidence suggest that they have isoform-
specific cellular functions (Denley et al., 2008). The gene PIK3CA, which 
encodes p110α, is frequently mutated in cancer and p110α is known to be 
oncogenic (Zhao and Vogt, 2008b). No cancer-associated mutations have been 
found in the non-alpha p110 isoforms, however, it has been reported that wild-
type p110β, p110δ, p110γ are oncogenic when overexpressed. In contrast, 
wild-type p110α is not oncogenic when overexpressed. Interestingly, unlike 
p110α, transformation by p110β and p110γ does not involve increased PI3K 
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signalling (Denley et al., 2008). Since elevated expression of the non-alpha 
isoforms has been observed in human cancers, it is possible that these 
isoforms contribute to human cancer (Benistant et al., 2000, Sujobert et al., 
2005, Mizoguchi et al., 2004, Zhao and Vogt, 2008b). It is possible that the 
increased activity/ expression of the non-alpha p110 isoforms contribute to 
RNMT dependence in breast cancer cells. It would therefore be of interest to 
explore whether the enhanced dependence of breast cancer cells on RNMT for 
survival is a feature specific to the p110α isoform.  
 
5.3.6 Summary 
The results presented in this chapter provide the first evidence that expression 
of activating p110α mutants enhance cellular sensitivity to RNMT depletion. 
This suggests that activating mutations in the gene PIK3CA at least partly 
sensitise breast cancer cells to RNMT depletion. Since an estimated 18-40% of 
breast tumours have activating mutations in PIK3CA, my findings could 
potentially have significant therapeutic implications. My work indicates that 
RNMT dependence in breast cancer is related to PI3K signalling/ activity. These 
data strongly suggest that RNMT should be explored as a therapeutic target in 







Chapter 6: Final Discussion and future work 
 
6.1 Final Summary 
Breast cancer is the leading cause of cancer death in women worldwide. 
Although significant advances have been made in the treatment of breast 
cancer, new therapeutic approaches are required. Protein synthesis is often 
found to be deregulated in cancer and there has been significant effort into 
developing strategies to inhibit protein synthesis for the treatment of cancer.  
The 7-methylguanosine cap structure found at the 5’ end of mRNA is 
essential for mRNA translation and it has been shown to promote several steps 
in gene expression. In humans, the methylation of the guanosine cap structure 
is catalysed by RNA guanine-7 methyltransferase (RNMT). RNMT expression is 
rate-limiting for efficient mRNA translation and cell proliferation (Fernandez-
Sanchez et al., 2009a, Cowling, 2009a, Aregger and Cowling, 2013). Several 
observations from our laboratory suggest there is strong biological rationale to 
explore RNMT as a therapeutic target in breast cancer. However, it has been 
unknown whether targeting RNMT would supress the proliferation of all cells, or 
has selectively towards cancer cells. 
The initial aim of this thesis was to investigate the impact of RNMT 
depletion on the proliferation of eight breast cancer cell lines and non-
transformed mammary epithelial cells. These experiments revealed that RNMT 
depletion selectively inhibits the proliferation of a subset of breast cancer cells, 
in comparison to non-transformed mammary epithelial cells. Moreover, it was 
found that RNMT depletion induces apoptosis in a subset of breast cancer cell 
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lines. Overall these results show that a subset of breast cancer cell lines exhibit 
an enhanced dependency on RNMT (mRNA cap methylation) for survival.  
The next aim of this thesis was to understand why only certain breast cancer 
cell lines are sensitive to RNMT depletion. Thus, I explored whether basic 
cellular parameters correlated with cellular sensitivity to RNMT depletion. It was 
demonstrated that cellular sensitivity to RNMT depletion does not correlate with 
cellular RNMT expression, RNMT enzymatic activity, global protein synthesis 
levels, basal cell proliferation rate or c-Myc protein expression.  
I next investigated whether a particular genetic mutation in the breast cancer 
cells conferred sensitivity to RNMT depletion. It was found that three out of the 
four breast cancer cell lines which are sensitive to RNMT depletion have 
activating mutations in the gene PIK3CA, which encodes the p110α catalytic 
subunit of PI3K. It was demonstrated that exogenous expression of the p110α 
mutants in cells result in hyper-activated PI3K signalling and lead to an 
enhanced dependence on RNMT for proliferation. These results suggest that 
activating mutations in the gene PIK3CA and enhanced PI3K signalling 
contribute to cellular sensitivity to RNMT depletion. My findings support the idea 
that targeting RNMT would be most suitable for breast cancer patients 
harbouring activating mutations in PIK3CA. Since an estimated 18-40% of 
breast tumours harbour activating mutations in PIK3CA (Bachman et al., 2004, 
Campbell et al., 2004, Lee et al., 2005, Levine et al., 2005, Saal et al., 2005, 
Network, 2012, Banerji et al., 2012, Stephens et al., 2012), these findings could 
have important therapeutic implications. The precise mechanisms by which 
PIK3CA activating mutations enhance RNMT dependency in breast cancer 
remain unknown.  
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It was found that the inhibition of PI3K signalling in an RNMT depletion 
sensitive breast cancer cell line reverses the sensitivity. This provides additional 
evidence to suggest that RNMT dependency in breast cancer is related to PI3K 
activity/ signalling. It remains unknown whether this effect is specific to PI3K 
activity, or is an effect of downstream PI3K pathway signalling. 
In summary, the results presented in this thesis demonstrate that a subset of 
breast cancer cell lines have an enhanced dependence on RNMT for survival, 
in comparison to immortalised mammary epithelial cells. This is the first 
evidence that targeting methyl cap synthesis can selectively inhibit the 
proliferation of cancer cells, in comparison to non-transformed cells. Moreover, I 
show that activating mutations in the gene PIK3CA, which encodes the p110α 
catalytic subunit of PI3K, contribute to cellular sensitivity to RNMT depletion. 
Overall, these findings strongly suggest that RNMT should be explored as a 
therapeutic target in breast cancer and this could potentially open up an exciting 
new avenue in cancer research. 
 
 
6.2 Final discussion and Future Work 
 
Taken together the data presented in this thesis indicate that RNMT should be 
investigated as a therapeutic target in breast cancer. Moreover, my results 
suggest that there is a link between the PI3K activity  and RNMT dependency in 
breast cancer. However, there are a lot of unanswered questions and future 




1) Do activating mutations in PIK3CA contribute to RNMT dependency in 
breast cancer? 
Further work is required to fully establish whether activating mutations in 
PIK3CA confer sensitivity to RNMT depletion in breast cancer cells. It would be 
interesting to study the effect of RNMT depletion on the proliferation of a larger 
breast cancer cell line panel. This will help further evaluate whether there is a 
link between activating mutations in PIK3CA and RNMT dependency in breast 
cancer cells, and it may also reveal additional genetic mutations that contribute 
to RNMT dependency. In this study I demonstrated that exogenous expression 
of p110α activating mutants enhances cellular sensitivity to RNMT depletion in 
two independent cell lines. It would be desirable to repeat these experiments in 
additional breast cancer cell lines. It is important to note that the above 
experiments were performed using exogenous expressed p110α constructs and 
it may be necessary to explore how endogenous PIK3CA mutations contribute 
to RNMT dependency in breast cancer. Isogenic cancer cell lines are created 
by modifying endogenous genes using homologous gene targeting and this 
ensures that the gene of interest is expressed to physiological levels. Isogenic 
cancer cell lines can be utilised to investigate how a particular genetic mutation 
contributes to drug sensitivities in cancer. Therefore, isogenic cancer cell lines, 
in which the endogenous PIK3CA gene harbouring an activating mutation has 
been replaced with wild-type PIK3CA, will be used to further explore whether 
PIK3CA mutations contribute to RNMT dependency in cancer.  
It remains unknown whether the link between RNMT dependency and PIK3CA 
activating mutations is specific to breast cancer. Activating mutations in PIK3CA 
are frequently found in several types of human cancer, such as colon cancer 
(Samuels and Waldman, 2010, Samuels et al., 2004a). It would therefore be of 
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interest to explore the effect of RNMT depletion on the proliferation of other 
human cancer cell lines with PIK3CA mutations. These experiments may reveal 
that RNMT should be explored as a therapeutic target in other types of human 
cancer. 
It is possible that other genes contribute to RNMT dependency in breast cancer 
and it would be of interest to perform a genome wide siRNA screen to identify 
candidate genes that are key modulators of RNMT dependency in breast 
cancer cells.  
2) Is there a link between PI3K signalling and RNMT dependency in breast 
cancer? 
My findings suggest that RNMT dependency in breast cancer is linked to PI3K 
activity/ signalling. In order to investigate this link further, inhibitors against 
different components of the PI3K pathway (such as Akt and mTORC1) will be 
used to dissect the role of the PI3K pathway in RNMT dependency. In addition, 
there are four isoforms of p110 (p110α, p110β, p110δ, p110γ) and it will be of 
interest to explore whether p110 isoform specific inhibitors can reverse the 
sensitivity of breast cancer cells to RNMT depletion. These experiments will 
allow me to investigate whether RNMT dependence in breast cancer is p110 
isoform specific. Overall, the above experiments will help assess whether there 
is a relationship between the PI3K pathway and RNMT depletion which has the 






3) What are the mechanisms of RNMT dependency in breast cancer? 
The mechanisms by which activating mutations in PIK3CA enhance cellular 
sensitivity to RNMT depletion are not yet understood and it will be important to 
perform mechanistic studies to investigate this. 
It is possible that the PI3K pathway influences the translation of specific 
transcripts by modulating RNMT target specificity. Thus, RNMT depletion may 
affect the proteome differently in breast cancer cells “sensitive” and in those 
“insensitive” to RNMT depletion and this may explain the differential 
dependence on RNMT for survival. It will therefore be of interest to use 
proteomics to compare the proteome of the breast cancer cell line panel in 
response to RNMT depletion. 
It has been previously been shown that methyl capped RNA is translated more 
efficiently compared to capped RNA (Gillian-Daniel et al., 1998, Drummond et 
al., 1985). It is possible that the differential cellular dependence on RNMT for 
survival is due to a differential ability to translate capped or methyl capped 
RNA. Therefore, it will be of interest to compare the rate of translation of 
capped and methyl capped RNA in the breast cancer cell line panel. Capped 
and methyl capped transcripts encoding luciferase will be transfected into 
breast cancer cells and the translational efficiency of these transcripts will be 
determined by measuring luciferase activity. 
It has previously been observed that certain transcripts are more dependent on 
the methyl cap for their translation and these are termed “methyl cap sensitive” 
transcripts (Cowling, 2009a). It is possible that the breast cancer cells with 
activating mutations in PIK3CA have an enhanced dependence on the 
translation of these “methyl cap sensitive” transcripts for survival. Since breast 
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cancer cells with activating mutations in PIK3CA have previously been shown to 
be highly dependent on the expression of SGK3 and PDK1 for survival 
(Vasudevan et al., 2009a), it would be interesting to investigate SGK3 and 
PDK1 protein expression levels in the RNMT depleted breast cancer cell line 
panel. It would also be interesting to explore the activation of components of the 
PI3K pathway (such as Akt and mTORC1), or of other oncogenic signalling 
pathways, in response to RNMT depletion in the breast cancer cell line panel. 
Since IRES-dependent translation is maintained during cellular conditions which 
repress cap-dependent translation, it is likely that the translation of IRES-
containing mRNAs will be maintained in response to RNMT depletion (Stoneley 
and Willis, 2004, Holcik and Sonenberg, 2005). Since many proteins which are 
translated in an IRES dependent manner are known regulators of cell survival, 
certain breast cancer cell lines may exhibit an enhanced dependence on IRES-
translated proteins for survival (Liwak et al., 2012, Miskimins et al., 2001, Yang 
et al., 2006). Thus, it is possible that breast cancer cells insensitive to RNMT 
depletion are highly dependent on IRES-mediated translation for survival, 
whereas breast cancer cells sensitive to RNMT depletion are highly dependent 
on cap-dependent translation for survival. However, since the full spectrum of 
endogenous mRNAs translated in an IRES-mediated manner remains 
unknown, it may be difficult to assess whether there is a correlation between 
IRES-dependent translation and RNMT dependency in breast cancer cells. 
The tumour suppressor protein p53 supresses cell transformation by inhibiting 
cell growth or inducing apoptosis. P53 is the most frequently mutated protein 
found in breast cancer and loss of p53 plays a key role in oncogenesis (Polyak 
and Metzger Filho, 2012, Vogelstein et al., 2000). Since p53 can be translated 
in an IRES-mediated manner, it is possible that p53 expression is maintained in 
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response to RNMT depletion and may be a modulator of RNMT depletion 
response (Yang et al., 2006). Interestingly, MCF7, the breast cancer cell line 
most sensitive to RNMT depletion, expresses WT p53 and would therefore 
likely remain responsive to p53-induced apoptosis. In the future, it would be of 
interest to explore whether p53 contributes to RNMT depletion response in 
breast cancer cells.  
 
4) Does RNMT depletion inhibit breast tumour growth in vivo? 
Although this study has provided the first evidence that RNMT depletion impairs 
the proliferation of breast cancer cell lines, it will be important to explore the in 
vivo significance of my findings using a mouse model of breast cancer. 
Therefore, mice with inducible RNMT knockout will be bred with an established 
breast cancer mouse model and the resulting transgenic mice will be used to 
assess whether RNMT deletion suppresses breast tumour growth in vivo. 
Moreover, it will be important to assess whether pharmacological inhibition of 
RNMT reduces tumour growth in a breast cancer mouse model. The results 
from these experiments will help further assess the suitability of RNMT as a 
therapeutic target in breast cancer.  
 
5) Suitability of a specific RNMT inhibitor as an anti-cancer therapeutic 
drug? 
There are currently no specific inhibitors against RNMT activity. However, our 
lab is currently screening for specific RNMT inhibitors in collaboration with the 
Drug Discovery Unit (College of Life Sciences, University of Dundee). To 
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establish the validity of my findings, it would be desirable to investigate the 
effects of an RNMT inhibitor on our breast cancer cell line panel. This will help 
us to decide whether the RNMT inhibitor should be further developed as a 
potential anti-cancer therapeutic drug. Since therapeutic resistance to RNMT 
inhibitors in breast cancer could potentially occur via the upregulation of 
proteins which are functionally redundant with RNMT, it will be important to 
extensively investigate whether other cap cellular methyltransferases exists in 
humans. Moreover, if therapeutic resistance to RNMT inhibitors occurs it would 
be of interest to perform a genome wide siRNA screen to identify candidate 










(Kao et al., 2009, Neve et al., 2006, Chavez et al., 2010, Koninki et al., 2010, 
Tanner et al., 2004) 
188 
 
8. References 
 
 
ADAMS, J. R., XU, K., LIU, J. C., AGAMEZ, N. M. R., LOCH, A. J., WONG, R. G., WANG, W., 
WRIGHT, K. L., LANE, T. F., ZACKSENHAUS, E. & EGAN, S. E. 2011. Cooperation between 
Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation. Cancer Research, 71, 
2706‐2717. 
ADELMAN, K. & LIS, J. T. 2012. Promoter‐proximal pausing of RNA polymerase II: emerging 
roles in metazoans. Nat Rev Genet, 13, 720‐731. 
ALESSI, D. R., DEAK, M., CASAMAYOR, A., CAUDWELL, F. B., MORRICE, N., NORMAN, D. G., 
GAFFNEY, P., REESE, C. B., MACDOUGALL, C. N., HARBISON, D., ASHWORTH, A. & 
BOWNES, M. 1997a. 3‐Phosphoinositide‐dependent protein kinase‐1 (PDK1): structural 
and functional homology with the Drosophila DSTPK61 kinase. Curr Biol, 7, 776‐89. 
ALESSI, D. R., JAMES, S. R., DOWNES, C. P., HOLMES, A. B., GAFFNEY, P. R., REESE, C. B. & 
COHEN, P. 1997b. Characterization of a 3‐phosphoinositide‐dependent protein kinase 
which phosphorylates and activates protein kinase Balpha. Curr Biol, 7, 261‐9. 
ALTMANN, M., EDERY, I., SONENBERG, N. & TRACHSEL, H. 1985. Purification and 
characterization of protein synthesis initiation factor eIF‐4E from the yeast 
Saccharomyces cerevisiae. Biochemistry, 24, 6085‐9. 
ALTMANN, M., HANDSCHIN, C. & TRACHSEL, H. 1987. mRNA cap‐binding protein: cloning of 
the gene encoding protein synthesis initiation factor eIF‐4E from Saccharomyces 
cerevisiae. Mol Cell Biol, 7, 998‐1003. 
AREGGER, M. & COWLING, V. H. 2012. E2F1‐dependent methyl cap formation requires RNA pol 
II phosphorylation. Cell Cycle, 11, 2146‐8. 
AREGGER, M. & COWLING, V. H. 2013. Human cap methyltransferase (RNMT) N‐terminal non‐
catalytic domain mediates recruitment to transcription initiation sites. Biochem J, 455, 
67‐73. 
ARRIBAS‐LAYTON, M., WU, D., LYKKE‐ANDERSEN, J. & SONG, H. 2013. Structural and functional 
control of the eukaryotic mRNA decapping machinery. Biochim Biophys Acta, 1829, 
580‐9. 
ARTEAGA, C. L., SLIWKOWSKI, M. X., OSBORNE, C. K., PEREZ, E. A., PUGLISI, F. & GIANNI, L. 
2012. Treatment of HER2‐positive breast cancer: current status and future 
perspectives. Nat Rev Clin Oncol, 9, 16‐32. 
ASSOULINE, S., CULJKOVIC, B., COCOLAKIS, E., ROUSSEAU, C., BESLU, N., AMRI, A., CAPLAN, S., 
LEBER, B., ROY, D. C., MILLER, W. H., JR. & BORDEN, K. L. 2009. Molecular targeting of 
the oncogene eIF4E in acute myeloid leukemia (AML): a proof‐of‐principle clinical trial 
with ribavirin. Blood, 114, 257‐60. 
AVDULOV, S., LI, S., MICHALEK, V., BURRICHTER, D., PETERSON, M., PERLMAN, D. M., 
MANIVEL, J. C., SONENBERG, N., YEE, D., BITTERMAN, P. B. & POLUNOVSKY, V. A. 2004. 
Activation of translation complex eIF4F is essential for the genesis and maintenance of 
the malignant phenotype in human mammary epithelial cells. Cancer Cell, 5, 553‐63. 
BACHMAN, K. E., ARGANI, P., SAMUELS, Y., SILLIMAN, N., PTAK, J., SZABO, S., KONISHI, H., 
KARAKAS, B., BLAIR, B. G., LIN, C., PETERS, B. A., VELCULESCU, V. E. & PARK, B. H. 2004. 
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol 
Ther, 3, 772‐5. 
BADER, A. G., KANG, S. & VOGT, P. K. 2006. Cancer‐specific mutations in PIK3CA are oncogenic 
in vivo. Proceedings of the National Academy of Sciences of the United States of 
America, 103, 1475‐1479. 
BANERJI, S., CIBULSKIS, K., RANGEL‐ESCARENO, C., BROWN, K. K., CARTER, S. L., FREDERICK, A. 
M., LAWRENCE, M. S., SIVACHENKO, A. Y., SOUGNEZ, C., ZOU, L., CORTES, M. L., 
FERNANDEZ‐LOPEZ, J. C., PENG, S., ARDLIE, K. G., AUCLAIR, D., BAUTISTA‐PINA, V., 
DUKE, F., FRANCIS, J., JUNG, J., MAFFUZ‐AZIZ, A., ONOFRIO, R. C., PARKIN, M., PHO, N. 
189 
 
H., QUINTANAR‐JURADO, V., RAMOS, A. H., REBOLLAR‐VEGA, R., RODRIGUEZ‐CUEVAS, 
S., ROMERO‐CORDOBA, S. L., SCHUMACHER, S. E., STRANSKY, N., THOMPSON, K. M., 
URIBE‐FIGUEROA, L., BASELGA, J., BEROUKHIM, R., POLYAK, K., SGROI, D. C., 
RICHARDSON, A. L., JIMENEZ‐SANCHEZ, G., LANDER, E. S., GABRIEL, S. B., GARRAWAY, 
L. A., GOLUB, T. R., MELENDEZ‐ZAJGLA, J., TOKER, A., GETZ, G., HIDALGO‐MIRANDA, A. 
& MEYERSON, M. 2012. Sequence analysis of mutations and translocations across 
breast cancer subtypes. Nature, 486, 405‐409. 
BARBARESCHI, M., BUTTITTA, F., FELICIONI, L., COTRUPI, S., BARASSI, F., DEL GRAMMASTRO, 
M., FERRO, A., DALLA PALMA, P., GALLIGIONI, E. & MARCHETTI, A. 2007. Different 
prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in 
breast carcinomas. Clin Cancer Res, 13, 6064‐9. 
BÄRLUND, M., FOROZAN, F., KONONEN, J., BUBENDORF, L., CHEN, Y., BITTNER, M. L., 
TORHORST, J., HAAS, P., BUCHER, C., SAUTER, G., KALLIONIEMI, O.‐P. & KALLIONIEMI, 
A. 2000. Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA 
and Tissue Microarray Analysis. Journal of the National Cancer Institute, 92, 1252‐
1259. 
BARTOLOMEI, M. S., HALDEN, N. F., CULLEN, C. R. & CORDEN, J. L. 1988. Genetic analysis of the 
repetitive carboxyl‐terminal domain of the largest subunit of mouse RNA polymerase 
II. Mol Cell Biol, 8, 330‐9. 
BAUER, C., DIESINGER, I., BRASS, N., STEINHART, H., IRO, H. & MEESE, E. U. 2001. Translation 
initiation factor eIF‐4G is immunogenic, overexpressed, and amplified in patients with 
squamous cell lung carcinoma. Cancer, 92, 822‐9. 
BELANGER, F., STEPINSKI, J., DARZYNKIEWICZ, E. & PELLETIER, J. 2010. Characterization of 
hMTr1, a human Cap1 2'‐O‐ribose methyltransferase. J Biol Chem, 285, 33037‐44. 
BENISTANT, C., CHAPUIS, H. & ROCHE, S. 2000. A specific function for phosphatidylinositol 3‐
kinase alpha (p85alpha‐p110alpha) in cell survival and for phosphatidylinositol 3‐
kinase beta (p85alpha‐p110beta) in de novo DNA synthesis of human colon carcinoma 
cells. Oncogene, 19, 5083‐90. 
BENJAMIN, D., COLOMBI, M., MORONI, C. & HALL, M. N. 2011. Rapamycin passes the torch: a 
new generation of mTOR inhibitors. Nat Rev Drug Discov, 10, 868‐80. 
BERDASCO, M. & ESTELLER, M. 2010. Aberrant epigenetic landscape in cancer: how cellular 
identity goes awry. Dev Cell, 19, 698‐711. 
BERETTA, L., GINGRAS, A. C., SVITKIN, Y. V., HALL, M. N. & SONENBERG, N. 1996. Rapamycin 
blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of 
translation. EMBO J, 15, 658‐64. 
BERTOS, N. R. & PARK, M. 2011. Breast cancer ‐ one term, many entities? J Clin Invest, 121, 
3789‐96. 
BLAGDEN, S. P. & WILLIS, A. E. 2011. The biological and therapeutic relevance of mRNA 
translation in cancer. Nat Rev Clin Oncol, 8, 280‐291. 
BLANCO‐APARICIO, C., RENNER, O., LEAL, J. F. & CARNERO, A. 2007. PTEN, more than the AKT 
pathway. Carcinogenesis, 28, 1379‐86. 
BOTH, G. W., BANERJEE, A. K. & SHATKIN, A. J. 1975. Methylation‐dependent translation of 
viral messenger RNAs in vitro. Proc Natl Acad Sci U S A, 72, 1189‐93. 
BRACHMANN, S., HOFMANN, I., SCHNELL, C., FRITSCH, C., WEE, S., LANE, H., WANG, S., 
GARCIA‐ECHEVERRIA, C. & MAIRA, S. 2009a. Specific apoptosis induction by the dual 
PI3K/mTor inhibitor NVP‐BEZ235 in HER2 amplified and PIK3CA mutant breast cancer 
cells. Proc Natl Acad Sci USA, 106, 22299 ‐ 22304. 
BRADFORD, M. M. 1976. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein‐dye binding. Anal Biochem, 72, 
248‐54. 
BRAUNSCHWEIG, U., GUEROUSSOV, S., PLOCIK, A. M., GRAVELEY, BRENTON R. & BLENCOWE, 
BENJAMIN J. 2013. Dynamic Integration of Splicing within Gene Regulatory Pathways. 
Cell, 152, 1252‐1269. 
190 
 
BRAUNSTEIN, S., KARPISHEVA, K., POLA, C., GOLDBERG, J., HOCHMAN, T., YEE, H., 
CANGIARELLA, J., ARJU, R., FORMENTI, S. C. & SCHNEIDER, R. J. 2007. A hypoxia‐
controlled cap‐dependent to cap‐independent translation switch in breast cancer. Mol 
Cell, 28, 501‐12. 
BRUNN, G. J., HUDSON, C. C., SEKULIĆ, A., WILLIAMS, J. M., HOSOI, H., HOUGHTON, P. J., 
LAWRENCE, J. C. & ABRAHAM, R. T. 1997. Phosphorylation of the Translational 
Repressor PHAS‐I by the Mammalian Target of Rapamycin. Science, 277, 99‐101. 
BRYANT, H. E., SCHULTZ, N., THOMAS, H. D., PARKER, K. M., FLOWER, D., LOPEZ, E., KYLE, S., 
MEUTH, M., CURTIN, N. J. & HELLEDAY, T. 2005. Specific killing of BRCA2‐deficient 
tumours with inhibitors of poly(ADP‐ribose) polymerase. Nature, 434, 913‐7. 
BURATOWSKI, S. 2009. Progression through the RNA polymerase II CTD cycle. Mol Cell, 36, 
541‐6. 
BURGERING, B. M. & COFFER, P. J. 1995. Protein kinase B (c‐Akt) in phosphatidylinositol‐3‐OH 
kinase signal transduction. Nature, 376, 599‐602. 
CADENA, D. L. & DAHMUS, M. E. 1987. Messenger RNA synthesis in mammalian cells is 
catalyzed by the phosphorylated form of RNA polymerase II. J Biol Chem, 262, 12468‐
74. 
CALERO, G., WILSON, K. F., LY, T., RIOS‐STEINER, J. L., CLARDY, J. C. & CERIONE, R. A. 2002. 
Structural basis of m7GpppG binding to the nuclear cap‐binding protein complex. Nat 
Struct Biol, 9, 912‐7. 
CAMPBELL, I. G., RUSSELL, S. E., CHOONG, D. Y., MONTGOMERY, K. G., CIAVARELLA, M. L., 
HOOI, C. S., CRISTIANO, B. E., PEARSON, R. B. & PHILLIPS, W. A. 2004. Mutation of the 
PIK3CA gene in ovarian and breast cancer. Cancer Res, 64, 7678‐81. 
CAO, Q., PADMANABHAN, K. & RICHTER, J. D. 2010. Pumilio 2 controls translation by 
competing with eIF4E for 7‐methyl guanosine cap recognition. RNA, 16, 221‐7. 
CAREW, J. S., KELLY, K. R. & NAWROCKI, S. T. 2011. Mechanisms of mTOR inhibitor resistance 
in cancer therapy. Target Oncol, 6, 17‐27. 
CAREY, L. A., PEROU, C. M., LIVASY, C. A., DRESSLER, L. G., COWAN, D., CONWAY, K., KARACA, 
G., TROESTER, M. A., TSE, C. K., EDMISTON, S., DEMING, S. L., GERADTS, J., CHEANG, 
M. C., NIELSEN, T. O., MOORMAN, P. G., EARP, H. S. & MILLIKAN, R. C. 2006. Race, 
breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 
2492‐502. 
CARTER, P., PRESTA, L., GORMAN, C. M., RIDGWAY, J. B., HENNER, D., WONG, W. L., 
ROWLAND, A. M., KOTTS, C., CARVER, M. E. & SHEPARD, H. M. 1992. Humanization of 
an anti‐p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A, 89, 
4285‐9. 
CENCIC, R., CARRIER, M., GALICIA, G., BORDELEAU, M., SUKARIEH, R., BOURDEAU, A. & BREM, 
B. 2009. Antitumour activity and mechanism of action of the cyclopenta benzofuran, 
Silvestrol. PLoS ONE, 4. 
CENCIC, R., CARRIER, M., TRNKUS, A., PORCO JR, J. A., MINDEN, M. & PELLETIER, J. 2010. 
Synergistic effect of inhibiting translation initiation in combination with cytotoxic 
agents in acute myelogenous leukemia cells. Leukemia Research, 34, 535‐541. 
CHAN, D. A. & GIACCIA, A. J. 2011. Harnessing synthetic lethal interactions in anticancer drug 
discovery. Nat Rev Drug Discov, 10, 351‐64. 
CHAN, S., SCHEULEN, M. E., JOHNSTON, S., MROSS, K., CARDOSO, F., DITTRICH, C., EIERMANN, 
W., HESS, D., MORANT, R., SEMIGLAZOV, V., BORNER, M., SALZBERG, M., OSTAPENKO, 
V., ILLIGER, H. J., BEHRINGER, D., BARDY‐BOUXIN, N., BONI, J., KONG, S., CINCOTTA, M. 
& MOORE, L. 2005. Phase II study of temsirolimus (CCI‐779), a novel inhibitor of mTOR, 
in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin 
Oncol, 23, 5314‐22. 
CHANG, H. W., AOKI, M., FRUMAN, D., AUGER, K. R., BELLACOSA, A., TSICHLIS, P. N., CANTLEY, 
L. C., ROBERTS, T. M. & VOGT, P. K. 1997. Transformation of chicken cells by the gene 
encoding the catalytic subunit of PI 3‐kinase. Science, 276, 1848‐50. 
191 
 
CHANG, J. H., JIAO, X., CHIBA, K., OH, C., MARTIN, C. E., KILEDJIAN, M. & TONG, L. 2012. Dxo1 is 
a new type of eukaryotic enzyme with both decapping and 5'‐3' exoribonuclease 
activity. Nat Struct Mol Biol, 19, 1011‐7. 
CHAVEZ, K. J., GARIMELLA, S. V. & LIPKOWITZ, S. 2010. Triple negative breast cancer cell lines: 
one tool in the search for better treatment of triple negative breast cancer. Breast Dis, 
32, 35‐48. 
CHENG, H., DUFU, K., LEE, C. S., HSU, J. L., DIAS, A. & REED, R. 2006. Human mRNA export 
machinery recruited to the 5' end of mRNA. Cell, 127, 1389‐400. 
CHIANG, P. K., GORDON, R. K., TAL, J., ZENG, G. C., DOCTOR, B. P., PARDHASARADHI, K. & 
MCCANN, P. P. 1996. S‐Adenosylmethionine and methylation. FASEB J, 10, 471‐80. 
CHIU, Y. L., HO, C. K., SAHA, N., SCHWER, B., SHUMAN, S. & RANA, T. M. 2002. Tat stimulates 
cotranscriptional capping of HIV mRNA. Mol Cell, 10, 585‐97. 
CHO, E. J., TAKAGI, T., MOORE, C. R. & BURATOWSKI, S. 1997. mRNA capping enzyme is 
recruited to the transcription complex by phosphorylation of the RNA polymerase II 
carboxy‐terminal domain. Genes Dev, 11, 3319‐26. 
CHOO, A. Y., YOON, S. O., KIM, S. G., ROUX, P. P. & BLENIS, J. 2008. Rapamycin differentially 
inhibits S6Ks and 4E‐BP1 to mediate cell‐type‐specific repression of mRNA translation. 
Proc Natl Acad Sci U S A, 105, 17414‐9. 
CHU, C. & SHATKIN, A. J. 2008. Apoptosis and autophagy induction in mammalian cells by small 
interfering RNA knockdown of mRNA capping enzymes. Mol Cell Biol, 28, 5829‐36. 
COHEN, N., SHARMA, M., KENTSIS, A., PEREZ, J. M., STRUDWICK, S. & BORDEN, K. L. 2001. PML 
RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. 
EMBO J, 20, 4547‐59. 
COLE, M. D. & COWLING, V. H. 2009. Specific regulation of mRNA cap methylation by the c‐
Myc and E2F1 transcription factors. Oncogene, 28, 1169‐1175. 
COLEMAN, L. J., PETER, M. B., TEALL, T. J., BRANNAN, R. A., HANBY, A. M., HONARPISHEH, H., 
SHAABAN, A. M., SMITH, L., SPEIRS, V., VERGHESE, E. T., MCELWAINE, J. N. & HUGHES, 
T. A. 2009. Combined analysis of eIF4E and 4E‐binding protein expression predicts 
breast cancer survival and estimates eIF4E activity. Br J Cancer, 100, 1393‐9. 
COLGAN, D. F. & MANLEY, J. L. 1997. Mechanism and regulation of mRNA polyadenylation. 
Genes Dev, 11, 2755‐66. 
COOKE, C. & ALWINE, J. C. 1996. The cap and the 3' splice site similarly affect polyadenylation 
efficiency. Mol Cell Biol, 16, 2579‐84. 
COPE, C. L., GILLEY, R., BALMANNO, K., SALE, M. J., HOWARTH, K. D., HAMPSON, M., SMITH, P. 
D., GUICHARD, S. M. & COOK, S. J. 2013. Adaptation to mTOR kinase inhibitors by 
amplification of eIF4E to maintain cap‐dependent translation. Journal of Cell Science. 
COWLING, V. H. 2009a. Enhanced mRNA cap methylation increases Cyclin D1 expression and 
promotes cell transformation. Oncogene, 29, 930‐936. 
COWLING, V. H. 2009b. Regulation of mRNA cap methylation. Biochemical Journal, 425, 295‐
302. 
COWLING, V. H. & COLE, M. D. 2006. Mechanism of transcriptional activation by the Myc 
oncoproteins. Semin Cancer Biol, 16, 242‐52. 
COWLING, V. H. & COLE, M. D. 2007. The Myc Transactivation Domain Promotes Global 
Phosphorylation of the RNA Polymerase II Carboxy‐Terminal Domain Independently of 
Direct DNA Binding. Molecular and Cellular Biology, 27, 2059‐2073. 
CULJKOVIC, B., TOPISIROVIC, I., SKRABANEK, L., RUIZ‐GUTIERREZ, M. & BORDEN, K. L. 2005. 
eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR. J Cell 
Biol, 169, 245‐56. 
DAN, S., OKAMURA, M., SEKI, M., YAMAZAKI, K., SUGITA, H., OKUI, M., MUKAI, Y., NISHIMURA, 
H., ASAKA, R., NOMURA, K., ISHIKAWA, Y. & YAMORI, T. 2010. Correlating 
phosphatidylinositol 3‐kinase inhibitor efficacy with signaling pathway status: in silico 
and biological evaluations. Cancer Res, 70, 4982‐94. 
DANG, CHI V. 2012. MYC on the Path to Cancer. Cell, 149, 22‐35. 
192 
 
DARGEMONT, C. & KUHN, L. C. 1992. Export of mRNA from microinjected nuclei of Xenopus 
laevis oocytes. J Cell Biol, 118, 1‐9. 
DARNELL, J. E., JR. 2013. Reflections on the history of pre‐mRNA processing and highlights of 
current knowledge: a unified picture. RNA, 19, 443‐60. 
DAS, B., GUO, Z., RUSSO, P., CHARTRAND, P. & SHERMAN, F. 2000. The role of nuclear cap 
binding protein Cbc1p of yeast in mRNA termination and degradation. Mol Cell Biol, 
20, 2827‐38. 
DE BENEDETTI, A. & GRAFF, J. R. 2004. eIF‐4E expression and its role in malignancies and 
metastases. Oncogene, 23, 3189‐99. 
DE BENEDETTI, A. & HARRIS, A. L. 1999. eIF4E expression in tumors: its possible role in 
progression of malignancies. Int J Biochem Cell Biol, 31, 59‐72. 
DE BENEDETTI, A., JOSHI‐BARVE, S., RINKER‐SCHAEFFER, C. & RHOADS, R. E. 1991. Expression 
of antisense RNA against initiation factor eIF‐4E mRNA in HeLa cells results in 
lengthened cell division times, diminished translation rates, and reduced levels of both 
eIF‐4E and the p220 component of eIF‐4F. Mol Cell Biol, 11, 5435‐45. 
DE BENEDETTI, A. & RHOADS, R. E. 1990. Overexpression of eukaryotic protein synthesis 
initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc Natl 
Acad Sci U S A, 87, 8212‐6. 
DEFATTA, R. J., TURBAT‐HERRERA, E. A., LI, B. D., ANDERSON, W. & DE BENEDETTI, A. 1999. 
Elevated expression of eIF4E in confined early breast cancer lesions: possible role of 
hypoxia. Int J Cancer, 80, 516‐22. 
DEHLIN, E., WORMINGTON, M., KORNER, C. G. & WAHLE, E. 2000. Cap‐dependent 
deadenylation of mRNA. EMBO J, 19, 1079‐86. 
DENLEY, A., KANG, S., KARST, U. & VOGT, P. K. 2008. Oncogenic signaling of class I PI3K 
isoforms. Oncogene, 27, 2561‐74. 
DI NICOLANTONIO, F., ARENA, S., GALLICCHIO, M., ZECCHIN, D., MARTINI, M., FLONTA, S. E., 
STELLA, G. M., LAMBA, S., CANCELLIERE, C., RUSSO, M., GEUNA, M., APPENDINO, G., 
FANTOZZI, R., MEDICO, E. & BARDELLI, A. 2008. Replacement of normal with mutant 
alleles in the genome of normal human cells unveils mutation‐specific drug responses. 
Proceedings of the National Academy of Sciences, 105, 20864‐20869. 
DI NICOLANTONIO, F., ARENA, S., TABERNERO, J., GROSSO, S., MOLINARI, F., MACARULLA, T., 
RUSSO, M., CANCELLIERE, C., ZECCHIN, D., MAZZUCCHELLI, L., SASAZUKI, T., 
SHIRASAWA, S., GEUNA, M., FRATTINI, M., BASELGA, J., GALLICCHIO, M., BIFFO, S. & 
BARDELLI, A. 2010. Deregulation of the PI3K and KRAS signaling pathways in human 
cancer cells determines their response to everolimus. J Clin Invest, 120, 2858 ‐ 2866. 
DIRENZO, J., SIGNORETTI, S., NAKAMURA, N., RIVERA‐GONZALEZ, R., SELLERS, W., LODA, M. & 
BROWN, M. 2002. Growth Factor Requirements and Basal Phenotype of an 
Immortalized Mammary Epithelial Cell Line. Cancer Research, 62, 89‐98. 
DRUMMOND, D. R., ARMSTRONG, J. & COLMAN, A. 1985. The effect of capping and 
polyadenylation on the stability, movement and translation of synthetic messenger 
RNAs in Xenopus oocytes. Nucleic Acids Res, 13, 7375‐94. 
DUMONT, A. G., DUMONT, S. N. & TRENT, J. C. 2012. The favorable impact of PIK3CA 
mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer, 
31, 327‐34. 
DUNCAN, R., MILBURN, S. C. & HERSHEY, J. W. 1987. Regulated phosphorylation and low 
abundance of HeLa cell initiation factor eIF‐4F suggest a role in translational control. 
Heat shock effects on eIF‐4F. J Biol Chem, 262, 380‐8. 
DYER, J. R., MICHEL, S., LEE, W., CASTELLUCCI, V. F., WAYNE, N. L. & SOSSIN, W. S. 2003. An 
activity‐dependent switch to cap‐independent translation triggered by eIF4E 
dephosphorylation. Nat Neurosci, 6, 219‐220. 
EBERLE, J., KRASAGAKIS, K. & ORFANOS, C. E. 1997. Translation initiation factor eIF‐4A1 mRNA 
is consistently overexpressed in human melanoma cells in vitro. International Journal 
of Cancer, 71, 396‐401. 
193 
 
EDERY, I. & SONENBERG, N. 1985. Cap‐dependent RNA splicing in a HeLa nuclear extract. Proc 
Natl Acad Sci U S A, 82, 7590‐4. 
EGLOFF, S. & MURPHY, S. 2008. Cracking the RNA polymerase II CTD code. Trends Genet, 24, 
280‐8. 
ENSINGER, M. J. & MOSS, B. 1976. Modification of the 5' terminus of mRNA by an RNA 
(guanine‐7‐)‐methyltransferase from HeLa cells. J Biol Chem, 251, 5283‐91. 
EVAN, G. I. & VOUSDEN, K. H. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature, 
411, 342‐348. 
FAN, S., LI, Y., YUE, P., KHURI, F. R. & SUN, S. Y. 2010. The eIF4E/eIF4G interaction inhibitor 
4EGI‐1 augments TRAIL‐mediated apoptosis through c‐FLIP Down‐regulation and DR5 
induction independent of inhibition of cap‐dependent protein translation. Neoplasia, 
12, 346‐56. 
FARMER, H., MCCABE, N., LORD, C., TUTT, A., JOHNSON, D., RICHARDSON, T., SANTAROSA, M., 
DILLON, K., HICKSON, I., KNIGHTS, C., MARTIN, N., JACKSON, S., SMITH, G. & 
ASHWORTH, A. 2005. Targeting the DNA repair defect in BRCA mutant cells as a 
therapeutic strategy. Nature, 434, 917 ‐ 921. 
FELDMAN, M., APSEL, B., UOTILA, A., LOEWITH, R., KNIGHT, Z., RUGGERO, D. & SCHOKAT, K. 
2009. Active‐Site Inhibitors of mTOR Target Rapamycin‐Resistant Outputs of mTORC1 
and mTORC2. 7, 371. 
FELSHER, D. W. & BISHOP, J. M. 1999. Reversible tumorigenesis by MYC in hematopoietic 
lineages. Mol Cell, 4, 199‐207. 
FERLAY, J., SHIN, H. R., BRAY, F., FORMAN, D., MATHERS, C. & PARKIN, D. M. 2010. Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893‐917. 
FERNANDEZ‐SANCHEZ, M. E., GONATOPOULOS‐POURNATZIS, T., PRESTON, G., LAWLOR, M. A. 
& COWLING, V. H. 2009a. S‐Adenosyl Homocysteine Hydrolase Is Required for Myc‐
Induced mRNA Cap Methylation, Protein Synthesis, and Cell Proliferation. Molecular 
and Cellular Biology, 29, 6182‐6191. 
FILIPOWICZ, W. 1978. Functions of the 5,‐terminal m7G cap in eukaryotic mRNA. FEBS Lett, 96, 
1‐11. 
FLAHERTY, S. M., FORTES, P., IZAURRALDE, E., MATTAJ, I. W. & GILMARTIN, G. M. 1997. 
Participation of the nuclear cap binding complex in pre‐mRNA 3' processing. Proc Natl 
Acad Sci U S A, 94, 11893‐8. 
FOLKES, A., AHMADI, K., ALDERTON, W., ALIX, S., BAKER, S., BOX, G., CHUCKOWREE, I., CLARKE, 
P., DEPLEDGE, P., ECCLES, S., FRIEDMAN, L., HAYES, A., HANCOX, T., KUGENDRADAS, 
A., LENSUN, L., MOORE, P., OLIVERO, A., PANG, J., PATEL, S., PERGL‐WILSON, G., 
RAYNAUD, F., ROBSON, A., SAGHIR, N., SALPHATI, L., SOHAL, S., ULTSCH, M., VALENTI, 
M., WALLWEBER, H., WAN, N. & WIESMANN, C. 2008a. The identification of 2‐(1H‐
indazol‐4‐yl)‐6‐(4‐methanesulfonyl‐piperazin‐1‐ylmethyl)‐4‐morpholin‐4‐yl‐thieno[3,2‐
d]pyrimidine (GDC‐0941) as a potent, selective, orally bioavailable inhibitor of class I 
PI3 kinase for the treatment of cancer. J Med Chem, 51, 5522 ‐ 5532. 
FONG, P. C., BOSS, D. S., YAP, T. A., TUTT, A., WU, P., MERGUI‐ROELVINK, M., MORTIMER, P., 
SWAISLAND, H., LAU, A., O'CONNOR, M. J., ASHWORTH, A., CARMICHAEL, J., KAYE, S. 
B., SCHELLENS, J. H. & DE BONO, J. S. 2009. Inhibition of poly(ADP‐ribose) polymerase 
in tumors from BRCA mutation carriers. N Engl J Med, 361, 123‐34. 
FORBES, S. A., TANG, G., BINDAL, N., BAMFORD, S., DAWSON, E., COLE, C., KOK, C. Y., JIA, M., 
EWING, R., MENZIES, A., TEAGUE, J. W., STRATTON, M. R. & FUTREAL, P. A. 2010. 
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate 
acquired mutations in human cancer. Nucleic Acids Res, 38, D652‐7. 
FORTES, P., KUFEL, J., FORNEROD, M., POLYCARPOU‐SCHWARZ, M., LAFONTAINE, D., 
TOLLERVEY, D. & MATTAJ, I. W. 1999. Genetic and physical interactions involving the 
yeast nuclear cap‐binding complex. Mol Cell Biol, 19, 6543‐53. 
FRESCO, L. D. & BURATOWSKI, S. 1996. Conditional mutants of the yeast mRNA capping 
enzyme show that the cap enhances, but is not required for, mRNA splicing. RNA, 2, 
584‐96. 
194 
 
FRUMAN, D. A. & ROMMEL, C. 2014. PI3K and cancer: lessons, challenges and opportunities. 
Nat Rev Drug Discov, 13, 140‐56. 
FUKUCHI‐SHIMOGORI, T., ISHII, I., KASHIWAGI, K., MASHIBA, H., EKIMOTO, H. & IGARASHI, K. 
1997. Malignant transformation by overproduction of translation initiation factor 
eIF4G. Cancer Res, 57, 5041‐4. 
FURUICHI, Y., LAFIANDRA, A. & SHATKIN, A. J. 1977. 5'‐Terminal structure and mRNA stability. 
Nature, 266, 235‐9. 
FURUICHI, Y. & MIURA, K. 1975. A blocked structure at the 5' terminus of mRNA from 
cytoplasmic polyhedrosis virus. Nature, 253, 374‐5. 
FURUICHI, Y., MORGAN, M., MUTHUKRISHNAN, S. & SHATKIN, A. J. 1975. Reovirus messenger 
RNA contains a methylated, blocked 5'‐terminal structure: m‐7G(5')ppp(5')G‐MpCp. 
Proc Natl Acad Sci U S A, 72, 362‐6. 
FURUICHI, Y. & SHATKIN, A. J. 2000. Viral and cellular mRNA capping: past and prospects. Adv 
Virus Res, 55, 135‐84. 
GAO, M., FRITZ, D. T., FORD, L. P. & WILUSZ, J. 2000. Interaction between a poly(A)‐specific 
ribonuclease and the 5' cap influences mRNA deadenylation rates in vitro. Mol Cell, 5, 
479‐88. 
GEORGIEV, O., MOUS, J. & BIRNSTIEL, M. 1984. Processing and nucleo‐cytoplasmic transport of 
histone gene transcripts. Nucleic Acids Research, 12. 
GHOSH, A., SHUMAN, S. & LIMA, C. D. 2011. Structural insights to how mammalian capping 
enzyme reads the CTD code. Mol Cell, 43, 299‐310. 
GILLIAN‐DANIEL, D. L., GRAY, N. K., ÅSTRÖM, J., BARKOFF, A. & WICKENS, M. 1998. 
Modifications of the 5′ Cap of mRNAs duringXenopus Oocyte Maturation: 
Independence from Changes in Poly(A) Length and Impact on Translation. Molecular 
and Cellular Biology, 18, 6152‐6163. 
GILMARTIN, G. M., MCDEVITT, M. A. & NEVINS, J. R. 1988. Multiple factors are required for 
specific RNA cleavage at a poly(A) addition site. Genes Dev, 2, 578‐87. 
GINGRAS, A. C., KENNEDY, S. G., O'LEARY, M. A., SONENBERG, N. & HAY, N. 1998. 4E‐BP1, a 
repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) 
signaling pathway. Genes Dev, 12, 502‐13. 
GINGRAS, A. C., RAUGHT, B. & SONENBERG, N. 1999. eIF4 initiation factors: effectors of mRNA 
recruitment to ribosomes and regulators of translation. Annu Rev Biochem, 68, 913‐63. 
GLOVER‐CUTTER, K., KIM, S., ESPINOSA, J. & BENTLEY, D. L. 2008b. RNA polymerase II pauses 
and associates with pre‐mRNA processing factors at both ends of genes. Nature 
Structural and Molecular Biology, 15, 71‐78. 
GONATOPOULOS‐POURNATZIS, T. & COWLING, V. H. 2014. RAM function is dependent on 
Kapbeta2‐mediated nuclear entry. Biochem J, 457, 473‐84. 
GONATOPOULOS‐POURNATZIS, T., DUNN, S., BOUNDS, R. & COWLING, VICTORIA H. 2011. 
RAM/Fam103a1 Is Required for mRNA Cap Methylation. Molecular cell, 44, 585‐596. 
GONATOPOULOS‑POURNATZIS, T. & COWLING, V. H. 2014. Cap‐binding complex (CBC). 
Biochemical Journal, 457, 231‐242. 
GRAFF, J. R., KONICEK, B. W., VINCENT, T. M., LYNCH, R. L., MONTEITH, D., WEIR, S. N., 
SCHWIER, P., CAPEN, A., GOODE, R. L., DOWLESS, M. S., CHEN, Y., ZHANG, H., SISSONS, 
S., COX, K., MCNULTY, A. M., PARSONS, S. H., WANG, T., SAMS, L., GEEGANAGE, S., 
DOUGLASS, L. E., NEUBAUER, B. L., DEAN, N. M., BLANCHARD, K., SHOU, J., STANCATO, 
L. F., CARTER, J. H. & MARCUSSON, E. G. 2007. Therapeutic suppression of translation 
initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest, 
117, 2638‐48. 
GREEN, M. R., MANIATIS, T. & MELTON, D. A. 1983. Human beta‐globin pre‐mRNA synthesized 
in vitro is accurately spliced in Xenopus oocyte nuclei. Cell, 32, 681‐94. 
GRUDZIEN, E., KALEK, M., JEMIELITY, J., DARZYNKIEWICZ, E. & RHOADS, R. E. 2006. Differential 
inhibition of mRNA degradation pathways by novel cap analogs. J Biol Chem, 281, 
1857‐67. 
195 
 
GUENTHER, M. G., LEVINE, S. S., BOYER, L. A., JAENISCH, R. & YOUNG, R. A. 2007. A chromatin 
landmark and transcription initiation at most promoters in human cells. Cell, 130, 77‐
88. 
GUERTIN, D. & SABATINI, D. 2007. Defining the role of mTOR in cancer. Cancer Cell, 12, 9 ‐ 22. 
GUIGUEN, A., SOUTOURINA, J., DEWEZ, M., TAFFOREAU, L., DIEU, M., RAES, M., 
VANDENHAUTE, J., WERNER, M. & HERMAND, D. 2007. Recruitment of P‐TEFb (Cdk9‐
Pch1) to chromatin by the cap‐methyl transferase Pcm1 in fission yeast. EMBO J, 26, 
1552‐1559. 
GYMNOPOULOS, M., ELSLIGER, M. A. & VOGT, P. K. 2007. Rare cancer‐specific mutations in 
PIK3CA show gain of function. Proc Natl Acad Sci U S A, 104, 5569‐74. 
HAGHIGHAT, A., MADER, S., PAUSE, A. & SONENBERG, N. 1995. Repression of cap‐dependent 
translation by 4E‐binding protein 1: competition with p220 for binding to eukaryotic 
initiation factor‐4E. EMBO J, 14, 5701‐9. 
HALABY, M. J. & YANG, D. Q. 2007. p53 translational control: a new facet of p53 regulation and 
its implication for tumorigenesis and cancer therapeutics. Gene, 395, 1‐7. 
HANAHAN, D. & WEINBERG, R. A. 2000. The hallmarks of cancer. Cell, 100, 57‐70. 
HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. Cell, 144, 
646‐74. 
HARDIE, D. G., ROSS, F. A. & HAWLEY, S. A. 2012. AMPK: a nutrient and energy sensor that 
maintains energy homeostasis. Nat Rev Mol Cell Biol, 13, 251‐62. 
HERS, I., VINCENT, E. E. & TAVARE, J. M. 2011. Akt signalling in health and disease. Cell Signal, 
23, 1515‐27. 
HESS, G., HERBRECHT, R., ROMAGUERA, J., VERHOEF, G., CRUMP, M., GISSELBRECHT, C., 
LAURELL, A., OFFNER, F., STRAHS, A., BERKENBLIT, A., HANUSHEVSKY, O., CLANCY, J., 
HEWES, B., MOORE, L. & COIFFIER, B. 2009. Phase III study to evaluate temsirolimus 
compared with investigator's choice therapy for the treatment of relapsed or 
refractory mantle cell lymphoma. J Clin Oncol, 27, 3822‐9. 
HIGGINS, M. J. & BASELGA, J. 2011. Targeted therapies for breast cancer. J Clin Invest, 121, 
3797‐803. 
HIREMATH, L. S., WEBB, N. R. & RHOADS, R. E. 1985. Immunological detection of the 
messenger RNA cap‐binding protein. J Biol Chem, 260, 7843‐9. 
HO, C. K. & SHUMAN, S. 1999. Distinct roles for CTD Ser‐2 and Ser‐5 phosphorylation in the 
recruitment and allosteric activation of mammalian mRNA capping enzyme. Mol Cell, 
3, 405‐11. 
HO, C. K., SRISKANDA, V., MCCRACKEN, S., BENTLEY, D., SCHWER, B. & SHUMAN, S. 1998. The 
guanylyltransferase domain of mammalian mRNA capping enzyme binds to the 
phosphorylated carboxyl‐terminal domain of RNA polymerase II. J Biol Chem, 273, 
9577‐85. 
HOCINE, S., SINGER, R. H. & GRUNWALD, D. 2010. RNA processing and export. Cold Spring 
Harb Perspect Biol, 2, a000752. 
HOFFMAN, B. & LIEBERMANN, D. A. 1998. The proto‐oncogene c‐myc and apoptosis. 
Oncogene, 17, 3351‐7. 
HOLCIK, M. & SONENBERG, N. 2005. Translational control in stress and apoptosis. Nat Rev Mol 
Cell Biol, 6, 318‐27. 
HOLZ, M. K., BALLIF, B. A., GYGI, S. P. & BLENIS, J. 2005. mTOR and S6K1 mediate assembly of 
the translation preinitiation complex through dynamic protein interchange and 
ordered phosphorylation events. Cell, 123, 569‐80. 
HONG, D. S., KURZROCK, R., OH, Y., WHELER, J., NAING, A., BRAIL, L., CALLIES, S., ANDRE, V., 
KADAM, S. K., NASIR, A., HOLZER, T. R., MERIC‐BERNSTAM, F., FISHMAN, M. & SIMON, 
G. 2011. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic 
evaluation of eIF‐4E antisense oligonucleotide LY2275796 in patients with advanced 
cancer. Clin Cancer Res, 17, 6582‐91. 
196 
 
HOSSAIN, M. A., CHUNG, C., PRADHAN, S. K. & JOHNSON, T. L. 2013. The yeast cap binding 
complex modulates transcription factor recruitment and establishes proper histone 
H3K36 trimethylation during active transcription. Mol Cell Biol, 33, 785‐99. 
HSIEH, A. C., COSTA, M., ZOLLO, O., DAVIS, C., FELDMAN, M. E., TESTA, J. R., MEYUHAS, O., 
SHOKAT, K. M. & RUGGERO, D. 2010. Genetic dissection of the oncogenic mTOR 
pathway reveals druggable addiction to translational control via 4EBP‐eIF4E. Cancer 
Cell, 17, 249‐61. 
HSIN, J. P. & MANLEY, J. L. 2012. The RNA polymerase II CTD coordinates transcription and RNA 
processing. Genes Dev, 26, 2119‐37. 
HUANG, C. H., MANDELKER, D., GABELLI, S. B. & AMZEL, L. M. 2008. Insights into the oncogenic 
effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle, 7, 
1151‐6. 
IKENOUE, T., KANAI, F., HIKIBA, Y., OBATA, T., TANAKA, Y., IMAMURA, J., OHTA, M., JAZAG, A., 
GULENG, B., TATEISHI, K., ASAOKA, Y., MATSUMURA, M., KAWABE, T. & OMATA, M. 
2005. Functional analysis of PIK3CA gene mutations in human colorectal cancer. 
Cancer Res, 65, 4562‐7. 
INOKI, K., LI, Y., XU, T. & GUAN, K. L. 2003a. Rheb GTPase is a direct target of TSC2 GAP activity 
and regulates mTOR signaling. Genes Dev, 17, 1829‐34. 
INOKI, K., LI, Y., ZHU, T., WU, J. & GUAN, K. L. 2002. TSC2 is phosphorylated and inhibited by 
Akt and suppresses mTOR signalling. Nat Cell Biol, 4, 648‐57. 
INOKI, K., ZHU, T. & GUAN, K.‐L. 2003b. TSC2 Mediates Cellular Energy Response to Control Cell 
Growth and Survival. Cell, 115, 577‐590. 
INOUE, K., OHNO, M., SAKAMOTO, H. & SHIMURA, Y. 1989. Effect of the cap structure on pre‐
mRNA splicing in Xenopus oocyte nuclei. Genes Dev, 3, 1472‐9. 
ISAKOFF, S., ENGELMAN, J., IRIE, H., LUO, J., BRACHMANN, S., PEARLINE, R., CANTLEY, L. & 
BRUGGE, J. 2005. Breast cancer‐associated PIK3CA mutations are oncogenic in 
mammary epithelial cells. Cancer Res, 65, 10992 ‐ 11000. 
IZAURRALDE, E., LEWIS, J., GAMBERI, C., JARMOLOWSKI, A., MCGUIGAN, C. & MATTAJ, I. W. 
1995. A cap‐binding protein complex mediating U snRNA export. Nature, 376, 709‐12. 
IZAURRALDE, E., LEWIS, J., MCGUIGAN, C., JANKOWSKA, M., DARZYNKIEWICZ, E. & MATTAJ, I. 
W. 1994. A nuclear cap binding protein complex involved in pre‐mRNA splicing. Cell, 
78, 657‐668. 
IZAURRALDE, E., STEPINSKI, J., DARZYNKIEWICZ, E. & MATTAJ, I. W. 1992. A cap binding protein 
that may mediate nuclear export of RNA polymerase II‐transcribed RNAs. J Cell Biol, 
118, 1287‐95. 
JACKSON, R. J., HELLEN, C. U. & PESTOVA, T. V. 2010. The mechanism of eukaryotic translation 
initiation and principles of its regulation. Nat Rev Mol Cell Biol, 11, 113‐27. 
JAMES, S. R., DOWNES, C. P., GIGG, R., GROVE, S. J., HOLMES, A. B. & ALESSI, D. R. 1996. 
Specific binding of the Akt‐1 protein kinase to phosphatidylinositol 3,4,5‐trisphosphate 
without subsequent activation. Biochem. J., 315, 709‐713. 
JANKU, F., TSIMBERIDOU, A., GARRIDO‐LAGUNA, I., WANG, X., LUTHRA, R., HONG, D., NAING, 
A., FALCHOOK, G., MORONEY, J., PIHA‐PAUL, S., WHELER, J., MOULDER, S., FU, S. & 
KURZROCK, R. 2011. PIK3CA mutations in patients with advanced cancers treated with 
PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther, 10, 558 ‐ 565. 
JARMOLOWSKI, A., BOELENS, W. C., IZAURRALDE, E. & MATTAJ, I. W. 1994. Nuclear export of 
different classes of RNA is mediated by specific factors. J Cell Biol, 124, 627‐35. 
JEMAL, A., CENTER, M. M., DESANTIS, C. & WARD, E. M. 2010. Global Patterns of Cancer 
Incidence and Mortality Rates and Trends. Cancer Epidemiology Biomarkers & 
Prevention, 19, 1893‐1907. 
JIAO, X., CHANG, J. H., KILIC, T., TONG, L. & KILEDJIAN, M. 2013. A mammalian pre‐mRNA 5' 
end capping quality control mechanism and an unexpected link of capping to pre‐
mRNA processing. Mol Cell, 50, 104‐15. 
JIAO, X., XIANG, S., OH, C., MARTIN, C. E., TONG, L. & KILEDJIAN, M. 2010. Identification of a 
quality‐control mechanism for mRNA 5'‐end capping. Nature, 467, 608‐11. 
197 
 
JOHANNES, G., CARTER, M. S., EISEN, M. B., BROWN, P. O. & SARNOW, P. 1999. Identification 
of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F 
concentrations using a cDNA microarray. Proc Natl Acad Sci U S A, 96, 13118‐23. 
JOHNSON, L. F., LEVIS, R., ABELSON, H. T., GREEN, H. & PENMAN, S. 1976. Changes in RNA in 
relation to growth of the fibroblast. IV. Alterations in theproduction and processing of 
mRNA and rRNA in resting and growing cells. J Cell Biol, 71, 933‐8. 
JONES, R. M., BRANDA, J., JOHNSTON, K. A., POLYMENIS, M., GADD, M., RUSTGI, A., 
CALLANAN, L. & SCHMIDT, E. V. 1996. An essential E box in the promoter of the gene 
encoding the mRNA cap‐binding protein (eukaryotic initiation factor 4E) is a target for 
activation by c‐myc. Mol Cell Biol, 16, 4754‐64. 
KALINSKY, K., JACKS, L., HEGUY, A., PATIL, S., DROBNJAK, M., BHANOT, U., HEDVAT, C., TRAINA, 
T., SOLIT, D., GERALD, W. & MOYNAHAN, M. 2009. PIK3CA mutation associates with 
improved outcome in breast cancer. Clin Cancer Res, 15, 5049 ‐ 5059. 
KAN, Z., JAISWAL, B. S., STINSON, J., JANAKIRAMAN, V., BHATT, D., STERN, H. M., YUE, P., 
HAVERTY, P. M., BOURGON, R., ZHENG, J., MOORHEAD, M., CHAUDHURI, S., TOMSHO, 
L. P., PETERS, B. A., PUJARA, K., CORDES, S., DAVIS, D. P., CARLTON, V. E., YUAN, W., LI, 
L., WANG, W., EIGENBROT, C., KAMINKER, J. S., EBERHARD, D. A., WARING, P., 
SCHUSTER, S. C., MODRUSAN, Z., ZHANG, Z., STOKOE, D., DE SAUVAGE, F. J., FAHAM, 
M. & SESHAGIRI, S. 2010. Diverse somatic mutation patterns and pathway alterations 
in human cancers. Nature, 466, 869‐73. 
KANG, S., BADER, A. G. & VOGT, P. K. 2005. Phosphatidylinositol 3‐kinase mutations identified 
in human cancer are oncogenic. Proceedings of the National Academy of Sciences of 
the United States of America, 102, 802‐807. 
KANG, S., DENLEY, A., VANHAESEBROECK, B. & VOGT, P. K. 2006. Oncogenic transformation 
induced by the p110β, ‐γ, and ‐δ isoforms of class I phosphoinositide 3‐kinase. 
Proceedings of the National Academy of Sciences of the United States of America, 103, 
1289‐1294. 
KAO, J., SALARI, K., BOCANEGRA, M., CHOI, Y. L., GIRARD, L., GANDHI, J., KWEI, K. A., 
HERNANDEZ‐BOUSSARD, T., WANG, P., GAZDAR, A. F., MINNA, J. D. & POLLACK, J. R. 
2009. Molecular profiling of breast cancer cell lines defines relevant tumor models and 
provides a resource for cancer gene discovery. PLoS One, 4, e6146. 
KATAOKA, N., OHNO, M., MODA, I. & SHIMURA, Y. 1995. Identification of the factors that 
interact with NCBP, an 80 kDa nuclear cap binding protein. Nucleic Acids Res, 23, 3638‐
41. 
KENTSIS, A., TOPISIROVIC, I., CULJKOVIC, B., SHAO, L. & BORDEN, K. L. 2004. Ribavirin 
suppresses eIF4E‐mediated oncogenic transformation by physical mimicry of the 7‐
methyl guanosine mRNA cap. Proc Natl Acad Sci U S A, 101, 18105‐10. 
KEREKATTE, V., SMILEY, K., HU, B., SMITH, A., GELDER, F. & DE BENEDETTI, A. 1995. The proto‐
oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J 
Cancer, 64, 27‐31. 
KEVIL, C., CARTER, P., HU, B. & DEBENEDETTI, A. 1995. Translational enhancement of FGF‐2 by 
eIF‐4 factors, and alternate utilization of CUG and AUG codons for translation 
initiation. Oncogene, 11, 2339‐48. 
KOMAR, A. A. & HATZOGLOU, M. 2011. Cellular IRES‐mediated translation: the war of ITAFs in 
pathophysiological states. Cell Cycle, 10, 229‐40. 
KOMARNITSKY, P., CHO, E.‐J. & BURATOWSKI, S. 2000a. Different phosphorylated forms of 
RNA polymerase II and associated mRNA processing factors during transcription. Genes 
& Development, 14, 2452‐2460. 
KONARSKA, M. M., PADGETT, R. A. & SHARP, P. A. 1984. Recognition of cap structure in splicing 
in vitro of mRNA precursors. Cell, 38, 731‐6. 
KONINKI, K., BAROK, M., TANNER, M., STAFF, S., PITKANEN, J., HEMMILA, P., ILVESARO, J. & 
ISOLA, J. 2010. Multiple molecular mechanisms underlying trastuzumab and lapatinib 
resistance in JIMT‐1 breast cancer cells. Cancer Lett, 294, 211‐9. 
198 
 
KOREN, S. & BENTIRES‐ALJ, M. 2013. Mouse models of PIK3CA mutations: one mutation 
initiates heterogeneous mammary tumors. FEBS J, 280, 2758‐65. 
KOROMILAS, A. E., LAZARIS‐KARATZAS, A. & SONENBERG, N. 1992. mRNAs containing 
extensive secondary structure in their 5' non‐coding region translate efficiently in cells 
overexpressing initiation factor eIF‐4E. EMBO J, 11, 4153‐8. 
KOVACINA, K. S., PARK, G. Y., BAE, S. S., GUZZETTA, A. W., SCHAEFER, E., BIRNBAUM, M. J. & 
ROTH, R. A. 2003. Identification of a proline‐rich Akt substrate as a 14‐3‐3 binding 
partner. J Biol Chem, 278, 10189‐94. 
LAHUDKAR, S., SHUKLA, A., BAJWA, P., DURAIRAJ, G., STANOJEVIC, N. & BHAUMIK, S. R. 2011. 
The mRNA cap‐binding complex stimulates the formation of pre‐initiation complex at 
the promoter via its interaction with Mot1p in vivo. Nucleic Acids Res, 39, 2188‐209. 
LAI, Y. L., MAU, B. L., CHENG, W. H., CHEN, H. M., CHIU, H. H. & TZEN, C. Y. 2008. PIK3CA exon 
20 mutation is independently associated with a poor prognosis in breast cancer 
patients. Ann Surg Oncol, 15, 1064‐9. 
LANGBERG, S. R. & MOSS, B. 1981. Post‐transcriptional modifications of mRNA. Purification 
and characterization of cap I and cap II RNA (nucleoside‐2'‐)‐methyltransferases from 
HeLa cells. J Biol Chem, 256, 10054‐60. 
LAPLANTE, M. & SABATINI, D. M. 2012. mTOR signaling in growth control and disease. Cell, 
149, 274‐93. 
LAPLANTE, M. & SABATINI, D. M. 2013. Regulation of mTORC1 and its impact on gene 
expression at a glance. J Cell Sci, 126, 1713‐9. 
LAYBOURN, P. J. & DAHMUS, M. E. 1990. Phosphorylation of RNA polymerase IIA occurs 
subsequent to interaction with the promoter and before the initiation of transcription. 
J Biol Chem, 265, 13165‐73. 
LAZARIS‐KARATZAS, A., MONTINE, K. S. & SONENBERG, N. 1990. Malignant transformation by a 
eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature, 345, 544‐547. 
LEE, J. W., SOUNG, Y. H., KIM, S. Y., LEE, H. W., PARK, W. S., NAM, S. W., KIM, S. H., LEE, J. Y., 
YOO, N. J. & LEE, S. H. 2005. PIK3CA gene is frequently mutated in breast carcinomas 
and hepatocellular carcinomas. Oncogene, 24, 1477‐80. 
LEHMANN, B., BAUER, J., CHEN, X., SANDERS, M., CHAKRAVARTHY, A., SHYR, Y. & PIETENPOL, J. 
2011. Identification of human triple‐negative breast cancer subtypes and preclinical 
models for selection of targeted therapies. J Clin Invest, 121, 2750 ‐ 2767. 
LENASI, T., PETERLIN, B. M. & BARBORIC, M. 2011. Cap‐binding protein complex links pre‐
mRNA capping to transcription elongation and alternative splicing through positive 
transcription elongation factor b (P‐TEFb). J Biol Chem, 286, 22758‐68. 
LENGAUER, C., KINZLER, K. W. & VOGELSTEIN, B. 1998. Genetic instabilities in human cancers. 
Nature, 396, 643‐9. 
LEVINE, D. A., BOGOMOLNIY, F., YEE, C. J., LASH, A., BARAKAT, R. R., BORGEN, P. I. & BOYD, J. 
2005. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer 
Res, 11, 2875‐8. 
LEWIS, J. D., IZAURRALDE, E., JARMOLOWSKI, A., MCGUIGAN, C. & MATTAJ, I. W. 1996. A 
nuclear cap‐binding complex facilitates association of U1 snRNP with the cap‐proximal 
5' splice site. Genes Dev, 10, 1683‐98. 
LI, B. D., LIU, L., DAWSON, M. & DE BENEDETTI, A. 1997. Overexpression of eukaryotic initiation 
factor 4E (eIF4E) in breast carcinoma. Cancer, 79, 2385‐90. 
LI, B. D., MCDONALD, J. C., NASSAR, R. & DE BENEDETTI, A. 1998. Clinical outcome in stage I to 
III breast carcinoma and eIF4E overexpression. Ann Surg, 227, 756‐6l; discussion 761‐3. 
LIANG, J., ZUBOVITZ, J., PETROCELLI, T., KOTCHETKOV, R., CONNOR, M. K., HAN, K., LEE, J. H., 
CIARALLO, S., CATZAVELOS, C., BENISTON, R., FRANSSEN, E. & SLINGERLAND, J. M. 
2002. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27‐
mediated G1 arrest. Nat Med, 8, 1153‐60. 
LINDSTROM, D. L., SQUAZZO, S. L., MUSTER, N., BURCKIN, T. A., WACHTER, K. C., EMIGH, C. A., 
MCCLEERY, J. A., YATES, J. R. & HARTZOG, G. A. 2003. Dual Roles for Spt5 in Pre‐mRNA 
199 
 
Processing and Transcription Elongation Revealed by Identification of Spt5‐Associated 
Proteins. Molecular and Cellular Biology, 23, 1368‐1378. 
LISTERMAN, I., SAPRA, A. K. & NEUGEBAUER, K. M. 2006. Cotranscriptional coupling of splicing 
factor recruitment and precursor messenger RNA splicing in mammalian cells. Nat 
Struct Mol Biol, 13, 815‐22. 
LIU, P., CHENG, H., ROBERTS, T. & ZHAO, J. 2009a. Targeting the phosphoinositide 3‐kinase 
pathway in cancer. Nat Rev Drug Discov, 8, 627 ‐ 644. 
LIU, P., CHENG, H., SANTIAGO, S., RAEDER, M., ZHANG, F., ISABELLA, A., YANG, J., SEMAAN, D., 
CHEN, C., FOX, E., GRAY, N., MONAHAN, J., SCHLEGEL, R., BEROUKHIM, R., MILLS, G. & 
ZHAO, J. 2011. Oncogenic PIK3CA‐driven mammary tumors frequently recur via PI3K 
pathway‐dependent and PI3K pathway‐independent mechanisms. Nat Med, 17, 1116 ‐ 
1120. 
LIWAK, U., FAYE, M. D. & HOLCIK, M. 2012. Translation control in apoptosis. Exp Oncol, 34, 
218‐30. 
LONG, X., LIN, Y., ORTIZ‐VEGA, S., YONEZAWA, K. & AVRUCH, J. 2005. Rheb binds and regulates 
the mTOR kinase. Curr Biol, 15, 702‐13. 
LU, H., FLORES, O., WEINMANN, R. & REINBERG, D. 1991. The nonphosphorylated form of RNA 
polymerase II preferentially associates with the preinitiation complex. Proc Natl Acad 
Sci U S A, 88, 10004‐8. 
LUCAS, D. M., EDWARDS, R. B., LOZANSKI, G., WEST, D. A., SHIN, J. D., VARGO, M. A., DAVIS, M. 
E., ROZEWSKI, D. M., JOHNSON, A. J., SU, B. N., GOETTL, V. M., HEEREMA, N. A., LIN, T. 
S., LEHMAN, A., ZHANG, X., JARJOURA, D., NEWMAN, D. J., BYRD, J. C., KINGHORN, A. 
D. & GREVER, M. R. 2009. The novel plant‐derived agent silvestrol has B‐cell selective 
activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and 
in vivo. Blood, 113, 4656‐66. 
LUCAS, D. M., STILL, P. C., PEREZ, L. B., GREVER, M. R. & KINGHORN, A. D. 2010. Potential of 
plant‐derived natural products in the treatment of leukemia and lymphoma. Curr Drug 
Targets, 11, 812‐22. 
LUO, J., SOLIMINI, N. L. & ELLEDGE, S. J. 2009. Principles of cancer therapy: oncogene and non‐
oncogene addiction. Cell, 136, 823‐37. 
MA, X. M. & BLENIS, J. 2009. Molecular mechanisms of mTOR‐mediated translational control. 
Nat Rev Mol Cell Biol, 10, 307‐18. 
MA, X. M., YOON, S.‐O., RICHARDSON, C. J., JÜLICH, K. & BLENIS, J. 2008. SKAR Links Pre‐mRNA 
Splicing to mTOR/S6K1‐Mediated Enhanced Translation Efficiency of Spliced mRNAs. 
Cell, 133, 303‐313. 
MACEJAK, D. G. & SARNOW, P. 1991. Internal initiation of translation mediated by the 5' leader 
of a cellular mRNA. Nature, 353, 90‐4. 
MADER, S., LEE, H., PAUSE, A. & SONENBERG, N. 1995. The translation initiation factor eIF‐4E 
binds to a common motif shared by the translation factor eIF‐4 gamma and the 
translational repressors 4E‐binding proteins. Mol Cell Biol, 15, 4990‐7. 
MAEHAMA, T. & DIXON, J. E. 1998. The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates 
the Lipid Second Messenger, Phosphatidylinositol 3,4,5‐Trisphosphate. Journal of 
Biological Chemistry, 273, 13375‐13378. 
MALINA, A., MILLS, J. R. & PELLETIER, J. 2012. Emerging therapeutics targeting mRNA 
translation. Cold Spring Harb Perspect Biol, 4, a012377. 
MAMANE, Y., PETROULAKIS, E., RONG, L., YOSHIDA, K., LER, L. W. & SONENBERG, N. 2004. 
eIF4E ‐ from translation to transformation. Oncogene, 23, 3172‐3179. 
MANDAL, S. S., CHU, C., WADA, T., HANDA, H., SHATKIN, A. J. & REINBERG, D. 2004b. 
Functional interactions of RNA‐capping enzyme with factors that positively and 
negatively regulate promoter escape by RNA polymerase II. Proc Natl Acad Sci U S A, 
101, 7572‐7. 
MANGONE, F. R., BOBROVNITCHAIA, I. G., SALAORNI, S., MANULI, E. & NAGAI, M. A. 2012. 
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer 
patients. Clinics (Sao Paulo), 67, 1285‐90. 
200 
 
MANNING, B. D. & CANTLEY, L. C. 2007. AKT/PKB signaling: navigating downstream. Cell, 129, 
1261‐74. 
MAO, X., SCHWER, B. & SHUMAN, S. 1995. Yeast mRNA cap methyltransferase is a 50‐
kilodalton protein encoded by an essential gene. Mol Cell Biol, 15, 4167‐74. 
MARCOTRIGIANO, J., GINGRAS, A. C., SONENBERG, N. & BURLEY, S. K. 1997. Cocrystal structure 
of the messenger RNA 5' cap‐binding protein (eIF4E) bound to 7‐methyl‐GDP. Cell, 89, 
951‐61. 
MARCOTRIGIANO, J., GINGRAS, A. C., SONENBERG, N. & BURLEY, S. K. 1999. Cap‐dependent 
translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol 
Cell, 3, 707‐16. 
MARSHALL, N. F., PENG, J., XIE, Z. & PRICE, D. H. 1996. Control of RNA polymerase II elongation 
potential by a novel carboxyl‐terminal domain kinase. J Biol Chem, 271, 27176‐83. 
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